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ABSTRACT 
X-linked cleft palate and ankyloglossia (CPX) is a semi-dominant condition 
caused by mutations in the T-box transcription factor gene TBX22, which 
accounts for around 5% of all cleft palate patients. The T-box proteins 
share a highly conserved DNA-binding domain between family members 
and across species. TBX22 is expressed in the developing palatal shelves 
and tongue in both human and mouse embryos, however, biochemical 
function of the protein and its precise role in the cleft palate phenotype are 
still lacking. Various types of mutations have been identified in CPX 
patients, but notably most of the missense mutations localize within the 
DNA-binding T-box domain. This project set out to investigate the effects 
of naturally occurring missense mutations on protein function. Full-length 
wild type and mutant proteins were expressed in vitro and compared for 
DNA binding ability, localization to the nucleus and transcriptional activity. 
Protein trafficking into the nucleus was unaffected for all ten mutants 
tested. Both DNA-binding and transcriptional repression was abolished or 
considerably compromised for many of the mutants compared to wild-type 
although some were more mildly affected, perhaps reflecting their role in 
protein-DNA or protein-protein interaction. Many transcriptional 
repressors are subject to post-translational modification by the small 
ubiquitin-related modifier SUMO. In silico analysis of TBX22 shows that it 
contains several consensus SUMOylation sequences. Direct interaction 
between the two proteins was demonstrated both by western blotting and 
co-immunoprecipitation studies. Treatment with SUMO-specific proteases 
or mutation of the SUMO attachment sites show that SUMOylation is 
required for transcriptional repression. Cell based analysis of the CPX 
missense mutants showed that they uniformly fail to be modified by 
endogenous SUMO, suggesting involvement of a common mechanism. 
Collectively, the data suggests that the CPX phenotype results from loss 
of TBX22 repressor activity and that SUMO conjugation is likely to be a 
key factor during normal craniofacial development. 
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CHAPTER 1: INTRODUCTION 
1, 
1. INTRODUCTION 
Development of multi-cellular organisms is a complex and tightly regulated 
process. The head and face are highly complex structures and even 
minor disturbances at any stage during these processes can cause 
defects in the fetus or embryo. 
Birth defects are the commonest cause of infant mortality and significantly 
contribute to disability. It is thus important to increase our understanding 
of the molecular pathways involved in development which may in turn lead 
to improved diagnosis, prevention and therapeutic strategies. 
1.1 CRANIOFACIAL DEVELOPMENT 
During the fourth to the eighth week of human development the head 
constitutes nearly half the total body size of the embryo. This ratio 
compares to twenty five percent of the body length at birth and around 
seven percent in the adult organism, and may indicate the importance of 
head development during the embryonic period (Sperber, 2001). 
The structures of the head develop from cells of both ectodermal and 
mesodermal lineages. These structures will form from loose embryonic 
connective tissue, the mesenchyme, which comes from the neural crest; 
paraxial and lateral plate mesoderm; and thickened ectodermal regions 
called placodes. The neural crest cells originate from neuroectoderm and 
migrate from the anterior neural folds into the pharyngeal arches. These 
cells then differentiate into mesenchyme, giving rise to the cartilage, bone 
and ligaments of the face area. The voluntary muscles and vascular 
endothelia of the face also develop from mesenchyme but of mesodermal 
origin already in the area. 
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In the early fourth week of human development five major prominences, 
consisting mainly of neural crest cells, form as a series of small buds in 
the anterior region of the embryo. These are the primordia that will go on 
to differentiate into all of the craniofacial structures. They initially form a 
shallow depression, which is called the stomodeum and marks the future 
mouth. The primordia include the single frontonasal prominence, which is 
vertically cranial to the stomodeum, and the paired maxillary and 
mandibular prominences, which define the lateral and caudal boundaries 
of the stomodeum respectively (Figure 1.1). The frontonasal process 
gives rise to the forehead and the two nasal prominences, which develop 
bilaterally before fusing both with each other and to the maxillary 
prominences. This event gives rise to the developing nose, upper lip and 
primary palate of the embryo. The maxillary processes will also form the 
maxilla, zygomatic bone and secondary palate. Merging of the mandibular 
prominences leads to development of the chin, lower jaw and lip, and the 
lower cheeks (Moore and Persaud, 2003; Sadler, 2004). 
15 
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Figure 1.1: Development of the face and palate. The five facial 
processes at the end of week 4 (A), the frontonasal prominence giving rise 
to medial and lateral nasal processes (B, C), where the different facial 
structures will form. The palatal shelves positioned above the tongue (D); 
looking up at the developing palate, with the shelves growing towards 
each other (E), and having met and fused in the midline, and with the 
nasal septum and primary palate, to form the intact palate (F). Images 
from hftp: //www. med. unc-edu/embryo_images/unit-hednk/headnk-htms 
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1.2. DEVELOPMENT OF THE PALATE 
Palatogenesis takes place from the end of the fifth to the twelfth week of 
human development; the most critical period is from the sixth to ninth 
week (Figure 1.2). 
During the sixth week of development, two projections appear from the 
lateral part of the maxillary prominences. These mesenchymal cell 
structures are the palatine or palatal shelves, which are directed obliquely 
downward either side of the developing tongue. Extracellular matrix 
(ECM) surrounds the core mesenchyme of the shelves, and a thin layer of 
epithelial cells covers the outside edges. The shelves proliferate and 
increase in size, then, during week nine, when the jaws have developed 
sufficiently, the tongue flattens and becomes lower, thus allowing a 
sudden elevation of the shelves to the horizontal position above the 
tongue. Here they continue to grow medially towards each other, meeting 
in the midline where the medial edge epithelial (MEE) cells will contact at 
their tips and the palatal shelves will start to fuse. This fusion initially 
occurs near the midline point of first contact and then the palate closes in 
both anterior and posterior directions, in a zip-like manner. The shelves 
also fuse with the nasal septum and the posterior part of the primary 
palate, with the whole process completed by the twelfth week of 
development. Bone develops gradually in the primary palate and extends 
laterally to generate the hard palate. The remainder of the palate remains 
as muscle without bone and is therefore termed the soft palate, with the 
most posterior region being the uvula (Ferguson, 1988; Moore and 
Persaud, 2003). 
17 
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Figure 1.2: Stages of pallatogenesis. Coronal sections of mouse 
embryos at El 1.5- E14.5. The palatal shelves appear at the lateral parts 
of the maxillary processes (A) as two bilateral buds (B), and grow 
downwards either side of the tongue (C). Soon they elevate to the 
horizontal position, meet in the midline and fuse (D). Thus the complete 
secondary palate is formed. PS: palatal shelves, T: tongue, M: molar 
tooth bud. From (Alappat et al., 2003) 
Z. 
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1.2. a. Palatal shelf elevation 
Palatal shelves initially grow in a vertical direction. At this stage the other 
structures in the oral cavity, especially the position and size of the tongue, 
hinder any lateral movement of the shelves. By the 9th week the jaws 
have grown and the tongue has moved downwards, thus allowing the 
palatal shelves the freedom of movement to undergo elevation to the 
horizontal position. The importance of this steric limitation is 
demonstrated in cases of abnormal tongue development. For instance in 
Hoxa2 -1- null mice, the insertion of the hyoglossus muscle into the hyoid 
bone is defective and leads to an abnormal position of the tongue and a 
resultant cleft palate in these mice (Barrow and Capecchi, 1999). 
Elevation of the palatal shelves occurs very rapidly, perhaps taking only a 
few minutes or hours (Ferguson, 1978; Lewis et al., 1980). The exact 
mechanism of shelf elevation is not known but is thought to occur by one 
or a combination of mechanisms. For example, it is believed that an 
intrinsic force is generated to push the shelves upwards but only when a 
threshold level is reached that exceeds the force of mechanical resistance 
factors. The ECM has a crucial role in this process, especially for the 
posterior two thirds of the palate. Prior and during palatal shelf elevation, 
there is an active synthesis of proteoglycans (Walker, 1961; Walker and 
Crain, 1961) and a rapid accumulation of extracellular matrices within the 
palatal mesenchyme (Larsson, 1960). A local accumulation of 
glycosaminoglycans, mainly hyaluronic acid (HA), which can retain about 
ten times its own weight of water, forms hydrated gels that result in 
expansion of the ECM (Laurent, 1970; Ferguson, 1988). Small changes in 
the concentration of HA bring about large changes in osmotic pressures. 
This process results in swelling of the ECM and an observed decrease in 
mesenchymal cell density, forcing the shelves upwards into the horizontal 
position (Ferguson, 1988). Meanwhile, collections of type I collagen fibres 
are seen vertically along the shelves, orientated from base to tip, and are 
believed to direct the shelf elevating force (Greene and Pratt, 1976). The 
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alignment of mesenchyrnal cells within the palatal shelves could also have 
a role in this directing mechanism (Brinkley and Morris-Wiman, 1984). 
It is also suggested that at the time of palatal shelf elevation, axial but not 
medio-lateral growth of the head encourages the palatal shelves to occupy 
the region above the tongue as the position of least resistance (Diewert, 
1978). Similarly, it has been proposed that the initiation of hiccupping of 
the embryo at around this time might cause pressure in the oronasal cavity 
that triggers a rapid elevation of the palatal shelves (Ferguson, 1988). 
There is a noticeable difference in the movement along the anterior- 
posterior axis of the palatal shelves. The anterior part is the first to move, 
by an apparent flipping motion, with the posterior part following by a 
remodelling flow mechanism (Ferguson, 1988). Recent experiments have 
suggested a difference between the middle part of the palate and the 
anterior and posterior parts. Inert carbon labelling along the anterior- 
posterior axes of mouse palatal shelves has provided evidence that the 
mid-palate undergoes medial rotation and elongation of the shelves 
horizontally, while in the anterior and posterior regions, remodelling of the 
medial edge wall of the vertical shelves mostly accounts for 
horizontal ization and palatal closure (Chou et al., 2004). 
This observation may point to different mechanisms being required at 
different levels of the palate. For example, the HA concentration gradient 
seen along the anterior-posterior axis of the palate midline, with highest 
concentrations at the posterior two thirds, may be a part of this process, 
playing a role in the remodelling and movement of the palatal shelves 
(Brinkley and Vickerman, 1982; Brinkley and Morris-Wiman, 1984). It has 
been shown for other tissues that production and accumulation of 
glycosaminoglycans has an important role in tissue swelling and 
morphogenetic movement (Bulow and Hobert, 2006). Furthermore, 
differential expression levels are seen for genes like Msxl and EGF 
receptor; the former accumulates in the anterior palate and is required for 
expression of downstream genes that support cell proliferation (Zhang et 
al., 2002), while the latter shows tightly regulated temporal expression and 
regional heterogeneity (Shiota et al., 1990). A rare form of cleft palate that 
may further support this theory is the Shox2-1- mouse which exhibits a cleft 
that only affects the hard palate, while the soft palate appears intact (Yu et 
al., 2005). 
Examples of mouse mutants where the palatal shelves fail to elevate are 
not common but one is illustrated in the phenotype of Jagged2-1- mice. 
These embryos die at birth, with palatal shelves that have grown but 
remain flanking the tongue (Jiang et al., 1998). An interesting observation 
is that at the posterior region, the epithelial surfaces of the palatal shelves 
have fused with the respective sides of the tongue. This points to a 
disruption in the programming of the epithelial cell layers, since under 
normal conditions they abut and fuse only to specified areas and surfaces. 
Palatal Fusion 
Following elevation, palatal fusion occurs in three main stages: i) shedding 
of the peridermal epithelial cell layer, ii) contact of the two opposing 
shelves creating a midline epithelial seam (MES), iii) degeneration of the 
seam, leading to continuity of mesenchymal cells along the secondary 
palate. 
The periderm is a thin layer of epithelial cells that covers the palatal 
shelves and is shed just prior to palatal fusion. The oral surface of 
peridermal cells is covered by sialoglycoproteins and microvilli. These 
structures confer specificity to the epithelial part of the palatal shelves, 
preventing them to fuse to other surfaces of adjacent epithelia (Fitchett 
and Hay, 1989). Shedding of this cell layer before the fusion process 
exposes adherens junctions of the underlying basal cells, thus allowing the 
-) I 
opposing MEE to meet and fuse. This is possibly one of the processes 
disturbed in the case of Jagged2-1- mice, the phenotype of which, as 
mentioned above, includes fusion of palatal shelves with other epithelial 
surfaces in the oral cavity. 
At the time of the palatal fusion, the MEE has been shown to be covered 
by structures including cellular debris, filamentous material, filopodia and 
lamilopodia (Schupbach et al., 1983; Abbott and Pratt, 1987). Later 
studies confirmed the presence of bulging cells at the tips of the palatal 
shelves, just prior to contact (Fitchett and Hay 1989; Martinez-Alvarez et 
al., 2000a). These cells are believed to facilitate contact of the opposing 
shelves in the midline, perhaps through adhesive cell surface molecules, 
including E-cadherin (Martinez-Alvarez et al., 2000b; Gato et al., 2002). 
The importance of these structures has been supported by morphological 
characteristics in the palates of mice deficient in TgfP3 (Taya et al., 1999; 
Marti nez-Alvarez et al., 2000b). TgfP3 null animals exhibit cleft palate due 
to defective fusion of the palatal shelves (Kaartinen et al., 1995; Proetzel 
et al., 1995). Histological and scanning electron microscopic examination 
of the palatal tissues reveals absence or significant decrease of the 
bulging epithelial cells and filopodia present in wild-type animals; the 
presence of adhesive molecules appears reduced by histological staining 
(Taya et al., 1999; Marti nez-Alvarez et al., 2000b). 
Several controversial theories have been proposed providing mechanisms 
for the disappearance of the MES cells (i. e. the mechanism underlying 
MES degeneration), leading to completion of palatal fusion. In some 
cases these are considered as exclusive, disputing other potential 
mechanisms, while others suggest that more than one pathway is 
involved. The main theories are: i) cell death (apoptosis) of the epithelial 
cells in the MES, ii) epithelia 1-to-mese nchyma I transformation, where the 
cells of the MES undergo transformation to become mesenchymal cells 
and thus allow mesenchymal continuity, and iii) cell migration, where 
epithelial cells migrate away from the MES into the nasal and oral 
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epithelial surfaces. These theories have been tested by different 
experimental systems and models, including light and electron 
microscopy, in vitro tissue and organ culture and the use of transgenic 
animal models. There are both advantages and disadvantages to each 
technique, which sometimes makes the reproducibility and analysis of the 
results along with the deduction of a universal theory for palate 
morphogenesis more challenging. 
Apoptosis 
Various studies have offered evidence at both microscopic and molecular 
levels to support the theory that the MES disappears through apoptosis of 
the cells that constitute it. A number of studies have identified apoptotic 
cells, as TUNEL-positive, in the MEE before and during formation of the 
seam (Marti nez-Alvarez et al., 2000b; Cuervo and Covarrubias, 2004). 
The presence of macrophages in the area has been suggested to be for 
phagocytosis of dying cells, thus supporting the apoptosis theory 
(Martinez-Alvarez et al., 2000b). 
Experiments of palatal shelves cultured in vitro have shown that in the 
presence of apoptosis inhibitors the palates fail to fuse (Cuervo and 
Covarrubias, 2004). At the same time, similar experiments in palatal 
explants cultured in suspension showed that the palates fused in the 
presence of apoptotic enzyme inhibitors (Takahara et al., 2004). These 
investigators suggested that the static culture systems used by their peers 
might not mimic the in vivo situation adequately. There have also been 
concerns about the stage of palatogenesis that should be examined to 
assess complete or absence of fusion (i. e. E14.5 or later) (Takahara et al., 
2004). 
A general criticism of experiments supporting the occurrence of apoptosis 
in the palatal region at the time of MES degeneration is that data showing 
I 
apoptosis might be due to accidental experimental error. It is possible that 
when palatal shelves are placed in culture too soon, the peridermal cells, 
that will normally slough off as the first step of palatal fusion, become 
trapped in the region of the seam and it is these cells that appear positive 
for apoptosis (Nawshad et al., 2004). 
Recent elegant experiments using transgenic mice have provided 
evidence in favour of the apoptosis theory (Vaziri Sani et al., 2005). The 
investigators crossed two strains of mice using a Cre-LoxP genetic 
approach to irreversibly mark epithelial cells with 9 -galactosidase, either 
through a widely used epithelial cell marker, keratin 14 or cells expressing 
Shh in the maxillary epithelia. These cells were followed throughout 
palatal shelf fusion, including both formation and disappearance of the 
MES. The results showed R-galactosidase staining of epithelial cells in 
the region, which were later seen as aggregates in epithelial islands and 
eventually disappeared completely from the confluent palate. No lacZ 
positive mesenchymal cells were detected at any of the developmental 
stages up to E18.5 in the mouse. Expression of activated caspase-3 was 
also seen in the areas of the degenerating MES and epithelial islands, 
supporting the idea that these cells were destined to undergo apoptosis. 
Epithelial-Mesenchymal Transformation (EMT) 
One possible reason why EMT has had strong support as a mechanism 
for MES regression may be the evidence of this process being involved in 
and/or responsible for other events in embryonic development and 
turnorigenesis. Moreover, experiments with cultured epithelial cells have 
demonstrated their ability to transform in vitro to mesenchymal cells and 
vice versa (Kang and Svoboda, 2005). 
During palate fusion it has been proposed that the fate of the epithelial 
cells, while the MES regresses, is to change their morphological and 
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molecular characteristics and transform into mesenchymal cells, thus 
providing the palate midline with mesenchymal continuity. The process 
begins with loss of cell-cell adhesion and breakdown of the basal lamina, 
both characteristics of epithelial cells, moving later to increased cell 
mobility, as seen in cells of the connective tissue. 
In static and suspension cultures, palates were incubated with a selection 
of lipophilic markers, usually Dil, CCFSE, or carbon particles (Chou et al., 
2004) to label epithelial cells prior to fusion and map their fate along MES 
formation and disintegration. Marked cells are then visualised by 
microscopy leading investigators to suggest that EMT and mesenchymal 
confluence occur by the time the palates have completely fused. Low 
amounts of incorporated label into the MEE, non-specific uptake of label 
by non-epithelial cells and loss of label through time are considered major 
disadvantages of such techniques (Kang and Svoboda, 2005). 
Transgenic mouse studies using a similar genetic system to the one 
employed to support apoptosis have also been used to investigate the 
occurrence of EMT (Jin and Ding, 2006). Employing a Cre-LoxP system 
of labelling epithelial cells (K14-expressing) with R-galactosidase, 
investigators reported R-gal positive cells outside the palate midline, 
during and after seam degeneration, with some of the labelled cell 
"patches" demonstrating typical mesenchymal cell morphology. They also 
explored one aspect of the apoptosis model by studying palate fusion in 
mice deficient in activated caspase-3 (Apafl mutants) and found no defect 
in formation or degeneration of the MES, thus concluding that apoptosis is 
not essential for palate fusion in vivo. 
iii) Cell migration 
Cell migration plays an important role in many developmental processes. 
During palatal fusion, mesenchymal cells migrate into the area of the 
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regressing MES, filling up the space occupied by its cells (Ferguson, 
1988). Migration of the epithelial cells of the seam has been considered 
as an alternative or additional process to explain MES cell fate after 
degeneration. Experiments have shown that following palate fusion, 
epithelial cells from the MES migrate away from the midline into the 
epithelial surfaces of the nasal and oral cavities (Cuervo and Covarrubias, 
2004; Jin and Ding, 2006). The observed thinning of the MES cell layer 
might not be due to active movement of the cells into the periphery, but 
rather due to mechanistic effects. Because the underlying mesenchyme 
continues to proliferate, the epithelial cells find themselves further apart, 
like the outer layer of an expanding sphere, and that process might be 
observed as epithelial cell migration (Fitchett and Hay, 1989). 
Thus, although several groups have claimed that their results have 
concluded the debate about the fate of the MES epithelia, no theory has 
yet been excluded beyond reasonable doubt. It may not be surprising if a 
combination of more than one mechanism facilitates degeneration of the 
seam, where several pathways need to collaborate for the end result. 
1.2. c. Molecular Regulation of Palatogenesis 
Over the last two decades a number of genes have been implicated in 
secondary palate formation, either through expression data, mouse 
transgenic studies or association studies in human cleft lip and/or palate 
patients. Studies with organ cultures and histological examination of 
transgenic animals have categorised these genes into three groups, 
depending on their effect on the basic steps in palatogenesis: palatal shelf 
growth, elevation and fusion. 
The most common factor leading to a cleft palate in transgenic animals is 
disturbance to the proliferation of the palatal mesenchyme, which affects 
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vertical and/or horizontal growth. In animal models, mutations in various 
genes have been shown to result in hypoplastic palatal shelves, which 
either fail to elevate, or elevate but fail to fuse. For example, mice lacking 
Msxl expression exhibit a cleft palate (Satokata and Maas, 1994) due to a 
reduction to the normal proliferation of the palatal mesenchyme (Zhang et 
al., 2002). Other genes in the Msxl biochemical pathway show similar 
effects. For example, Bmp4, believed to function upstream of Msxl, can 
rescue the cleft phenotype in Msxl-l- mice when it is transgenically 
expressed in the palatal mesenchyme of the null animals (Zhang et al., 
2002). 
Defective cell proliferation is also seen in mice deficient for Fgf1O and its 
receptor Fgfr2b, affecting both the mesenchymal and epithelial tissues of 
the palate and accompanied by increased apoptosis; FgHO loss of 
function in the epithelia disrupts their selectivity for fusion structures, and 
like Jagged2 null mice, leads to palatal shelves fusing with the tongue and 
mandible surfaces (Rice et aL, 2004; Alappat et al., 2005). p63 may have 
a role in healthy development of the epithelial cells and regulate their 
interactions with the underlying mesenchyme (Carroll et al., 2006). 
There is a requirement for cell proliferation to continue after the palatal 
shelves have elevated, in order to make contact and fuse. Several genes 
have been shown to have an important role in this process includingTgfbr2 
(Ito et al., 2003), the plate let-de rived growth factor c (Pdgfc) (Ding et al., 
2004), and single-minded 2 (Sim2) (Shamblott et al., 2002) which all 
demonstrate normal elevation but horizontal growth deficiencies in mutant 
mice. Tgfbr2 is perhaps the most interesting, since its absence in the 
mesenchyme causes reduced cell proliferation, while loss of function in 
the epithelial layer leads to epithelial overgrowth in the MEE that impedes 
palatal fusion (Xu et al., 2006). 
Alk5 deficiency results in a similar phenotype, but from the other end of 
the regulation balance during palate development. In this case the 
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abnormality lies in over-proliferation of the palatal mesenchyrne and the 
tissue exhibits elevated levels of apoptosis (Dudas et al., 2007). On the 
other hand, lack of epithelial Alk5 results in non-degeneration of the MES 
due to reduced apoptosis. 
The elevation of the palatal shelves is regulated by intrinsic forces as well 
as external events that need to occur in a controlled manner, for 
development to proceed normally. Osr2, Pdgfc, Jagged2, FoXf2 and 
Hoxa2 have all been linked with palatal shelf elevation, either through 
delayed or hindered shelf elevation in their respective mouse mutants 
(Jiang et al., 1998; Wang et al., 2003; Ding et al., 2004; Lan et al., 2004). 
In the case of Hoxa2-1- animals, the tongue muscle fails to locate correctly 
into the hyoid bone. This results in a mechanical obstacle for the palatal 
shelves that cannot move normally within the oral cavity and elevate. In 
Foxf2-1- mice, abnormal tongue location hinders normal palatal shelf 
elevation (Wang et al., 2003). 
In the case of Osr2 and Pdgfc, the phenotype might also be due to 
abnormal cell proliferation. Osr2 and Osrl are the vertebrate homologues 
of the Drosophila odd-skipped related gene odd and are both expressed in 
the palatal shelves during palate development, although in different 
patterns (Lan et al., 2004). Studies on the Osr2 transgenic animals show 
abnormal mesenchymal proliferation and delayed elevation of palatal 
shelves, compared to the wild-type. Osrl-'- mice die before palatogenesis 
is complete, but the expression data reveal a possible role in mediolateral 
patterning and epithelial-mesenchymal interactions. The human 
homologue OSR2 has been localised on 8q23, a region that has shown 
strong association with non-syndromic cleft palate (Prescott et al., 2000), 
thus making it a good candidate gene for genetic contribution to isolated 
clefting. 
The most widely studied gene in relation to clefting and palatogenesis is 
TgfI33. In Tgf133 null mice, palatogenesis appears to proceed normally 
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until reaching the fusion stage (Kaartinen et al., 1995; Proetzel et al., 
1995). These mice exhibit cleft palate due to a persistent medial edge 
epithelial seam that fails to degenerate normally. The palatal shelves also 
show a problematic ability to form adherens junctions that normally 
facilitate fusion (Tudela et al., 2002). Thus, investigators have suggested 
a role for TgfI33 in regulating contact and adherence of palatal shelves, 
possibly through the formation of filopodia in the epithelial cell layer and by 
regulating the expression of E-cadherin (Taya et al., 1999; Martinez- 
Alvarez et al., 2000b). Similarly, mice deficient in Egfr appear to have a 
cleft palate as a result of a distinct cellular mechanism. Here the palatal 
shelves grow, elevate and contact normally, but as the initial fusion of 
epithelial cells occurs by the formation of the MES, this seam persists and 
does not disintegrate, thus blocking mesenchymal cell fusion and 
continuity along the palate (Miettinen et al., 1999). 
Other members of the TgfR superfamily have also been implicated in 
palate development, with roles in cell proliferation, migration and 
apoptosis, and also extra-cellular matrix synthesis and degradation of the 
basement membrane during seam degeneration (Pelton et al., 1990; 
Kaartinen et al., 1997). TgB31 and TgfI32 mRNA is present in the palate 
during development, the former initially in the epithelium and later in 
distinct cell populations among the mesenchyme, while the latter shows 
more general expression in the mesenchymal cells, especially in those 
directly adjacent to the MEE (Fitzpatrick et al., 1990; Pelton et al., 1990). 
TgfI32 may have a role in ECM synthesis and proliferation of the 
mesenchyme, with animals deficient in this gene showing mandibular and 
maxillary defects and around one out of four showing cleft palate (Sanford 
et al., 1997). TgfI3 I-/- mice die before palatogenesis is complete, but a role 
in palatal shelf growth and apoptosis, possibly involving the peridermal 
cells has been suggested for this growth factor (Oberhammer et al., 1996; 
Yamamura et al., 2000). The TgfR receptors have also been implicated in 
palatogenesis, and deficiency in T&11 (type 11 Tgfp receptor) results in 
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complete cleft palate, due to a defect in the proliferation of mesenchyrnal 
cells originating from the cranial neural crest (Ito et al., 2003). 
Not surprisingly, the investigation of genes involved in palatal shelf fusion 
has been closely linked to the problem of identifying the mechanism of 
midline epithelial seam degeneration. This has sometimes led to the 
reporting of seemingly different and often contradictory results. One 
example is the characterization of the apoptotic protease activating factor 
1 deficient (Apafl-l-) mice. ApafI has a crucial role in the caspase-3 
mediated process of regulated cell death, and according to the apoptosis 
theory for MES degeneration, disturbance of this pathway may lead to 
problems with palate closure. Cecconi et al (Cecconi et al., 1998) 
reported that these mice had a cleft palate, because of a MES that failed 
to disappear. A few years later, another group, more inclined towards the 
EMT theory, analysed a different strain of Apafl-l- mice and found them 
normal in palate development (Jin and Ding, 2006). 
Many mutant mice include cleft palate as part of a selection of defects 
which in humans is normally referred to as a syndrome. In many cases 
the cleft palate, even when not accompanied by a cleft lip, is likely to be a 
secondary defect resulting from other craniofacial abnormalities. In these 
cases the specific mutations might not point to a distinct defect in palate 
development, but may be affecting a wider selection of tissues. For 
example, Dlx5 and Dlx6 mouse mutants show severe skeletal and limb 
malformations, accompanied by anomalies in craniofacial and ear 
development as a result of a defect in derivatives of the first pharyngeal 
arch (Robledo et al., 2002). The cleft palate observed in GH71- and GH3-1- 
animals is believed to occur due to defects in cell populations derived from 
the neural crest, where tooth and bone development are also affected (Mo 
et al., 1997). The Hoxa2-1- mutant is another example, with abnormal 
positioning of the tongue muscles obstructing palatal shelf elevation 
(Gendron-Maguire et al., 1993; RijIi et al., 1993). Interestingly, the cleft 
palate in this case can be rescued by a further mutation in Hoxal which 
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results in a more severe overall phenotype, affecting the abnormal 
positioning of the tongue in Hoxa2-1- and thereby allowing the palate to 
close (Barrow and Capecchi, 1999). 
The Extracellular Matrix 
Remodelling of the extracellular matrix (ECM) is essential in many 
developmental processes, such as bone morphogenesis and mammary 
development (Page-McCaw et al., 2007). The synthesis and degradation 
of ECM in the palatal shelves is involved in normal palatogenesis. In the 
palatal shelf structure, epithelial and mesenchymal cells are separated by 
a specialised ECM structure, the basement membrane. This membrane 
consists of proteins such as collagens, laminin, fibronectin and tenascin, 
and polysaccharides such as HA, heparan sulphate, chondroitin and 
keratin sulphate. 
Immunostaining experiments have shown that collagen types I and 111, 
chondroitin sulphates and fibronectin are fairly ubiquitous during 
palatogenesis (Silver et al., 1981). Collagen type IX is absent from the 
palate at days E12 to E13, and is expressed just prior to palatal shelf 
elevation on the surface of the medial edge epithelia (Ferguson, 1988). 
The appearance of this molecule at the precise time of signalling for MEE 
differentiation and its absence from chick palates that are naturally cleft 
has led to the suggestion that it may act as a linker to connect ECIVI 
components with each other and the surface of epithelial cells (Ferguson 
et al., 1984; Fyfe et al., 1988). 
Deficiencies in various ECM components have been shown to affect 
normal palate development. Collagen type 11 has a role in gene activity 
and matrix organization; mice deficient in this protein exhibit cleft palate 
and a smaller mandible, with reduced anterior-posterior length (Savontaus 
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et al., 2004). Missense mutations can present with a similar phenotype, 
for example mice homozygous for a G904C change in Col2al die at birth 
with CP (So et al., 2001). 
Remodelling of the ECM is essential for normal mammalian palate 
development, and proteolytic degradation of the matrix is an important 
step in palatal fusion (Blavier et al., 2001; Brown et al., 2002). These 
processes are regulated by a number of enzymes, including matrix 
meta I loproteinases (MMP) and their inhibitors, tissue inhibitors of 
metal loprotei nases (TIMP). Different members of the MMP and TIMP 
families are expressed in distinct temporal windows during palate 
development (Morris-Wiman et al., 1999; Mansell et al., 2000). It has 
been suggested that their role in ECM remodelling is necessary for fusion, 
with a possible involvement in the craniofacial defects of the Tgfl33-'- 
mouse (Blavier et al., 2001). 
MMP enzymes hydrolyse collagens in the basement membrane, and 
degrade elastin, fibronectin and fibrillin molecules, which is a principal 
component of ECIVI elastic microfibrils (Ferguson, 1988; Page-McCaw et 
al., 2007). The catabolism of these macromolecules is necessary for the 
maintenance of all connective tissues, most of which excrete MMPs 
(Verma and Hansch, 2007). The proteolytic action of MMP enzymes can 
lead to loss of epithelial phenotype, which can be relevant to the MEE 
seam degeneration, since the cells of the seam are joined by cell-cell 
adhesion molecules, principally E-cadherin and syndecan-1. Both of 
these are cleaved by MMPs, and the expression of which is lost at the 
time of seam degeneration (Kajita et al., 2001; Noe et al., 2001; Endo et 
al., 2003). 
Although individual mouse mutants of different MMP enzymes show only 
minimal phenotypes that do not include craniofacial anomalies (Shapiro, 
1997), extended disruption of MMP activity may result in CP (Brown et al., 
2002). For example, treatment with MMP inhibitors results in a significant 
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increase in the occurrence of cleft palate in wild-type mice, and prevents 
palatal contact in a culture system (Brown et al., 2002). The same study 
showed that expression of MMP-2 and MMP-3 is upregulated during 
palate development, peaking at the time of palatal fusion, which suggests 
that MMPs can induce epithelial cell breakdown if present in high enough 
concentrations. Another member of the MMP family, stromelysin-1, has 
been linked to loss of epithelial phenotype and a possible subsequent 
transformation to mesenchyme, for example through the cleavage of E- 
cadherin (Lochter et al., 1997). 
MMPs are regulated by their natural inhibitors, tissue inhibitors of 
meta I loprotei nases (TIMPs), to avoid excessive proteolysis and tissue 
damage (Gomez et al., 1997). TIMPs also have a role in craniofacial 
development, especially development of the mandible, tongue and teeth 
(Mohan et aL, 1998; Abiko et al., 1999; Miettinen et al., 1999). The 
distribution of MMPs and TIMPs in the developing palate correlates with 
the changes in expression of ECM molecules, especially fibronectin, 
laminin, tenascin and collagens III and IV, which are re-organised during 
the reorientation and elevation of the palatal shelves (Brinkley and Morris- 
Wiman, 1984; Morris-Wiman et al., 2000). TIMP-3 in particular is uniquely 
expressed in the nasal and oral palatal epithelium, where extensive 
reorganization occurs during palatal shelf reorientation (Brinkley and 
Morris-Wiman, 1984; Morris-Wiman et al., 2000). 
Accumulation of ECM molecules within different regions of the palate 
could modulate the response of cells to various growth factors (Roberts et 
al., 1990; Sporn and Roberts, 1990). ECM molecules such as fibronectin 
could even bind and sequester growth factors, for example TGF91 (Fava 
and McClure, 1987), releasing them for activity on either a different cell 
population or at the appropriate time in development (Dixon and Ferguson, 
1992). Cleavage of these ECM proteins that leads to release of growth 
factors, including FGFs, and may regulate cell-cell and cell-matrix 
interactions, is mediated by MMPs (Fowlkes et al., 1995; Whitelock et al., 
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1996). In addition, synthesis of MMPs and TIMPs is regulated by EGF 
and TgfR, both molecules that are absolutely required for normal 
palatogenesis (Page-McCaw et al., 2007). 
OROFACIAL CLEFTING 
CUP and CP 
Orofacial clefts (OFC) describe a range of developmental disorders of the 
mouth and face, including cleft lip and/or cleft palate (CUP), which 
collectively are among the commonest birth defects in live born humans. 
The prevalence varies between 1/300 and 1/2500 births depending on 
geographic origin, ethnic variation and socio-economic status (Wyszynski 
et al., 1996). Isolated cleft palate (CP) accounts for almost half of all 
orofacial clefts, with an occurrence estimate of around 1/1500 births 
(Wyszynski et al., 1996). Although these defects are not a significant 
cause of mortality, besides the obvious aesthetic problems, children born 
with clefts frequently suffer from associated difficulties with feeding, 
hearing, speech and psychological development (Schutte and Murray, 
1999; Stanier and Moore, 2004). 
The commonest forms of OFC fall into two main categories: (i) Clefts of 
the lip with or without cleft palate (CUP) which, as the name suggests, 
either involve the upper lip and anterior part of the maxilla, and may or 
may not affect regions of the secondary palate. Involvement of the 
secondary palate in these patients is thought to be determined primarily as 
a secondary effect to disruption of the primary palate. (ii) Isolated clefts of 
the secondary palate (CP). These can appear in various forms, from 
submucous clefts involving only the muscle and bone, to cleft uvula to 
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more extensive soft palate clefts and those extending into the hard palate 
(Figure 1.3). There is also a rare type of cleft palate that only affects the 
hard palate, while the soft palate is intact, as seen in Shox2-1- mice (Yu et 
al., 2005), but also humans and other animals (Schupbach 1983). In most 
cases, CLIP and CIP are not usually seen in the same family. Thus CIP is 
reported as aetiologically distinct from CLIP (Wilkie and Morriss-Kay, 
2001). 
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Figure 1.3: Cleft Lip and/or Palate phenotypes. Isolated unilateral 
clefts of either the palate or lip (a and b respectively), clefts of both lip and 
primary palate (c), and including the secondary palate (d). Bilateral cleft of 
the secondary palate (e), of the lip only (f), including the primary palate (g), 
and also the secondary palate (h). Figure adapted from Muenke, 2002. 
htti): //vvww. nature. com/nq/iOurnal/v32/n2/images/nql 002-219-Fl -gi 
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Treatment of CP 
Most clefts can be surgically corrected, at least in the developed parts of 
the world. The correction process requires the co-operation of a number 
of specialists, including the surgeon, paediatrician, orthodontist, 
otorinolaryngologist, speech therapist and in some cases a clinical 
geneticist and a psychologist. 
Palatal closure is delayed because large amounts of blood that can be lost 
during surgery. The repair procedure takes place preferably between 6 
and 18 months. At six months, the orofacial muscles are adequately 
developed and it is possible to close the soft palate. After 12 months the 
hard palate can be closed, and gingivoperiosteoplasty can also be 
performed at this stage. Palatal closure involves the use of a bridged or 
pedicled flap, depending on the width of the cleft, along with the palatal 
mucosa that covers the cleft margins (Von Langenback, 1861 b; Von 
Langenback, 1861a; Ernst, 1925b; Ernst, 1925a; Veau, 1931; Axhausen, 
1936). An acrylic palatal plate is inserted to control maxillary growth and 
separate the nose from the oral cavity. This normalizes the position of the 
tongue and facilitates swallowing. Palate closure is not always achieved 
in one surgery. The correction process is usually prolonged by the 
difference in growth rates between healthy developing and scar tissues 
and it is common for the repair to split open again. Consecutive surgical 
procedures are often necessary, which can begin at the infant stage and 
be completed when the patient reaches adulthood. Orthodontic treatment 
is performed usually when adult teeth appear, to aid tooth alignment in the 
cleft area (Bill et aL, 2006). 
Abnormal mid-facial growth, accompanied by other side effects, including 
teeth and speech problems may still exhibit in some patients. Recently, a 
CUP correction method has been suggested using feto-endoscopic 
surgery. Such an approach may have advantages including scarless 
wound healing, bone healing without callus formation, better maxillary 
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growth and normal speech development (Papadopulos et al., 2005) but 
undoubtedly needs to be balanced against the risk to the mother and 
inducing pregnancy loss. 
1.3. c. Embryological basis of CP 
The various stages of palatogenesis were detailed in 1.2. a-c, and as 
described for the mouse mutants detailed above, disturbance to any of 
these processes can lead to CP. Unlike in animal models, it is impossible 
to look at a human cleft palate in the various stages before the palate 
would naturally close, therefore one only sees the end result. As a 
consequence, at birth one cleft may look similar to another despite quite 
different aetiology. Nevertheless it is widely accepted that the following 
may all contribute independently to the overall incidence of cleft palate in 
humans: 
Disturbance of the migration of neural crest (NC) cells into the 
maxillary prominences of the first pharyngeal arch. If NC cells 
do not transform and migrate normally, if the cell number is 
insufficient or if they fail in their induction capacity, this may lead 
to clefts. 
Obstruction of vertical and/or horizontal growth of palatal 
shelves, possibly due to deficiencies in cell division and/or cell 
migration. The palatal shelves are hypoplastic, or they grow 
and elevate but remain too short and fail to meet in the midline. 
Delayed or inhibited elevation of palatal shelves, due to 
mechanical obstacles, for example incorrect position of the 
tongue; or insufficient production and concentration of 
glycosaminoglycans, e. g. HA, to drive the intrinsic elevating 
force. 
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iv) Failure of palatal fusion. This can be a result of failure of MEE 
adhesion or MEE seam degeneration. Defective interactions 
between epithelial and mesenchymal cells and excessive palatal 
shelf movement can also hinder correct fusion. 
V) Post-fusion rupture. In some cases the epithelial seam persists 
after palatal shelf contact and fusion, preventing mesenchymal 
continuity along the palate. 
Inheritance of CP 
CIP can be divided into non-syndromic, where an isolated cleft of the 
palate is the only phenotypic feature in patients, and syndromic forms, 
where the cleft is present along with one or more additional feature, 
perhaps affecting other tissues or organs. It is reported that non- 
syndromic isolated CIP occurs more frequently in females than males, 
whereas non-syndromic CL is more frequent in males (Fraser, 1970). 
Since the female palate closes approximately 1 week later than in males, 
a possible explanation for this statistic is the susceptibility of palatogenesis 
to environmental exposure (Sadler, 2004). 
In general, cleft palate falls into the category of complex or multifactorial 
disorders, i. e. those that are strongly influenced by both genetic and 
environmental components but with no consistent inheritance pattern. For 
example, a family history can only be identified in around 50% of CP 
cases (Murray, 2002). Deciphering the aetiology of these traits is 
therefore a lot more difficult than for those conforming to standard 
Mendelian inheritance, and attempts to identify causative mutations or 
susceptibility loci via family and case-control studies have proved difficult. 
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. 3. e. Environmental factors. 
Many environmental factors have been implicated in the aetiology of clefts, 
perhaps reflecting the delicate balance of processes required for normal 
craniofacial development, with a cleft being one of the first major indicators 
of sub-optimal conditions. It is interesting to note the suggestion that 
familial occurrence of clefts, apart from pointing towards genetic 
components, may also be a result of shared environment (Hayes, 2002) 
hence the substantially increased recurrence risk. Typical environmental 
risk factors for clefts include high levels of alcohol consumption by the 
mother (Munger et aL, 1996; Shaw and Lammer, 1999) as well as 
cigarette smoking through pregnancy, possibly resulting in a hypoxic 
environment (Jugessur and Murray, 2005). Use of chemotherapeutic 
agents such as the anti-epileptic drugs phenytoin or valproic acid or 
corticosteroids, which have a use in treating a wide variety of conditions, 
are well documented risk factors for clefts (Greene and Kochhar, 1975; 
Goldman, 1984; Rodriguez-Pinilla and Martinez-Frias, 1998; Wide et al., 
2004; Alsdorf and Wyszynski, 2005). Nutrition status of the mother during 
pregnancy more generally has a role in the healthy development of the 
embryo, but low intake of B vitamins as well as insufficient or excessive 
vitamin A uptake increase the risk of cleft development (Munger, 2002; 
Finnell et al., 2004). Food restriction can have similar effects, as shown in 
pregnant mice that developed high corticosteroid levels, leading to greater 
numbers of embryos being resorbed, and cleft palate and general delayed 
ossification in their progeny (Hemm et al., 1977). Exposure to the 
cholesterol-lowering statin drugs early in embryonic development may 
present a risk for midline malformations, including cleft palate (Edison and 
Muenke, 2004). It has also been suggested that impaired folate 
metabolism (or folic acid deficiency) may be a risk factor linked with 
clefting (Munger et al., 2004) and indeed some studies have suggested 
that oral folate supplementation can have a protective effect against clefts 
(Tolarova and Harris, 1995). 
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Bille et al., (2005) showed that parental age is an important risk factor for 
clefts with the more elderly parents being at greater risk. Interestingly, 
while the age of both parents is associated with CUP, in isolated CP 
cases, it is the paternal age that appears most important with the maternal 
age effect almost disappearing. 
Various forms of stress during pregnancy are associated with OFC. 
Oxidative stress, for example elevated homocysteine levels leading to 
apoptosis (Knott et al., 2003) and increased generation of free radicals 
together with depletion of anti-oxidants mechanisms, as measured by 
excessive oxidative DNA damage, has been shown to be higher in 
mothers of children with clefts (Hozyasz et al., 2004). Furthermore, 
emotional stress during pregnancy has also been implicated in cleft palate 
phenotypes. Stress can act either as a direct psycho-endocrinological or 
autonomous effect, or can indirectly lead to maternal smoking, alcohol and 
substance abuse and malnutrition (Blomberg, 1980b; Blomberg, 1980a). 
Studies in mice have demonstrated that elevated plasma corticosterone, 
as a response to stress, can be a cause for developing clefts (Barlow et 
al., 1975). 
In the mid-90s, a study of a Chilean population in an area that suffered an 
earthquake ten years previously, found that the proportion of clefts 
increased after the incident. The highest occurrence in newborns occurred 
six months afterwards. The effect of earthquake-induced stress on clefting 
was studied further in a model system where pregnant mice were placed 
in a vibrator cage to stimulate the earthquake conditions. Compared to 
controls, there were greatly increased number of clefts in one of the two 
mouse strains used suggesting a genetic difference in susceptibility, 
although both strains showed significantly elevated numbers of embryo 
resorptions (Montenegro et al., 1995). 
The interactions between the genetic background and environment have 
been addressed by epidemiological studies investigating the combined 
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effect of certain environmental factors on specific genotypes. The risk of 
CLIP becomes higher in mothers with high alcohol intake that carry infants 
with a rare MSX1 genotype (Romitti et al., 1999). Uncommon Msxl 
alleles can also affect the rate of clefting in collaboration with multivitamin 
use (Munger et al., 1995). Maternal smoking has been studied in 
association with infants with a rare TGFa allele, and the risk for cleft was 
found to increase significantly (Prescott et al., 2001). Further studies 
showed that in infants with an uncommon TGFa genotype the likelihood of 
developing clefts was associated with the use of folic acid-containing 
multivitamin supplements by smoking mothers (Shaw et al., 1998). It has 
been suggested that the decrease in serum folate seen after cigarette 
smoking may have a role in this association (Witter et al., 1982; Shaw et 
al., 1998). 
As perhaps is the case for most multifactorial disorders, an increasing 
number of environmental factors have been associated with elevated risks 
of orofacial clefts (Prescott et al., 2001). These influences are more 
challenging to study compared to genetic linkage and association 
approaches, for reasons that include the exact definition of each 
environmental factor and the fact that it is more difficult to set proper 
controls. However, the last few decades have seen the publication of very 
encouraging data sets revealing specific environmental agents that may 
aid the prevention of orofacial clefts (Murray, 2002). Such studies may 
also help to elucidate the relationship between such external factors and 
the genetic background, which will be necessary in order to get a complete 
picture of the pathways leading to cleft formation. 
Genetic Components 
A genetic component for clefts was first identified through the studies of 
Fogh-Anderson (Fogh-Andersen, 1949), with most cases displaying a 
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multi-factorial mode of inheritance. Despite many genes being identified in 
mice that when mutated cause various cleft phenotypes (WIlkie and 
Morriss-Kay, 2001), remarkably few genes or loci have been implicated in 
the occurrence of isolated clefts in humans. Whilst genetic heterogeneity 
in humans has undoubtedly confounded many studies, analysis of 
recurrence risk patterns of CUP points towards only a few major loci being 
involved and interaction with an oligogenic background (Farrall and 
Holder, 1992). 
Nevertheless, in recent years, progress has been made primarily with 
syndromic clefts that occur as single gene defects (Stanier and Moore, 
2004). The study of such syndromes can be more straightforward than 
with potentially multifactorial non-syndromic patients. This is because they 
are more often familial and can be much easier to selectively group 
together due of the additional distinctive features. Syndromic clefts 
comprise a heterogeneous mixture of over three hundred documented 
syndromes (Gorlin et al., 2001). Some important examples that have 
been extensively studied are presented below. 
i) Velocardiofacial syndrome (VCFS) 
VCFS is characterised by pharyngeal dysfunction, cleft palate, cardiac 
anomalies, dysmorphic facies and learning disabilities, and has a 
minimum prevalence of 1 in 4000 live births (Goldberg et al., 1993; Wilson 
et al., 1993; Goodship et al., 1998). It is the commonest syndrome with 
palatal abnormality as a major feature, with 9% of patients displaying cleft 
palate (Ryan et al., 1997). VCFS is frequently associated with a 
hemizygous deletion of chromosome 22ql 1.2, which is also detected in 
patients with DiGeorge syndrome (Scambler et al., 1992; Kelly et al., 
1993; Ryan et al., 1997). It is believed that most of the physical 
malformations result from haploinsufficiency of, or point mutations in the T- 
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box transcription factor gene TBXI (Yagi et al, 2003; Paylor et al., 2006), 
which occurs in the common deletion region. The phenotype of Tbxl 
transgenic mice supports the hypothesis that TBX1 has a role in the 
aetiology of VCFS; Tbxl-l- animals display a wide range of developmental 
anomalies that encompass most VCFS (and DiGeorge syndrome) features 
(Jerome and Papaioannou, 2001), while mice with deletions 
corresponding to the human 22ql 1.2 can be patially rescued by TBX1 
overexpression (Merscher et al, 2001). 
ii) Van der Woude Syndrome (VDWS) 
VDWS is thought to be the commonest form of syndromic CLIP and is 
responsible for 2% of all CLIP cases (Burdick, 1986). Inheritance of the 
disorder occurs in a Mendelian autosomal dominant manner. It provides a 
very good model for non-syndromic CLIP since most patients have only 
minor additional phenotypes of lip pits and occasional hypodontia, with no 
other craniofacial anomalies and normal intelligence. Some patients only 
have isolated CLIP. VIDWS is one of the few cases where clefts of the lip 
and primary palate segregate in the same family with isolated clefts of the 
secondary palate. 
Genetic linkage analysis for VDWS pointed to the long arm of 
chromosome one (1q32) and mutations were identified in the interferon 
regulatory factor 6 gene (IRF6) (Kondo et al., 2002). IRF6 is a 
transcription factor with a winged helix DNA binding domain and a protein- 
binding SMID (Smad- interferon regulatory factor) domain. Expression 
studies of Irf6 in mice show localization in the palatal medial edge 
epithelium before and during fusion. 
Popliteal pterygium syndrome (PPS) is clinically similar to VIDWS with 
additional features of popliteal pterygiurn (an extensive web running from 
behind the knee down to the heel), syngnathia, synclactyly, toe/nail 
43 
abnormalities and genito-urinary malformations. Because the phenotypes 
within the families are highly variable, clinical expressions of the two 
syndromes can overlap considerably. This led to the proposition that the 
two syndromes may be caused by mutations in the same gene. This was 
confirmed with the identification of IRF6 mutations in 13 PPS families 
(Kondo et al., 2002). Furthermore, a genotype-phenotype correlation has 
been demonstrated between mutations in IRF6 and VDWS or PPS 
symptoms. Mutations that cause protein truncations, missense mutations 
in the protein- binding region and missense mutations in the DNA-binding 
region at positions that are not involved in DNA binding, result in VDWS 
while mutations in amino acid positions that do affect DNA binding present 
as PIPS. 
Treacher Collins Syndrome (TCS) 
Treacher Collins syndrome is the commonest form of mandibulofacial 
dysostosis, the phenotype of which includes cleft palate. It has an 
autosomal dominant inheritance pattern and a prevalence of around 
1/50,000 live births. Mutations have been identified in the Treacher 
Collins Franceschetti syndrome-1 (TCOFI) gene that codes for the highly 
phosphorylated nucleolar trafficking protein, Treacle (Wise et al., 1997). 
Mutations resulting in truncated proteins cause them to mislocalise within 
the cells (Marsh et al., 1998). A role for TCOF1 has been suggested in 
methylation of the 18S rRNA, rDNA transcription and ribosome biogenesis 
(Gonzales et al., 2005; Dixon et al., 2006). Disturbances in these 
processes through TCOF1 haploinsufficiency have been linked with 
defective neural crest cell formation and proliferation (Dixon et al., 2006). 
iv) Ectrodactyly, Ectodermal Dysplasia and CUP (EEC) 
EEC syndrome is inherited as an autosomal dominant trait and is one of 
five orofacial developmental disorders in which mutations in p63 are 
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implicated (Celli et al., 1999; Barrow et al., 2002). Analysis of the different 
p63 mutations has revealed a high level of genotype-phenotype 
association. Missense mutations in the DNA-binding domain of p63 result 
in CLP and mutations in the C-terminal end lead to CLP or CP, while 
mutations in the N-terminal end outside the DNA-binding domain can 
cause a CP only or no clefting phenotype at all (Celli et al., 1999). 
V) CLP with ectodermal dysplasia (CLPED1) 
CLPED appears as an autosomal recessive disorder characterised by cleft 
lip and palate, ectodermal dysplasia, syndactyly and occasional mental 
retardation. Positional cloning in affected families in Margarita island and 
greater Venezuela area has identified mutations in the PVRL1 gene 
(Suzuki et al., 2000). Its product is a cell adhesion molecule, nectin-1, and 
is expressed in the skin surface epithelium of the developing face and the 
medial edge epithelium of the palate. A common mutation W185X was 
identified in affected families, which results in protein truncation that 
obstructs the NAP (nectin-afadin-ponsin)-dependent cell adhesion system. 
Patients are homozygous for the nonsense mutation, while heterozygosity 
is frequent in the unaffected population. However, association analyses 
have suggested that heterozygosity may be a significant risk factor for 
non-syndromic CLP in these populations (Sozen et al., 2001). 
vi) Kallmann Syndrome 
Kallmann syndrome is characterised by hypogonadotropic hypogonadism, 
usually accompanied by hypo/anosmia and 5-10% of patients have CUP 
as part of their phenotype. Mutations have been identified in the FGFR1 
gene (Dode et al., 2003; Kim et al., 2005; Dode et al., 2007) and cause 
autosomal dominant inheritance. Due to variation in alleles some patients 
exhibit CUP as their only phenotype (Jugessur and Murray, 2005), thus 
making FGFRI an attractive candidate gene for non-syndromic clefting. 
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An involvement of FGFR1 in craniofacial development, as shown through 
expression studies that localise it to the oral epithelial tissues during 
palatogenesis (Britto et al., 2002), and functional assays pointing to a role 
of FGFR1 in neural crest cell migration, cell survival and EMT (Trokovic et 
al., 2003; Xian et al., 2007), further supports this hypothesis. A number of 
FGF protein family members and their receptors were sequenced in a 
large cohort of non-syndromic CUP patients, and mutations were 
identified in FGFRI, FGFR2, FGFR3 and FGF8 (Riley et al., 2007). 
Polymorphic changes (SNPs) in further 4 family members have been 
associated with CUP. Combined with some cases of reduced penetrance 
of the Kallmann syndrome phenotype, these mutations may account for 
5% of non-syndromic clefts (Riley et al., 2007) although functional analysis 
of the proposed mutations have yet to be studied. 
vii) X-linked cleft palate (CPX) 
The examples detailed above predominantly involve CUP, however, an 
unusual example of a cleft affecting only the secondary palate is the 
Mendelian inherited X-linked cleft palate and ankyloglossia (CPX; OMIM 
303400). CPX is characterized by an isolated cleft of the secondary 
palate, or in some cases a bifid uvula, with or without submucous cleft of 
the soft palate, frequently accompanied by ankyloglossia (tongue-tie) 
(Figure 1.4). Due to the latter feature, CPX is often considered syndromic. 
CPX is classified as semi-dominant, with female carriers displaying 
variable phenotypes, ranging from asymptomatic to complete CP and 
severe ankyloglossia (Margano et al., 2004). Although not a major 
anomaly, the presence of ankyloglossia makes an important diagnostic 
marker for CPX 
Linkage analysis of a large Icelandic family and a native family in British 
Columbia (Canada) connected the Xq21 region to the CPX phenotype 
(Gorski et al., 1992; Stanier et aL, 1993; Gorski et al., 1994). Mutation 
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screening of positional candidate genes in CPX families resulted in the 
identification of TBX22 as the gene responsible for the disorder 
(Braybrook et al., 2001). Mutations were largely unique within families and 
include frame-shift, splice site, nonsense and missense changes 
(Braybrook et al., 2001; Braybrook et al., 2002; Margano et al., 2004; 
Chaabouni et al., 2005) (Table 1.1). 
Since TBX22 was identified as the gene causing CPX, further studies 
have screened non-syndromic cleft palate patients, finding around 4-5% 
with changes in the gene sequence (Margano et al., 2004; Chaabouni et 
al., 2005). By analysing extended families, it has been shown that 20% of 
males carrying a mutation have a cleft palate only, strongly supporting the 
idea that TBX22 is an important genetic factor for random isolated cleft 
palate cases. 
It is worth noting that penetrance of these various features is often variable 
and it is not uncommon to find relatives to the proband with apparently 
isolated clefts. Genes identified as causative for these syndromes may 
often be worth investigating in the general cleft patients population since 
these not-fully penetrant syndromic patients are certainly present in this 
group. 
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Figure 1A Classic phenotypes of X-linked cleft palate with 
ankyloglossia. Patient with mild CPX presenting a bifid uvula (A); 
complete cleft of the secondary palate - notice the nasal septum 
underneath (B); ankyloglossia (tongue-tie). The extended frenulum can be 
seen attaching the tongue tip to the base of the mouth. 
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Table 1.1: Mutations in TBX22, identified in CPX and CPO patients. 
Family Selection' Mutation Exon Effect 
Brazil x2 A -9 C>G 1 5'UTR/Sp 
Filipino x3 RC 72C>T 1 L24L poly 
Brazil A 105-106 delGC 1 Frame shift 
I rish A 166G>T 1 E56X Stop codon 
Brazil RC IVS1 +41-42insA Intronic 
USA x2 RC IVS1 -1 3C>A Intronic/ sp 
UK x 306G>C 2 W102C Missense 
Canada X+A 352G>T 2 G1 18C Missense 
Tunisia X+A 358C>T 3 R120W Missense 
Brazil A 361A>G 3 M121V Missense 
USA RC IVS3+30G>A Intronic 
USA A 548C>T 4 P1 83L Missense 
UK A 600G>T 4 C184F Missense 
Br+USA RC 559G>A 4 E187K poly 
Brazil A 581-582insCAG 4 S195-196ins 
Brazil X+A IVS4+1 G>A Splice site 
UK A IVS4+1 G>A Splice site 
S. Africa A 641 T-C 5 L214P Missense 
Brazil X+A 664delC 5 Frame shift 
Canada X+A 779C>T 5 T260M Missense 
UK A 790A>T 5 N264Y Missense 
Icelandic X+A IVS6+1G>C 6 Splice site 
Brazil x6 RC 883T>C 7 L295L poly 
Br + Filipino RC IVS7+56-57de1C Intronic 
Brazil RC 1544C>A 8 A515E Missense 
Filipino RC 1591 A> G 8 3'UTR 
'Selection criteria: cleft palate was seen in all families, either as a random cleft 
palate (RC), or with X-linkage (X) and/or presence of ankyloglossia (A). 
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1.4. THE T-BOX FAMILY 
Brachyury: the founding member 
The Brachyury or T (for short-tail) mutation was the first recognised 
phenotype due to a T-box gene mutation and was identified 80 years ago, 
(Dobrovolskaia-Zavadskaia, 1927). Absence of T caused homozygous 
mice to die in the embryonic stage lacking a notochord and heterozygous 
progeny to be born with a short tail. The gene was cloned some 60 years 
later, revealing that the T mutation was a deletion of the T gene 
(Herrmann et al., 1990), which codes for a 436 amino acid protein that 
localises into the nucleus (Schulte-Merker et al., 1992). This observation 
suggested that T may have a role in controlling gene expression. 
Later experiments revealed the function of T as a DNA-binding protein and 
used a binding site selection assay to identify a 20 base-pair double 
stranded palindromic oligonucleotide T(G/C)ACACCTAGGTGTGAAATT 
that represents the preferred binding sequence (Kispert and Herrmann, 
1993). Gel shift assays with full length and truncated forms of the protein 
and DNA, sequence showed that: i) one half of the palindrome is not 
sufficient for DNA binding, ii) T most likely binds DNA as a dimer, and iii) 
the N-terminal half of the protein is required for DNA binding (Kispert and 
Herrmann, 1993). Sequence comparisons between T homologues in 
mouse, Xenopus and zebrafish showed that this N-terminal domain was 
conserved between them and it was thus suggested to name this novel 
DNA-binding domain the T domain. 
Using T proteins from various species, T was shown to also bind to direct 
repeats of T half-sites (Kispert et al., 1995; Muller and Herrmann, 1997; 
Papapetrou et al., 1997). Casey et al (Casey et al., 1998) showed that 
Xenopus T (Xbra) could bind to a half-site alone, as a monomer, and 
tested this finding further in a reporter assay that might mimic an in vivo 
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situation more closely. Xbra can bind aT half-site like element in the 
regulatory region of eFGF, a gene that was already thought to genetically 
interact with T in mesoderm formation. This 10 base-pair element located 
around 1 kb upstream of the transcription start site, is conserved in the 
promoter sequences of mouse and human FGF4, the most closely related 
gene to eFGF (Isaacs et al., 1992). 
Transactivation experiments demonstrated that T functions as an activator 
of transcription, up-regulating reporter gene expression through interacting 
with T binding sites of various spacing and orientation. Two activation and 
two repression domains were mapped to the C-terminal part of the protein 
and the activation sites were shown to act additively (Kispert et al., 1995). 
The same study showed some initial evidence that accessory proteins 
might be involved in the transcription regulatory function of the T protein. 
The structure of the T protein bound to DNA was elucidated by X-ray 
crystallography. The DNA-T protein complex appeared as a dimer of two 
T molecules bound to the T palindrome, with the C-terminal helix of the 
protein lying inside an enlarged minor groove of the DNA without bending 
it, and thus presenting a novel protein-DNA interaction (Figure 1.5). The 
DNA-binding occurs via the T-box domain which folds so that certain 
amino acids can make contact with the specific DNA bases of the DNA 
backbone (Muller and Herrmann, 1997). 
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Figure 1.5: A dirner of Xbra T-domains binding to DNA. The T 
palindrome (DNA double helix) is shown in blue; T-domain sheets and 
loops are shown in red, helices in orange. View perpendicular to the DNA 
axis in (a), and rotated by 90' around DNA axis in (b). From Muller and 
Herrmann, 1997 
1.4-b. Identification of a gene/protein family 
Following the identification of its DNA-binding domain, Brachyury was 
suspected to be a member of a protein family because transcription 
factors often appear in families. This speculation was supported when a 
substantial similarity was identified between its T-box domain and the 
protein encoded by the Drosophila gene optomotor-blind (omb) 
(Pflugfelder et al., 1992). Since then, through homology searches and 
genome sequencing, more than 50 T-box genes have been identified in all 
metazoan species, from invertebrates to humans and defined as a family 
of transcription factors that share the T-box domain, an evolutionary 
conserved sequence of around 180 amino acids, (Agulnik et al., 1996; 
Agulnik et al., 1997) (Figure 1.6). Mammalian genomes contain 17 
functional T-box genes, many of which now have well defined roles in 
organism development. Mutations in Drosophila, zebrafish, mouse and 
human have profound developmental effects (Papaioannou, 2001). The 
fundamental role of mammalian T-box genes in development has been 
demonstrated by clinical studies identifying mutations in various family 
members with human congenital disease and some forms of cancer, as 
well as by targeted deletions in the mouse (Packham and Brook, 2003). 
An overview of these genes and a brief description of the phenotype they 
create in human and mouse is given in Table 1.2. 
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TBX22 
TBX22 was first identified in human Xq21.1 through a screen for candidate 
genes for X-linked mental retardation syndromes (Laugier-Anfossi and 
Villard, 2000). In this report, TBX22 was described as an unusual 
truncated member of the T-box protein family, since the 5' UTR and the first 
exon were missing from the cDNA sequence. Based on data from linkage 
analysis and sequencing of CPX patients in a large Icelandic family, and 
families from British Columbia, Brazil, North America and UK areas, TBX22 
was shortly afterwards identified through a positional cloning approach as 
the gene mutated in CPX (Braybrook et al., 2001). The full-length TBX22 
sequence was also identified, now revealing a complete T-box domain, with 
the gene spanning a genomic interval of around 10 kb and to be composed 
of at least 8 exons, with a coding sequence of 1.54kb. 
TBX22 mRNA transcripts were detected by RT-PCR in a range of human 
fetal tissues, including the key tissues involved in palatogenesis, such as 
tongue and mandible, at the time of palate development (8 to 12 weeks). 
Despite expression also detected in heart, eye, brain, limb, stomach and 
kidney, no other organs or tissues appear to be affected in CPX patients. It 
is possible that there might be functional compensation by other T-box 
genes co-expressed in those tissues (Braybrook et al., 2001). 
TBX22 expression has been studied during human, mouse and chick 
embryonic development in more detail using in situ hybridization 
(Braybrook et al., 2002; Bush et al., 2002; Haenig et al., 2002; Herr et al., 
2003). In human embryos, TBX22 is generally expressed in the 
mesenchyme of the developing face by the end of week 6. In particular, 
strong TBX22 signals are seen in the palatal shelves, the nasal septum and 
at the base of the tongue (Figure 1.7a, b). In the palatal shelves, 
TBX22 
expression appears stronger medially than laterally. This expression 
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pattern continues until week 8, while the palatal shelves proliferate, growing 
in a vertical direction either side of the tongue. Expression is markedly 
reduced by week 9, when the shelves have elevated to a horizontal 
position, have made contact and are starting to fuse (Braybrook et al., 
2002). 
The expression of Tbx22 in the mouse and chick supports the data from the 
human (Braybrook et al., 2002; Bush et al., 2002; Herr et al., 2003; Haenig 
et al., 2002). Tbx22 expression follows a similarly restricted spatial and 
temporal pattern, with signals only detected in the craniofacial region at the 
time of palatogenesis (Bush et al., 2002). Interestingly, after the palatal 
shelves have fused, mouse and chick Tbx22 is strongly expressed in the 
mesenchyme surrounding the eyes (Braybrook et al., 2002; Bush et al., 
2002; Haenig et al., 2002). 
The TBX22ITbx22 data from all three species studied are in general 
agreement and there seems to be no major species-specific differences in 
expression. One possible difference between the human and mouse data 
is that in mouse, expression at the site of palate formation seems to last 
longer than in the human. There is expression of Tbx22 around E15.5, at 
the region of palatal shelf contact and fusion and at the base of the nasal 
septum, after fusion. However, this might not be a straightforward 
comparison, since the mouse tissues were also studied at later stages than 
the respective human ones. Thus, it is generally accepted that the mouse 
would make a good model to study Tbx22 deficiency in a potential CPX or 
CPX-like phenotype. 
The data therefore show that Tbx22 is transcribed at the early to mid 
stages of palatogenesis and at the appropriate sites consistent with the 
CPX phenotype. Expression analysis especially in the human suggests a 
role in cell proliferation and elongation of the palatal shelves, since the 
59 
temporal limits of TBX22 expression surround these processes during 
palatogenesis. 
mb mb 
Figure 1.7: TBX22ITbx22 expression analysis. In situ hybridization in 
coronal sections of mouse embryos, using a TBX22- specific probe. 
Expression of TBX22 is seen in the human embryo (42dpo in A, 48 dpo in 
B) in the palatal shelves and at the base of the tongue (Braybrook et al., 
2002); Tbx22 is expressed in a similar pattern in the mouse (E13.5 in C, 
E14.5 in D), and expression ceases when palatogenesis is complete 
(E14.5) (Bush et al., 2002). Note the Tbx22 signals around the eye at day 
E 14.5 (D). 
lý PP'ý . ., ý0 
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1.4. d 
family 
Functional characteristics of the T-box 
Outside the T-box domain, little identity is seen among family members 
despite the similarity between them. In some instances members are 
considered gene pairs, as for example Tbx2 and Tbx3, and Tbx4 and Tbx5 
(Papaioannou and Silver, 1998), however the N- and C-terminal parts 
flanking the T-box domain are generally not conserved. Some of the 
specificity for downstream genes lies within the T-box domain of each 
protein, as demonstrated by the differential induction of target genes by 
isolated T-box sequences from different proteins (Conlon et al., 2001). It is 
likely that different sequences outside the T-box also confer part of the 
specificity, which discriminates between their individual target genes. 
Besides sharing a DNA-binding domain, usually present in the N-terminal 
half of the protein, T-box proteins also appear to share a general 
preference for DNA sequences they recognise and are likely to bind to. All 
T-box proteins studied until now have been shown to be transcription 
factors. They may act either as activators or repressors, although several 
contain both activation and repression domains, for example, mouse 
Brachyury has been shown to act as a transcriptional activator (Kispert et 
al., 1995), yet subsequent experiments have demonstrated the presence of 
both activation and repression sites in its protein sequence (Casey et al., 
1998). 
T-box proteins can exert their function as monomers or through formation 
of homo- and heterodimers; sometimes both monomeric and dimeric 
species can exist for the same protein. A more detailed analysis of the 
basic characteristics of T-box proteins, including some representative 
examples for each one, is presented below. 
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i) DNA Binding Specificity and DNA-protein Complex Formation 
Most of the preferred T-box binding sequences (commonly referred to as T- 
box binding elements or TBEs) that have been described for different T-box 
proteins in some way resemble the originally described T palindromic site 
or just one of the two halves J half-site). Multiple T-box proteins can bind 
to the complete T palindrome and/or the T half-site, but also show binding 
specificity to slightly different DNA sequences, often unique to each protein 
(Tada and Smith, 2001). Where TBEs have been discovered in vivo, the 
majority of these consist of several T half-sites arranged at different 
spacing and orientations. Sequence requirement for the Brachyury protein 
itself appears more stringent, since although other T-box proteins can bind 
to the T site, the T protein does not appear to successfully bind to many 
other TBEs in the reciprocal situation. 
The binding properties of TBX1 and TBX2 were studied in comparison to 
Xenopus Brachyury (Xbra) (Sinha et al., 2000). Rather than identifying 
separate TBEs for each protein, the investigators used the T palindrome 
and half-site in electromobility shift assays (EMSA) to assess recognition 
and binding of the proteins. TBX1 showed very similar binding behaviour to 
Xbra, binding the T palindrome but not the T half-site, while TBX2 could 
bind both DNA fragments equally well (Sinha et al., 2000). Certain 
nucleotide positions within the TBEs, particularly the middle 5'- GTGT -3' in 
both T half-sites were shown to be crucial for protein-DNA interactions in 
both TBX1 and TBX2, while mutations of those nucleotides abolished 
binding (Sinha et aL, 2000). In other reports, Xbra has been shown to also 
bind a palindromic sequence of half-sites arranged at the opposite 
orientation to the original T palindrome, with a spacing of 4 nucleotides 
(Conlon et al., 2001). VegT and Eomesodermin, both T-box genes 
expressed very early in development, can bind to T half-sites and 
palindromic sequences, separated by 3,4 or 5 base pairs; Eomesodermin 
also binds to TBEs arranged in direct repeats (Conlon et al., 2001). 
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Similarly, TBX5 has been shown to bind to both single and paired non- 
palindromic sites (Ghosh et al., 2001). Single TBX5 TBEs are DNA 
fragments that contain the core consensus sequence 
(A/G)GGTGT(C/G/T)(A/G). This sequence also appears in TBEs together 
with a second core sequence, (A/G/T)GGTG(T/C)(T/C/G)(A/G/C). Where 
the second site is present, the two sites appear in tandem or inverted 
orientation, spaced by 1 to 14 nucleotides. As well as its own binding sites, 
TBX5 can bind to the T palindromic site and the T half-site, while the T 
protein will not bind to the TBX5 TBE. 
Some T-box proteins can bind to DNA in both monomeric and dimeric 
forms. Mouse Brachyury binds DNA as a monomer in solution, but can 
show up as a monomer in EMSA reactions, and appears dimerised on its 
DNA sequence in its crystal structure (Kispert and Herrmann, 1993; Muller 
and Herrmann, 1997). DNA binding assays for Xbra and TBX1 have 
shown that they preferentially form dimers as they bind to DNA, while TBX2 
binds to either the T half-site or palindrome as a monomer (Sinha et al., 
2000). VegT, Eomesodermin and TBX5 bind as either monomers or 
dimers, depending on the target DNA sequence. So, VegT binds the T 
palindrome and half-site as a monomer, but dimerizes on a sequence of 
two TBEs arranged tail to tail spaced by four nucleotides, while 
Eomesodermin binds to the latter sequence as a monomer, and dimerizes 
on two TBEs spaced by 3 to 5 bases and arranged in a direct repeat or 
head-to-head (Conlon et al., 2001; Ghosh et al., 2001). TBX5 binds as a 
dimer to paired TBEs arranged tail-to-tail spaced by up to nine bases, while 
monomeric binding is seen with single TBEs and paired sequences in 
similar arrangement to the T palindrome, regardless of spacing (Ghosh et 
al., 2001). 
It has been shown that addition of specific antibodies can stabilize the 
DNA-protein complex. For example, this is the case for mouse T and Xbra, 
with the T/Xbra-DNA complex appearing stronger upon addition of antibody 
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(Kispert and Herrmann, 1993; Sinha et al., 2000). In contrast, TBX1-, 
TBX2-, and TBX5-DNA complexes show the same intensity in the presence 
or absence of antibodies (Sinha et al., 2000; Ghosh et al., 2001). 
ii) Regulation of transcription and target genes 
Potential target genes for different T-box proteins have been suggested 
based on expression studies in normal and mutant genetic model 
organisms. Some of these results have been complemented by molecular 
biology techniques, to show direct and functional interactions between the 
macromolecules in vivo. TBE sequences have often been identified in the 
regulatory regions of target genes and regulation through direct binding to 
these sequences has been demonstrated. For example, the Brachyury 
homologue in Ciona intestinalis binds to 5' T half-sites present in the 
enhancer region of Ci-tropomyosin-like, a protein involved in cellular 
morphogenesis (Di Gregorio and Levine, 1999; Takahashi et al., 1999). 
The half-sites are arranged in three sequences: one tandem repeat, one 
inverted repeat and a single half-site. Xenopus Brachyury (Xbra) activates 
eFGF through binding to TBE sequences 2.5kb upstream and 123 bases 
downstream of the eFGF transcription start site, and there is some 
evidence for a regulatory loop between the two proteins (Smith et al., 1997; 
Tada et al., 1997; Casey et al., 1998). The distal of the two TBE 
sequences is a perfect T half-site, while the proximal one, in the 5' UTR, is 
a closely related sequence (AACCACACCT) (Casey et al., 1998). The 
presence of the TBEs is conserved in the promoter region of mouse and 
human FGF4, a homologue of eFGF (Isaacs et al., 1992; Casey et al., 
1998). Another Xenopus T-box gene, VegT, activates Bix4 and Xnrl (a 
TGFbeta growth factor) through binding to TBE sequences in their 
regulatory regions (Tada et al., 1998; Kofron et al., 1999; Hyde and Old, 
2000). There are three T-box binding sequences upstream of Bix4 and two 
in the Xnrl promoter. Xbra can also bind the Bix4 sites, but induction of 
Bix4 by VegT appears more efficient (Casey et al., 1998; Tada et al., 1998). 
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In mammals, T-box proteins can activate or repress the expression of 
reporter genes driven by one or more TBE sequences, but also native 
promoters that contain TBE or TBE-like sequences. T and TBX5 are potent 
activators of transcription, while TBX2 and TBX3 mainly act as repressors, 
but contain activation and conserved repression domains (Carreira et al., 
1998; He et al., 1999; Sinha et al., 2000). Human TBX2 represses 
transcription of a luciferase reporter construct containing 4T half-sites, 
while TBX1 had no effect on the same construct, even though both proteins 
could bind the DNA sequence in EIVISA reactions (Sinha et al., 2000). 
Similarly, mouse Tbx2 binds to T half-sites upstream of the tyrosine-related 
protein 1 (TRP-1) and represses transcription in melanocytes (Carreira et 
al., 1998). 
Both TBX2 and TBX5 have been shown to interact with Nkx2.5 and 
modulate the atrial natriuretic factor (ANF) through binding to T-box 
elements (TBE) and NKE on its regulatory regions (Ghosh et al., 2001; 
Habets et al., 2002). The Tbx2-Nkx2.5 complex represses while Tbx5 and 
Nkx2.5 are components of the activation pathway of the ANF promoter 
(Tanaka et al., 1999; Bruneau et al., 2001). The genetic relationship of 
these factors has been demonstrated both in vivo and in cell culture 
transcription assays. It has been suggested that Tbx2 may have a role in 
the variable phenotype of Holt-Oram syndrome, together with Tbx5 and 
Nkx2.5 mutations, especially in the AVC cardiac region where all three 
genes are expressed (Habets et al., 2002; Kasahara and Benson, 2004). 
The activation potential of mouse Tbrl is enhanced by its interaction 
between this protein and the membrane- associated guanylate kinase 
CASK/LIN2. The Tbrl- CASK/LIN2 complex can induce reporter gene 
expression through binding to two T half-sites in the promoter of the reelin 
gene (Hsueh et al., 2000). The developmental phenotypes of mice 
deficient in reelin are very similar to Tbrl-l- animals. 
65 
Thus, T-box proteins can regulate their individual target genes through 
binding to TBE sequences in their promoter regions, and this interaction is 
often facilitated by accessory proteins that may stabilize the DNA-protein 
complex, connect two T-box proteins bound to T-box sites in close 
proximity, or determine the activation or repression potential of the T-box 
protein (Papaioannou, 2001). 
1.5. EUKARYOTIC TRANSCRIPTION FACTORS 
The central dogma of molecular genetics states that DNA is transcribed to 
RNA, which is in turn translated into protein. Thus, to transfer from the 
genotype (DNA) to the corresponding phenotype (protein) the genetic 
information must be converted into an RNA intermediate. Transcription 
factors are the main proteins facilitating this process and can act in a 
number of ways. Traditionally in eukaryotic cells, most transcription factors 
were thought to be activators of transcription, since due to the tight 
chromatin structure, gene activation was usually regarded as the relief of 
repression. In more recent years, however, increasing numbers of 
transcriptional repressors have been identified in eukaryotes, supporting 
the theory that repressor proteins are not restricted to gene regulation in 
prokaryotic organisms (Latchman, 1991). 
If binding to DNA is a prerequisite for a protein to affect transcription, it is 
certainly not sufficient. Interactions with other proteins, co-factors or RNA 
polymerases are as important in achieving correct gene regulation. Studies 
of transcription factors over the years have illustrated a generic structure of 
these proteins. Transcription factors are classically modular proteins, with 
distinct domains along their amino acids sequence, which are dedicated to 
specific functions. Hence they will usually possess a DNA-binding domain, 
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one or more activation or repression domains - sometimes both - and 
possibly homo- or heterodimerization domains, interaction domains with 
other proteins, cofactors or hormones. In some cases there can be an 
overlap between some of the above domains, but generally the DNA- 
binding and the activation or repression modules tend to be distinct and 
able to separate from each other. 
Mammalian Transcriptional Repressors 
Transcriptional repressors can be categorised into two classes: i) the 
passive repressors, that do not have intrinsic repressor ability and ii) the 
active repressors that do. Although the function of both types results in 
inhibition of gene expression, they use different mechanisms to reach this 
result (Thiel et al., 2004). 
Passive repressors exert their repression role mainly by preventing the 
function of activators. This is achieved by blocking the binding site for 
activators or by immobilizing the activator outside of the nucleus. Because 
they have DNA-binding domains and can recognise and bind to specific 
sequences, as all transcription factors, the simplest way of achieving 
repression is to bind to a DNA element in a regulatory region, and prevent a 
transcriptional activator from binding to the same sequence. The repressor 
protein can also bind to sequences on a promoter adjacent to the elements 
that bind activators and neutralise the activity of those proteins, for example 
by blocking the availability of their activation domains. Another way of gene 
silencing does not require the repressor binding to DNA and involves 
formation of a protein-protein complex between the repressor and the 
activator protein. In this complex the activator is sequestered, often in the 
cytosol, and cannot bind to the promoter element and activate transcription 
(Latchman, 1991; Ogbourne and Antalis, 1998). 
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Active transcriptional repressors in mammals have an intrinsic repression 
activity that targets the chromatin structure of the genome. Repression can 
occur in two ways, either by histone deacetylation or via histone 
methylation and formation of heterochromatin. Transcriptional repressors 
can recruit histone deacetylases in a promote r-s pecifi c way, either by 
binding to them either directly or via adaptor proteins and corepressors. 
Deacetylation of histones increases their binding affinity for DNA and 
maintains a compact nucleosome with the DNA wrapped around the 
histone octamer inaccessible to transcriptional activators (Ng and Bird, 
2000; Ng et al., 2000; Free et al., 2001). Methylation of DNA has also been 
linked with transcriptional repression. Methylated DNA can block the 
sequence-specific binding of transcriptional activators and result in 
repression of gene expression. Some transcriptional repressors have a 
specificity for methylated DNA, interacting with the DNA via a methyl-CpG- 
binding domain and recruiting histone deacetylases to the site, thus 
resulting in a denser chromatin structure and gene silencing (Nan et al., 
1993; Nan et al., 1997; Jones et al., 1998). 
1.6. PROTEIN MODIFICATION BY SUMO 
The small ubiquitin-related modifier (SUMO) belongs to a large family of 
proteins related to ubiquitin (Ub) and the small ubiquitin-like proteins (Ulp). 
The overall sequence identity with ubiquitin is small (around 18%), but the 
C-terminus of the protein, which confers most of its activity, is almost 
superimposable to the equivalent region of ubiquitin (Bayer et al., 1998; Jin 
et al., 2001). Although SUMO shares similar attachment mechanisms to 
Ub, its function is completely different, and sometimes counteractive to the 
ubiquitin pathway. Conjugation of SUMO can block the sites of attachment 
for ubiquitin, and can thus protect proteins from degradation. 
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Attachment of SUMO to target proteins occurs via an isopeptide bond 
between the glycine residue at the C-terminal end of SUMO to the E-amino 
group of an internal lysine residue within the substrate. Enzymes 
analogous to the ubiquitin pathway, but specific for SUMO modification, 
catalyze the formation of this bond in four steps (Hay, 2005). The SUMO 
peptide is initially translated as a precursor ending with the GGHSTV 
sequence at its carboxyl end. Proteolytic cleavage of the last four amino 
acids of this sequence converts SUMO to its mature form. SUMO-specific 
peptidases, for example members of the sentrin-specific protease (SENP) 
family, catalyse this step. SUMO-activating enzymes, also called El, 
activate the mature SUMO in an ATP-aependent reaction. Active SUMO is 
then transferred onto the E2 SUMO-conjugating enzyme Ubc9. 
Conjugation of SUMO to target proteins occurs through Ubc9 with the aid of 
an E3 ligase (Gill, 2005). Substrate specificity for SUMO is conferred by 
both Ubc9 and various E3 ligases, the former by forming the covalent 
attachment of SUMO to its targets, while the latter probably interacts with 
other areas of the substrate and provides more specificity (Melchior et al., 
2003; Hay, 2005). 
A general consensus recognition site for SUMO attachment is VKXE (Minty 
et al., 2000; Rodriguez et al., 2001), where V is a large hydrophobic amino 
acid, like leucine, isoleucine or valine; K is the lysine residue at which the 
attachment takes place; X is any amino acid, and E is a glutamic acid. 
Although this consensus site is conserved, a number of alternatives have 
been described, where for example aD can be present at the position of 
the E, or the amino acid before the lysine can be a different one from the 
three consensus residues. Other sequences may also be involved, since in 
some cases, proteins have been shown to be sumoylated that either do not 
contain the consensus site, use a different motif for binding SUMO (Song et 
al., 2004), or maintain sumoylation after the site has been mutated. More 
extensive SUMO recognition motifs have also been described; it has been 
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suggested that acidic residues downstream of the core SUMOylation motif 
have a role in enhancing specificity for substrates (Yang et al., 2006). 
Besides ubiquitination, other modifications have been associated with the 
SUMO modification process. SUMOylation of proteins including GATA1 
and heat shock factors HSF1 and HSF4b has been shown to be dependent 
on their phosphorylation status. A phosphorylation-dependent 
SUMOylation motif (PIDSM) has been described for such proteins 
(Hietakangas et al., 2006). Furthermore, the association of SUMO with 
histones supports a role in genome organization and stability. Histone 
deacetylases, including HIDAC2 and HDAC6, have been shown to 
preferentially interact with SUIVIO-modified substrates (Girdwood et al., 
2003; Yang and Sharrocks, 2004). It has been suggested that 
deacetylation of histones by HDAC enzymes may make more lysine (K) 
residues available for SUMOylation (Gill, 2005). A SUMOylation switch 
based on acetylation/deacetylation has been described (Stan kovic-Valentin 
et al., 2007), and increased SUMOylation of H4 correlates with decreased 
acetylation of the gene, when Ubc9 is targeted to the promoter region 
(Shiio and Eisenman, 2003). 
SUMO attachment is a reversible and highly transient modification. The 
same enzymes that facilitate the initial maturation of SUMO molecules also 
catalyse the cleavage from their substrates (Hay, 2005). Six members of 
the SENIP family in human tissues, SIENIPs 1-3 and 5-7 have been shown to 
be SUMO-specific proteases (Melchior et aL, 2003). In contrast to the 
SUMO-conjugating enzymes, SUMO proteases are not similar to the 
equivalent enzymes in the ubiquitin pathway, but the homology they share 
appears closely related to viral proteases (Azuma et al., 2001). Differences 
in the sub-cellular localization of the SENIP proteins is believed to be 
dictated by non-conserved N-terminal sequences, and provides the 
specificity for the SUMO-substrate complexes they regulate (Bailey and 
O'Hare, 2004; Mukhopadhyay and Dasso, 2007). SENP1 is localized 
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mainly in the nucleus with little, albeit persistent, cytoplasmic presence 
(Gong et al., 2000; Bailey and O'Hare, 2002); SENP2 is associated with the 
nuclear pore (Hang and Dasso, 2002); SENP3 and SENP5 are nucleolar 
(Gong and Yeh, 2006), while contradictory reports place SENP6 in both the 
nucleoplasm and the cytosol (Kim et al., 2000; Mukhopadhyay et al., 2006). 
Since the SUMO species described to date are predominantly nuclear, the 
mainly nuclear localization of the SENP proteins is perhaps expected 
(Ayaydin and Dasso, 2004). Specificity may still be achieved through the 
sub-nuclear location of each protease. 
SUMO is highly conserved in all eukaryotic cells, and in higher organisms it 
is present in all tissues and developmental stages. It has been shown to be 
essential for cell viability both at the organism level and in cells in culture. 
The number of SUMO genes differs between organism families, and there 
are four SUMO species in mammals, termed SUIVIO-1, SUMO-2, SUMO-3 
and SUMO-4. SUMO-4 is the most recently identified gene, through an 
86% similarity to SUIVIO-2. mRNA transcripts show limited expression 
compared to the other SUMO species, and are present mainly in kidney, 
lymph system and spleen (Bohren et al., 2004). No native SUMO-4 protein 
has yet been detected in any tissue, and it has been suggested that 
SUMO-4 might be an expressed pseudogene (Bohren et al., 2007). 
SUMO-1 is 50% identical in sequence to SUMO-2 and -3, while SUMO-2/3 
share a 95% identity. This observation translates to functional activity as 
well; activity of SUM02/3 is almost indistinct, while SUMO-1 has a 
dissimilar function. Furthermore, SUMO-1 is rarely found unattached within 
cells, but there are pools of free SUMO-2/3 available (Saitoh and Hinchey, 
2000). There is a preference between SUMO-1 and SUMO-2/3 in 
conjugation to certain proteins, but others can be modified equally well by 
both SUMO species. The SUMO protein sequence is around 100 amino 
acids, with a molecular weight of -11 kDa, but when modified substrates are 
analysed by SDS-PAGE gels, the extra molecular weight often appears 
nearer 20kDa (Johnson, 2004). 
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SUMO attachment has been implicated in a number of cell processes, such 
as transcription, nuclear transport, DNA repair, cell cycle and chromatin 
structure. Although its function is as diverse as its substrates, one 
generalisation could be that modification of a protein substrate by SUMO 
alters its interactions with other protein and DNA molecules. In mammalian 
systems studied so far, SUMO modification has been associated mostly 
with transcriptional repression. 
At any given time, only a very small amount of substrate is modified, 
usually around 1%. This may be one reason why SUMO and the modified 
forms of substrate proteins were only recently discovered (Johnson, 2004). 
Since its identification, however, a great many proteins that are modified by 
SUMO species are now being revealed, and the various effects of the 
modification are beginning to be elucidated. 
1.7. AIMS OF STUDY 
Identifying genes responsible for an inherited birth defect will have the 
immediate benefit of allowing both screening and genetic counselling for 
parents. This has been the case with TBX22 and X-linked cleft palate. 
Furthermore, identification of genes that function in the same molecular 
cascade are likely to provide novel candidate genes that may involve 
similar phenotypes and will facilitate further screening. These cases 
provide important models to provide insight into the pathways leading to 
normal development and fusion of the palatal shelves. The identification of 
genes and factors, both upstream and downstream of TBX22, will reveal 
valuable information about embryonic development and disruption of 
mechanisms that can lead to disease. TBX22 is also very interesting o 
study as an example of the T-box family of genes. Previous studies 
have 
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shown that family members are involved in a variety of developmental 
processes across many species of the animal kingdom. Mutations of these 
genes in various species have shown profound phenotypes ranging from 
lack of specific somite development to cardiovascular abnormalities and 
embryonic death. 
The principal goal of this study was therefore to understand the functional 
role of TBX22 in craniofacial development. It was intended to perform 
functional assays to investigate binding site specificity and transcriptional 
regulation as well as to determine whether TBX22 acts as a transcriptional 
activator or repressor. It was anticipated that this information would assist in 
the identification and characterisation of possible downstream target genes. 
In addition it was also intended to make use of naturally occurring 
mutations identified in patients with CPX, to use as tools to investigate 
perturbation of normal function. This will aid in our understanding of their 
role in the causality of an abnormal phenotype. Most of the known 
missense mutations in TBX22 alter amino acids within the T-box domain, 
which is the region of the protein thought to make contact with the target 
gene(s) promoter sequence. Furthermore, all of these mutations result in 
more or less the same classical CPX phenotype. In males with only one 
gene copy, it can be inferred that the phenotype arises from complete loss 
of TBX22 function. Thus, a selection of these mutations was chosen to 
study their effects compared to the wild-type protein. Mutant proteins will 
be screened for effects on DNA-binding and transcriptional regulation as 
well as altered localization within the cell and their ability to be post- 
translational modified. These studies will complete the first stages of 
functionally characterizing TBX22. 
CHAPTER 2: MATERIALS AND METHODS 
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MATERIALS & METHODS 
MATERIALS 
Chemicals & Solvents 
All chemicals and solvents used were of analytical grade and obtained from 
VWR, Merck House, Poole, UK. Additional reagents used as follows: 
30% Acrylamide/Bis solution (37.5: 1) Sigma-Aldrich 
Agarose Bioline 
Ammonium persulphate (APS) Sigma-Aldrich 
Ampicillin Sigma-Aldrich 
Bromophenol blue Sigma-Aldrich 
Crystal violet Sigma-Aldrich 
Ethidium bromide BDH Electran 
HEPES buffer (1 M) Sigma-Aldrich 
Imidazole Qiagen 
Isopropyl-b-D-thiogalactopyranoside (IPTG) Bioline 
Nonidet-P40 Fluca Biochemica 
NEM Sigma 
Phenol Invitrogen 
PMSF Sigma-Aldrich 
Sodium acetate Sigma-Aldrich 
TEMED Sigma-Aldrich 
Triton-X BDH Chemicals 
Tween 20 BDH Chemicals 
p-mercaptoethanol Sigma-Aldrich 
Radiochemicals 
[32p] y-ATP, Amersham Biosciences Ltd. 
-600OCi/mmol, lOmCi/ml 
Enzymes 
Calf intestinal alkaline phosphatase (CIP) MBI Fermentas 
Restriction endonucleases Promega, 
New England Biolabs (NEB) 
Rnasin RNase inhibitor Promega 
T4 DNA ligase Promega & Fermentas 
T4 polynucleotide kinase Promega 
Taq DNA polymerase Bioline 
Membranes 
Hybond ECL nitrocellulose Amersham Biosciences 
Miscellaneous 
Big-Dye Terminator III (BDT) Applied Biosystems, 
Cheshire, UK 
Blue/Orange loading dye, 6x (agarose gel 
electophoresis of DNA samples) Promega 
Cling film Saran 
Coelenterazine substrate Calibrochem, Beeston, UK 
Complete protease inhibitors Roche 
DNA ladders Promega 
DNA midiprep kit Qiagen 
ECL Western blotting detection kit Amersham Biosciences 
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Filtration units 
FuGENE transfection reagent 
LucLite reporter gene assay kit 
Nucleotide triphosphates 
Oligonucleotides 
Orange G 
Protein A/G sepharose 
Rainbow protein markers 
QuikChange site-directed mutagenesis kit 
Skimmed milk powder 
Wizzard plus SV miniprep DNA purification kit 
Midiprep DNA purification kit 
TOPO cloning kit 
Millipore 
Roche 
Packard, Groningen, Holland 
Promega/Invitrogen 
I nvitroge n/Thermo- Electron 
Sigma 
Sigma 
Amersham 
Stratagene 
Merck, Darstadt, Germany 
Promega 
Qiagen 
Invitrogen 
TNT Coupled Transcription/Translation system Promega 
Dual-luciferase reporter assay system Promega 
Plasmids 
pcDNA3.1 V5/His 
pGL3 Basic 
pGL3. hPO(T22) 
pSP64G. myc 
pSP64G. TBX22. myc 
pcDNA3. T. myc 
pcDNA3. TBX8. myc 
pcDNA3. TBX18. myc 
pcDNA3. TBX2. FLAG 
pcDNA3. TBX1 
pRL-CMV 
pSG5-SUMO-1 (wild type) 
pSG5-SUMO-1-GG 
pcDNA3-FH-SENP1 
Invitrogen 
Promega 
E. Pawus, our laboratory 
A. Kispert, Hannover, Germany 
A. Kispert, Hannover, Germany 
A. Kispert, Hannover, Germany 
A. Kispert, Hannover, Germany 
A. Kispert, Hannover, Germany 
C. Godding, UK 
P. Scambler, ICH, London, UK 
Promega 
J. Brosens, IRDB, London, UK 
J. Brosens, IRDB, London, UK 
J. Brosens, IRDB, London, UK 
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pcDNA3-FH-SENPlC603S (inactive) 
pCMV-Tag2B-Flag-SENP2 
pCMV-Tag2B-Flag-SENP2(71-590) 
(hyperactive fragment) 
Bacterial Strains 
XL-1 0 
XL-1 Blue 
JM109 
TOPO-10 
Antibodies and Probes 
Primary 
Anti-V5 mouse monoclonal 
Anti-myc mouse monoclonal 
Anti-FLAG mouse monoclonal 
Anti-TBX22 rabbit polyclonal 
Anti-GMP1 (a-SUMO-1) mouse 
monoclonal 
Secondary 
Rabbit anti-mouse HRP 
Goat anti-rabbit-HRP 
Donkey anti-mouse-FITC 
J. Brosens, IRDB, London, UK 
J. Brosens, IRDB, London, UK 
J. Brosens, IRDB, London, UK 
Stratagene 
Stratagene 
Promega 
Invitrogen 
Invitrogen 
Roche 
Sigma 
CovalAb (custom made) 
Zymed 
Sigma 
Sigma/DACO 
Jackson Laboratories Inc., USA 
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Buffers and Solutions 
All solutions were made with Milli-Ro cleionised water and were stored at 
room temperature, unless otherwise stated. 
Protein Extraction Buffers 
Buffer A (cytosolic) 10 mM HEPES, 10 mM KCI, 0.1 mM 
EIDTA, 0.1 mM EGTA, 2 mM IDTT, 
Complete Protease Inhibitors (Roche). 
Stored at 
-20'C 
Buffer B (nuclear) as buffer A, with 400 mM NaCl and 1% 
NP-40. Stored at -200C 
IP lysis buffer 20 mM Tris-HCI pH 7.5,300 mM NaCl, 
1% NP-40,10 mM NEM, Complete 
Protease Inhibitors 
Western Blot Buffers 
RIPA buffer (cell extraction) 1% NP-40,1% TRITON X-100,1% 
sodium deoxycholate, 0.1% SDS, 150 
mM NaCl, 10 mM Tris (pH 8), 2 mM NaF 
Gel Juice 50 mM Tris-HCI, pH 6.8,50 mM 
imidazole, pH 6.81 1% w/v SIDS, 10% v/v 
glycerol, 
2% v/v P-mercaptoethanol, 0.002% 
bromophenol blue 
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Laemli buffer 62.5 mM Tris-Hcl (pH 6-8), 0.01% SIDS, 
0.025% P-mercaptoethanol, 25% 
glycerol, 0.005% bromophenol blue (1% 
in EtOH) 
lOx Running buffer 0.247 M Tris-Base, 1.9 M glycine, pH 8.3. 
When ready to use, add 0.1 % SDS 
Transfer buffer 1x Running buffer plus 20% methanol 
and 0.05% SIDS 
Washing buffer (PBST) Phosphate buffered saline plus 0.05% 
Tween 20 
Blocking buffer PBST plus 5% skimmed milk powder 
Polyacrylarnicle gel (7.5-12%) 1.5 -2 ml 30% acrylamide/ 0.8% 
bisacrylamide, 1.2 ml 1.88 M Tris-Hcl (pH 
8.8), 1.2 ml 0.5% SIDS. Make up to 6 ml 
with H20 and add 10[d TEMED and 60[d 
10% APS 
EMSA Buffers 
BBO Buffer 25 mM HEPES, 75 mM NaCl, 10% 
glycerol, 0.25% EDTA, 0.1% NP-40,1 
MM MgC12. Just before use, add 10[tg/ml 
BSA, 1 mM IDTT, 1 mM PIVISF and 1x 
Complete Protease Inhibitors (Roche) 
lOx Running buffer (TG buffer) 142 g glycine, 30 g Tris base, 3.95 g 
EDTA in 11 of H20. Adjust pH to 8.3. 
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Poly-acrylamide gel (4.5%) 15 ml 30% acrylamide/ 0.8% 
bisacrylamide, 10 ml 10x running buffer. 
Make up to 100 ml with H20 and add 200 
[d TEMED and 500 [d 10% APS. 
DNA Electrophoresis 
Agarose gel (0.8-2%) Gels were prepared by dissolving 0.8-2 g 
of agarose in 100 ml TAE buffer 
TAE buffer (lx) 40 mM Tris, 20 mM acetic acid, 1 mM 
EDTA 
Gel loading buffer (Orange G) 1.5g Ficoll 400, H20 to 10 mL- add small 
amounts of Orange G dye, until solution 
colour is dark orange. 
Crystal violet agarose gel 1% agarose in TAE buffer with 0.1 mg/mI 
crystal violet 
TE buffer 10 mM Tris-HCI pH 8.0,1 mM EDTA pH 
8.0 
Reporter Assay Buffers 
Renilla buffer 0.5 M HEPES pH 7.8,40 mM EDTA 
Renilla reagent 10 ng/[tl Coelenterazine in Renilla buffer. 
Stored at -200C 
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Bacterial Media 
L-agar 
L-broth 
2YT medium 
TB (transformation buffer) 
1% w/v bactotryptone, 0.5% w/v yeast 
extract, 0.5% NaCl, 0.1% glucose, 1.5% 
bactoagar 
w/v bactotryptone, 0.5% w/v yeast 
extract, 0.5% w/v NaCl, 0.1 % w/v glucose 
1.6 % w/v bactotryptone, 1% w/v bacto 
yeast extract, 0.5% NaCl. pH adjusted to 
7.0 with NaOH 
10 mM PIPES, 15 mM CaC12,250 mM 
KCI, adjust pH to 6.7 with KOH, add 55 
mM MnC12, filter-sterilize. Stored at 40C. 
Cell Culture Materials and Media 
All media stored at 40C, unless otherwise stated. 
Dulbecco's Modified Eagle's Medium (DMEM), 
with and without 1 mg/ml phenol red 
Foetal Bovine Serum 
20C) 
Optimem 
Pen icill in/Streptomycin 
L-glutarnate 
Non-essential amino acids 
Trypsin-EDTA 
Sigma 
Sigma (stored at - 
Gibco BRL 
Sigma 
Gibco BRL 
Gibco BRL 
Gibco BRL 
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Freezing medium 
Tissue culture plastic ware 
2.2 METHODS 
2.2. a. Bacteria 
Storage of bacteria 
60% FCS, 30% DMEM, 10% DMSO 
Corning, Falcon, NUNC, Orange 
The Escherichia coli strains JM109 and XL-10 were used for the 
propagation of most plasmids. The pcDNA3.1. TBX22. V5/His construct was 
transformed and propagated into TOPO 10 cells, while plasmids created 
through in vitro mutagenesis were maintained in XL-1 Blue cells. All 
plasmids used in this thesis carried the ampicillin resistance gene. 
Bacterial transformants were grown in L-broth (LB) or on L-agar containing 
100 [tg/ml ampicillin. Bacteria were stored in 50% (v/v) glycerol in L-broth 
with ampicillin, at -80'C. 
Preparation of chemically competent bacteria 
Bacteria were streaked out on L-agar plates without antibiotic and 
incubated at 370C overnight (o/n). Single colonies of the appropriate strain 
were then picked and used to inoculate 10 ml of LB. The culture was 
incubated o/n at 37'C, with continuous shaking at 250 revolutions per 
minute (rpm). 250 ml of 2YT medium was inoculated with the overnight 
culture and grown at room temperature (RT) with 250 rpm shaking, until the 
bacteria reached an OD600of 0.6. The culture was then placed on ice for 
10 minutes, centrifuged for 10 minutes at 2,500 times gravity (xg), at 40C 
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and the pellet gently re-suspended in 80ml of cold TB buffer. The cooling 
and centrifugation steps were repeated and the new pellet was re- 
suspended in 20 ml of cold TB buffer, to which DIVISO was added to 7%. 
The solution was cooled on ice for 10 minutes, aliquoted and snap-frozen in 
liquid N2. Samples were stored at -800C. Transformation efficiency was 
tested after the overnight storage and found to be around 107 CfU/ý, g. 
Transformation of competent bacteria by heat shock 
Competent cells were thawed on ice and typically, 50 [il or 100 [tl of cells 
were used for the transformation of pre-chilled supercoiled DNA and 
ligation products respectively (less than 1 ng DNA per pl cells). After 15 
minutes on ice, cells were heat shocked at 420C for 90 seconds and then 
returned on ice for a further two minutes. 250 pl LB was added to the 
reaction and the cells were incubated at 37'C for 45 minutes. Finally the 
cells were spread on L-agar plates containing 100 [tg/ml ampicillin, left for 
15 to 30 minutes at RT for the suspension to become absorbed into the L- 
agar, and then plates were inverted and incubated at 370C o/n. 
2.2. b. Cell Culture 
Maintenance of cell stocks 
Mammalian cells were routinely grown in a monolayer in 75 CM2 tissue 
culture flasks (T-75) at 37'C in a humid atmosphere maintained at 5% (v/v) 
carbon dioxide (C02)- Cells were cultured in Dulbecco's Minimum 
Essential Medium (DMEM) supplemented with 2 mM L-glutamate, 10% v/v 
fetal bovine serum (FBS), 0.1 mM non-essential amino acids and 50 
units/ml penicillin/streptomycin solution. Cells were typically seeded at 1/10 
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dilutions and passaged once a week, as follows: the medium was removed 
from the flask and the cells were washed with 5 ml of phosphate-buffered 
saline (PBS). 1 ml of trypsin-ethylenediaminetetraacetic (trypsin-EDTA) 
solution was added to the flask and the cells incubated at room 
temperature for 5-15 minutes. Most cells came off the flask after this time, 
aided by gentle tapping to dislodge any remaining cells, and were collected 
by adding 4 or 9 ml of complete medium (DMEM with supplements) to 
neutralise the trypsin. The cell suspension was transferred to 15 ml or 50 
ml tubes and aerated by vigorous pipetting up and down. A suitable 
dilution was made by adding part of the suspension to 10-13 ml of medium 
for a T-75 flask, and cells were incubated as normal. 
Freezing and Thawing Cells 
Typically 2 or 3 T-75 flasks were used for a freezing round for each cell line. 
Cells were seeded with trypsin-EDTA, as described above, and counted in 
a haemocytometer. The suspensions were centrifuged at 1800 rpm for 8 
minutes and pellets were re-suspended in Freezing Medium. According to 
the cell counting, 1 ml of Freezing Medium was used for every million cells, 
and the end suspension was divided between labelled cryogenic vials, 
adding 1 ml in each vial. The cells were frozen in a cryogenic chamber 
(surrounded by propanol) at -80'C o/n, and transferred to liquid N2 storage 
on the next day. 
For thawing cells, vials were removed from liquid nitrogen storage and 
thawed rapidly in a 37'C water-bath. Cells were transferred to 15 ml 
conical bottom tubes and re-suspended slowly in 10% FIBS in DMEM, drop 
by drop, to a 10 ml final volume. Suspensions were centrifuged at 1800 
rpm for 6-8 minutes, the supernatants discarded and the pellets re- 
suspended in 100 [d and then 1 ml of complete medium. The volume was 
taken up to 4 ml, the cells were placed in a T-25 flask and incubated under 
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normal conditions, usually for 2-3 days, before being transferred into a T-75 
flask. 
2.2. c. DNA Manipulation and Cloning 
Preparation of Plasmid DNA 
Depending on the quantity required, plasmid DNA was prepared by both 
small and medium-scale methods. 
Small-scale preparation of plasmid DNA (Mini-prep) 
The Wizard Plus SV miniprep DNA purification system (Promega) was 
routinely used to prepare up to 20 [tg of high copy plasmid DNA. Single 
colonies were used to inoculate 5 ml LB medium containing 100 [tg/ml 
ampicillin and incubated o/n at 37'C with 180 rpm shaking. The bacterial 
culture was harvested by centrifugation at 2,500 xg for 15 minutes and the 
plasmid DNA prepared according to the manufacturers' instructions. 
The procedure is based on alkaline lysis of bacterial cells followed by 
adsorption of the DNA onto silica in the presence of high salt. The alkaline 
denaturation method exploits the difference in denaturation and 
renaturation characteristics of circular plasmid DNA, which is covalently 
closed, and chromosomal DNA fragments. Bacteria were lysed under 
alkaline conditions in the presence of RNase A, and the lysate was 
subsequently neutralised and adjusted to high-salt binding conditions, for 
purification on silica-gel membrane. The membrane allowed selective 
adsorption of plasmid DNA in a high-salt buffer. The salts were then 
removed by an ethanol-based wash and the DNA eluted in an aqueous 
low-salt buffer, 100 [d of either Tris-EDTA (TE) buffer or water, depending 
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on the later use of DNA. Plasmid DNA prepared this way was used for 
transient transfections and sequencing. 
Medium-scale preparation of plasmid DNA (Midi-prep) 
The Qiagen midiprep kit was routinely used to prepare up to 200 [Ig of high- 
copy plasmid DNA. Single colonies were used to inoculate 2 ml of LB 
containing 100 [tg/ml ampicillin and grown for 7 hours at 370C with 180 rpm 
shaking. The culture was then taken up to 100 ml with LB and incubated 
under the same conditions o/n. 25 ml of the culture were harvested by 
centrifugation at 2,500 xg for 15 minutes at 4'C and the plasmid DNA 
purified from the bacterial pellet according to the manufacturers' 
instructions. 
The protocol is based on a modified alkaline lysis procedure in which 
bacterial cells are lysed in sodium hydroxide- sodium dodexylsulphate 
(NaOH-SDS) in the presence of RNase A. SDS solubilises the 
phospholipid and protein components of the cell membrane, leading to cell 
lysis and release of the cell contents. NaOH denatures proteins and the 
chromosomal and plasmid DNA, while RNase A digests the RNA released 
during lysis. The lysate was neutralised by acidic potassium acetate and 
the denatured proteins, chromosomal DNA and cellular debris precipitated 
in salt-detergent complexes. Plasmid DNA re-natured and remained in 
solution, because it is smaller and covalently closed. Bacterial lysates were 
cleared by centrifugation, where debris was precipitated and plasmid DNA 
remained in the supernatant. This clear supernatant was loaded onto a 
pre-equilibrated anion-exchange column, which operates by gravity flow 
under specific salt and pH conditions. Plasmid DNA binds to the column, 
while RNA, protein and other impurities are washed into the flow-through. 
A high-salt buffer was used to elute the plasmid DNA from the column. The 
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eluted DNA was then desalted and concentrated by isopropanol 
precipitation followed by a wash with 70% ethanol. The DNA pellet was air- 
dried and dissolved in 100 [d of TE buffer, pH 8.0. The DNA concentration 
and purity were determined by measurement of the OD2ro and OD280on a 
spectrophotometer. 
Extraction of DNA from solution with phenol and chloroform 
Solutions for DNA extraction were transferred to a 1.5 ml tube and taken up 
to 500 [d with water. 500 [d of phenol was added to that, the contents of 
the tube were mixed by vortexing and samples were centrifuged at 13,000 
rpm for 5 minutes. By the end of the centrifugation step, two layers had 
formed, and the upper aqueous layer contained the DNA. That layer was 
removed into a clean tube and 1x volume of equal amounts of 
phenol/chloroform (v/v) was added, to further purify the DNA, and the 
mixing and centrifugation steps were repeated. Once the new aqueous 
layer was isolated, the DNA was normally concentrated with ethanol-salt 
precipitation. 
Precipitation and concentration of DNA with ethanol and 
salt 
Plasmid DNA and restriction fragments were precipitated and concentrated 
in 1.5 ml tubes by the addition of 2.5x volumes of 100% ethanol and O. 1x 
volumes of 5M sodium acetate, pH 5.2. The mix was incubated on ice or 
at -200C for 30 to 60 minutes, allowing the DNA to precipitate. 
After 
incubation, the DNA was pelleted by centrifugation at 13,000 rpm for 5 
minutes. The DNA pellet was washed with cold 70% ethanol and 
centrifuged as before. After removing the supernatant and air-drying the 
pellet for 10 minutes, the pellet was re-suspended in an appropriate amount 
of TE buffer or water. 
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DNA agarose gel electrophoresis 
Agarose gels of 0.8%-2% (w/v) in 1x TAE buffer were routinely used to 
analyse DNA samples. Gels were prepared by heating the agarose-TAE 
suspension in a microwave until dissolved. After the solution had cooled to 
approximately 50'C, ethidium bromide was added to 0.1 mg/ml and the 
solution poured into an appropriate gel tray. Once set, the gel was 
submerged in 1x TAE running buffer and DNA samples containing 0.75 x 
blue/orange loading dye (Promega) were loaded into the wells. 
Electrophoresis was carried out at 70 to 120 volts (V), until DNA fragments 
were resolved. DNA was visualised under ultra-violet (UV) light in the 
ImageMaster (Pharmacia Biotech). The size of the DNA fragments was 
estimated by comparison to DNA markers, run simultaneously with the 
samples. 100 base-pair (bp) and 1 kb ladders (Promega) were routinely 
used. 
DNA sequencing 
Midi- and mini-preparations of DNA were sequenced by a linear PCR 
method using dye-labelled terminators from Applied Biosystems. 10 [d 
reactions were routinely used, which contained 4 [tl Big Dye Terminator 111, 
150-300 ng plasmid DNA and 20 ng of primer. PCR reactions consisted of 
an initial denaturation at 96'C for 1 minute, and 35 cycles at 96'C for 30 
seconds, 560C for 15 seconds and 60'C for 4 minutes. When the PCR was 
completed, DNA in the reactions was precipitated with ethanol and salt, as 
described above. The air-dried pellet was processed by a sequencing 
service run "in house" by Sally Newman at the Institute of Reproductive and 
Developmental Biology. 
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Polymerase Chain Reaction 
Polymerase chain reactions (PCR) were performed using DNA Taq 
polymerase (Bioline), or a proof-reading polymerase, like Pfu Turbo or 
Platinum Pfx polymerase (both Invitrogen). Typically, 50 [d reactions were 
prepared, which included the following: 1 pl dNTP mix (dATP, dCTP, dGTP, 
dTTP, 10 mM each), 1 pl of each forward and reverse primer (100 ng/pl), 
20 ng plasmid or 0.5 [tg genomic DNA used as template, lx Taq buffer 
containing 1-2 mM Mg2' as supplied by the manufacturer, and 0.5-2.5 units 
of enzyme. DNA templates were initially denatured by heating the reaction 
to 94'C for 2 minutes, the reaction mixture was then subjected to 30 to 35 
thermo-cycles of: 94'C for 30 seconds, appropriate annealing temperature 
(50-60'C) for 60 seconds, and 72'C for 2 minutes (depending on the length 
of the amplified fragment, the extension step was calculated at 1 kb per 
minute). This was followed by a final extension of 72'C for 5 minutes. 
Final products were analysed by gel electrophoresis, before further use. 
Restriction endonuclease digestion 
Restriction enzyme digestions were performed at 37'C or 50'C depending 
on the optimum working temperature for each enzyme, in the buffers 
supplied by the manufacturer. Routinely, 0.2 to 4 [tg of DNA was digested 
with 5 tolO-fold excess of enzyme, with the final volume not exceeding 5% 
(v/v) glycerol. Reactions were terminated by addition of DNA loading buffer 
and analysed by gel e lectroph ores is. Alternatively, the digested DNA was 
purified by phenol/chloroform extraction and ethanol-salt precipitation and 
then resolved by gel electrophoresis. 
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Preparation of vectors 
In order to prepare vectors for cloning, 2 [tg of plasmid DNA was typically 
digested with the appropriate restriction enzyme(s). A sample of the 
digestion was resolved by routine agarose gel electrophoresis, to confirm 
the success of the reaction. The digested DNA was then treated with 10 
units of calf intestinal phosphatase (CIP) in 1x CIP buffer, at 37*C for 30 
minutes, to remove the 5' terminal phosphates from the vector and prevent 
self-ligation. DNA loading buffer with orange D was added to the reaction, 
which was loaded on a 1% agarose gel with 10 [tg/ml crystal violet and 
electrophorised until a clear vector band was visible on the gel by naked 
eye. The band was cut off the gel and the DNA purified from the agarose 
by loading on a polystyrene wool column and centrifuging at 13,000 rpm for 
5 minutes. The DNA concentration was estimated in a spectrophotometer 
and a concentration step followed, if required. 
Preparation of inserts 
DNA fragments to be cloned into vectors were either amplified by PCR or 
restricted out of a plasmid construct. PCR products were amplified using 
primers that integrated restriction sites at either end of the insert. The 
fragment was then digested with the appropriate restriction enzyme. Both 
amplified fragments and the ones restricted out of constructs were purified 
by gel extraction from a crystal violet gel, as described above. 
For the OSRI and TBXIO promoter constructs, a2 kb sequence upstream 
of their putative transcription start site was amplified from a human genomic 
DNA preparation from blood, available in our laboratory. The full-length 
TBX22 1.54 kb cDNA fragment (for the pcDNA3.1. V5/His plasmid) was 
amplified from IMAGE clone 3952809 by PCR with primers T22KozakF and 
T22NOTAAR. Inserts for the truncated TBX22 pSP64G. myc constructs 
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were made by restriction digestion and PCR: TBX22 1-298 (base pairs 1- 
894) was digested out of full length pSP64G. TBX22. myc with Ncol enzyme, 
the sites for which already existed in the TBX22 sequence (see Appendix). 
TBX22 94-520 (base pairs 281- 1560) was created by 2-step cloning: the 
94-298 fragment was PCR amplified from the full length construct, with 
addition of an Ncol site at its start (a site already exists at 298), while the 
299-520 fragment was digested from the full-length construct with a 
NcollNdel double digest. Both inserts were gel purified and ligated into a 
NcollNdel digested pSP64G. myc empty vector in two steps: first the 299- 
520 fragment was cloned, to create a pSP64G. TBX22 299-520 construct; 
this intermediate construct was then digested with Ncol and the TBX22 94- 
298 fragment was cloned in, to create the final TBX22 94-520. The TBX22 
sequence showing the sites of truncation and primer sequences are 
presented in the Appendix. 
Ligations 
Ligations were performed with 20 to 50 ng of vector DNA, and 1: 1,1: 3 and 
1: 6 molar ratios of vector to insert DNA were used. Insert DNA was a 
purified DNA fragment, either from PCR or restriction reactions. Ligation 
reactions were performed in 10 [tl total volume, containing 1x T4 DNA 
ligase buffer, 1 mM ATP and 6 units of T4 DNA ligase, and incubated 
overnight at 40C. 
The amplified TBX22 product was inserted into pcDNA3. lV5/His vector by 
TOPOI TA cloning. The vector in this kit is supplied linearised with 3' T 
overhangs; this allows PCR inserts that have 3' A overhangs (after 
amplification or short treatment with Taq polymerase) to ligate efficiently 
with the plasmid. The reaction uses topoisomerase I that binds double- 
stranded DNA and cleaves the phosphodiester bond after 5' -CCCTT 
sequences, resulting in a covalent bond between the enzyme and the DNA. 
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The bond is reversible, as it can be attacked by the 5' OH- of the cleaved 
strand and release topoisomerase 1. The kit uses this reaction to aid 
cloning of PCR products into pcDNA3.1. Transformed colonies were 
selected for ampicillin resistance on L-agar plates and propagated in liquid 
cultures. Plasmids were purified at a mini-prep scale and checked for 
containing the TBX22 insert by colony PCR and restriction digest with Bstxl 
enzyme, which cuts in the vector either side of the insert and once into the 
insert. The entire insert and flanking vector sequences of 
pcDNA3.1. TBX22. V5/His were confirmed for accuracy by DNA sequencing. 
Site-Directed Mutagenesis 
Individual base pairs in plasmid DNA were mutated using the QuikChange 
site-directed mutagenesis kit (Stratagene), according to the manufacturer's 
instructions. For each mutation, complementary oligonucleotides of 30 to 
40 base pairs were made, that had the mutation point approximately in the 
middle, and 15-20 nucleotides flanking this site on either side. The primers 
contained the desired base change necessary to alter the amino acid 
sequence in the resulting protein. The mutagenesis was achieved with a 
PCIR reaction containing 125 ng of each primer, lx reaction buffer, 0.2 mM 
dNTPs, 35 to 70 ng template DNA and 2.5 units of FYu Turbo DNA 
polymerase in a final volume of 50 [d. The amplification had a denaturing 
step at 950C for 30 seconds, followed by annealing at 55'C for 1 minute 
and extension at 680C for 7 minutes, for 12 cycles, by the end of which the 
base change was incorporated into the newly amplified plasmid DNA. After 
the PCR, reactions were treated with Dpnl for 1 hour at 37C to remove the 
methylated template DNA and leave the newly synthesised one in the 
mixture (the enzyme selectively digests methylated DNA). Transformations 
took place into XL1 Blue competent cells, which can repair nicks in double- 
stranded DNA, and in this case, the ones left by the primers during the 
amplification of complete plasmid DNA sequences. Cells were selected by 
91) 
ampicillin resistance, and DNA from candidate colonies was isolated by 
mini-prep and sequenced to confirm the presence of the desired mutation. 
2.2. d Protein Analysis 
In vitro Protein Synthesis 
Proteins were synthesised in vitro from various pSP64G. myc constructs 
using the TNT Coupled Transcription/Translation system (Promega), which 
uses rabbit reticulocyte lysates. Typically, 1 [tg of plasmid DNA template 
was used in each 50 [Al reaction, according to the manufacturer's 
instructions. Reactions were carried out with SP6 RNA polymerase at 300C 
for 90 minutes and then stored at -800C. 2 to 3 [tl of the reaction was 
subjected to SDS-PAGE and western blotting with an appropriate antibody, 
to assess the size and yield of the protein product. 
Transient Transfections 
For luciferase reporter assays, 293T and COS-1 cells were routinely 
transfected in 96-well plates with FuGENE 6 transfection reagent (Roche). 
For co-immunoprecipitation experiments, COS-1 cells were transfected with 
FuGENE 6. For the SUMO western blot experiments, 
immunohistochernistry, and for confirming protein expression from 
constructs, 293T and COS-1 cells were transfected in 6-, 12- and 24-well 
plates with FuGENE 6. 
Transfection in 6-well, 12-well and 24-well plates using FuGENE 6 
Cells were seeded on the day prior to transfection at a suitable dilution, to 
reach 50-80% confluency the next day. Simple kinetics experimen s 
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showed that for 293T and COS-1 cells, 4x 10 5,2x 105 and 1X 105 cells 
should be plated in each well of a 6-, 12- and 24-well plate respectively. 
Cells were counted in a haemocytometer prior to plating. Cells were 
transiently transfected 24 hours after seeding, using FuGENE 6 
transfection reagent. FuGENE is a non-toxic lipid-based transfection 
reagent, which allows efficient delivery of DNA ranging from small 
oligonucleotides to large plasmids. Plasmid DNA solutions were prepared 
in separate tubes for each well, according to the desired transfection. 
FuGENE 6 reagent was mixed with Optimem (serum free cell medium) and 
incubated at RT for 5 minutes. An appropriate amount of this solution was 
added to each DNA mix and incubated at RT for 15 minutes. For each 
well, 3 ld FuGENE and 2 [tg total DNA, 1.5 ýtl FuGENE and 1 [tg total DNA, 
or 1 ýd FuGENE and 0.5 [tg total DNA were used, for 6-, 12-, and 24-well 
plates respectively. The transfection mix was then added to the cells and 
mixed in the medium by careful pipetting. The medium was refreshed 24 
hours later and cells were harvested 38-42 hours after transfection. 
Transfection in 96-well microtitre plates 
The basic FuGENE transfection guidelines described were also followed 
here. On the day prior to transfection, cells from a confluent T-75 cm 2 flask 
were treated with trypsin and diluted 1: 10 in phenol red-free DMEM 
containing all the usual supplements, and 100 [tl of the suspension were 
plated in each well. This seeding made sure that on the day of transfection 
the confluency of each well would be 50-80%. Phenol red-free medium 
was used, as phenol red may interfere with the luciferase reading in 
subsequent reporter assays with these cells. 20 ng of a reporter plasmid, 
with 5 ng of the internal control vector pCMV-Renilla, were transfected into 
each well. 0.15 [d of FuGENE 6 reagent were used per well and mixed with 
Optimem (4.2 [d/well). A DNA mix containing the reporter and control 
plasmids as well as expression plasmids encoding the relevant 
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transcription factors and appropriate empty vectors (to a total DNA 
concentration of 50 ng per well) were added to the FuGENE mix and 
incubated at RT for 15 minutes. The appropriate volume of DNA/FuGENE 
mix was added to the cells and mixed into the medium by light pipetting, the 
plate was lightly shaken, and the cells were incubated at 37'C as normal. 
Protein extraction for SUMOylation experiments 
COS-1 cells were transfected in 6- or 12-well plates, as described. 38-42 
hours after transfection, the medium was discarded from the wells and the 
cells washed in PBS. Cells in each well were scraped in 30 or 40 [d (for a 
6- or 12-well plate respectively) of Gel Juice, pre-warmed at 85'C, and 
transferred into 1.5 ml tubes. Cell suspensions were sonicated for 10 
seconds in the SONICS Vibra Cell ultra-sonic processor (Jencons PLS, 
Bedfordshire, UK), centrifuged briefly at 13,000 rpm and heated to 950C for 
5 minutes in a heat block. 10 [tl samples were used for SDS-PAGE and 
remaining samples placed at -200C, until further use. 
Separation of nuclear and cytosolic extracts from cells 
COS-1 cells were transfected with wild-type and mutant 
pcDNA3.1. TBX22. V5/His in 60 MM2 dishes, as previously described. 
Buffers A and B were thawed on ice, and the cell monolayer was scraped 
twice with 200 [d of Buffer A. Cells were transferred to 1.5 ml tubes and 
placed on ice for 5 to 20 minutes. 20 [d of 20% NP-40 was added to each 
tube, to a final concentration of 1%, and the tubes were vortexed for 10 
seconds followed by centrifugation for 30 seconds at 13,000 rpm at 40C. 
The supernatants were the cytosolic extracts and were aspirated and 
placed into clean, labelled 1.5 ml tubes. The pellets were re-suspended in 
40 [d Buffer B each, rotated for 15 minutes in the cold room (4'C) and 
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centrifuged at 13,000 rpm for 5 minutes at 40C. The supernatants were the 
nuclear extracts and were placed in clean tubes, as before. Both the 
cytosolic and nuclear extracts were snap-frozen in liquid N2 and place at - 
800C, until use. 
SDS Poly-Acrylamide Gel Electrophoresis (SDS-PAGE) 
Proteins were analysed on discontinuous poly-acrylamide gels using the 
Biorad Mini-Protean gel analysis chamber. Gels were prepared from two 
solutions to form the stacking and resolving gel. The resolving gel 
contained 7.5 to 10% poly-acrylamide (30% acrylamide/ 0.8% 
bisacrylamide stock), 375 mM Tris-Hcl pH 8.8 and 1% SIDS. Typically, 
7.5% gels were used for SUMOylation and 10% gels for all other 
experiments. The stacking gel contained 5% acrylamide, 125 mM Tris-Hcl 
pH 6.8,1% SIDS and 80 mM imidazole. Polymerization of the gels was 
facilitated by the addition of TEMED and ammonium persulphate (APS). 
The resolving gel solution was first poured in-between the glass plates to 
within 2 cm of the base of the wells and overlaid with butan-2-ol saturated 
in water. Once the gel polymerised, the butan-2-ol was poured off, and the 
stacking gel poured on top of the resolving gel, after addition of TEMED 
and APS. An appropriate comb was inserted in the stacking gel, and was 
removed after the gel had set. The wells were washed in running buffer to 
remove any unpolymerised poly-acrylamide. Protein samples in 1x Laemli 
buffer were loaded along with 10 [d of Rainbow Molecular Weight Markers 
(Amersham). Electrophoresis was carried out in 1x Running Buffer at 70 to 
80 V until the dye front had migrated to the bottom of the gel or was run off 
it. The plates were then separated and the gel removed for processing. 
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Western Blotting (WB) 
Protein samples were resolved by SDS-PAGE and then transferred to a 
nitrocellulose membrane using a wet blotting method. A gel sandwich was 
prepared by placing one fibre pad on one side of the cassette, the placing a 
sheet of filter paper on the fibre pad, the poly-acrylamide gel on the filter 
paper and the nitrocellulose membrane on top of that. Another sheet of 
filter paper and another fibre pad were added to complete the sandwich. 
All fibre pads, filter papers and membrane were pre-wetted in transfer 
buffer. A glass tube was used to roll out any bubbles that may have formed 
in the gel sandwich. The sandwich was then enclosed in a cassette and 
placed in the Mini Trans-Blot tank (Biorad) in transfer buffer, with the 
nitrocellulose towards the anode and the gel towards the cathode. Transfer 
was performed at 100 V for 30 to 60 minutes. Following that, the 
membranes were inspected for the presence of the Rainbow markers to 
confirm the transfer of the proteins. The membrane was briefly washed in 
PBS-Tween 20 (PBST) and then incubated in Western blocking buffer for 1 
hour at room temperature with gentle shaking. Two 5-minute washes in 
PBST followed, and the membrane was incubated in the appropriate 
primary antibody in blocking buffer, overnight at 40C with gentle shaking. 
After incubation with the primary antibody, the membrane was washed 
twice in PBST, as before, and then incubated for 1 hour at room 
temperature with a horseradish peroxidase secondary antibody (anti-mouse 
or anti-rabbit), 1: 10000 in blocking buffer. The membrane was finally 
washed twice (10 minutes each) in PBST and the proteins visualised with 
the ECL Plus Western blot detection system (Amersham), according to the 
manufacturer's instructions. 
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Stripping and Re-probing WB Membranes 
Nitrocellulose membranes that needed to be re-probed with different 
primary antibodies were stripped from any previous reagents (e. g. ECL 
solution, antibodies, blocking buffer) by extensive washing in PBST. 
Typically, the membrane was washed in 20 ml of PBS T for 3 to 4 hours at 
RT with shaking, changing the washing solution once or twice during that 
period. The membrane was then bl ocked again and incubated with 
antibodies as described above. 
BCA Protein Assay 
Protein concentrations of cell lysates were measured using the BCA 
Protein Assay Kit. The kit combines the biuret reaction, which is a 
reduction Of CU+2 to Cu" by protein, with colorimetric detection of cuprous 
cations (Cu") using a reagent containing bicinchoninic acid (BCA). 2 
molecules of BCA chelate with one cuprous ion to produce a purple 
coloured product, which exhibits strong absorbance at 562 nm with 
reference to a standard containing BSA. The assay was carried out on a 
96-well plate and set up in duplicate. Briefly, a standard curve was created 
by setting up BSA samples of 0 to 4 mg/ml. 10 [d of each protein sample 
were diluted with 90 [d of the appropriate cell extraction buffer (the same as 
in the sample). The BCA working reagent was prepared by mixing 50 parts 
of BCA reagent A with 1 part BCA reagent B, and 100 [d of that were added 
to each well. The samples were incubated for 15 minutes at 37'C and 
absorbance at 562 nrn was measured using the Optimax microplate reader. 
Immunoprecipitation 
For pulling down proteins from cell lysates, typically one T-75 cell culture 
flask was transfected per immunoprecipitation reaction. Cells were 
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collected after 36 to 48 hours by scraping in 1 ml IP lysis buffer per flask. 
The lysates were transferred in 1.5 ml tubes and frozen at -80'C overnight. 
The next day the cell lysates were defrosted, spun for 10 minutes at 13000 
rpm in the cold room (40C). The supernatants were transferred to clean 
tubes. Protein concentration was measured using the BCA Kit (Perkin- 
Elmer), and concentrations of samples were standardised to 1 mg/mI with 
IP lysis buffer. Before the immunoprecipitation reactions, 20 [Ag of the 
lysate was used as input for Western Blotting to check the success of the 
transfections. Typically, 1 mg of cell lysate was immunoprecipitated. The 
lysates were pre-cleared with 20 [d Protein A/G sepharose by placing for 30 
minutes on a rotor at 40C. The beads were pelleted by centrifugation at 
13000 rpm for 5 minutes. Supernatants were transferred to clean tubes 
and incubated with primary antibody for 2 hours, on a rotor at 40C. Anti-V5 
antibody (Invitrogen) was used at 1/200, while anti-TBX22 antibody 
(CovalAb, custom made) was used at 1/100. After the 2 hours, 200 [LI 
protein A/G sepharose was added to the tubes, which were incubated 
overnight rotating at 40C. The next day, the beads were collected by 
centrifugation at 2500 rpm for 2 minutes at 40C. The supernatants were 
discarded and the pellets washed 3 times with PBS, repeating the 
centrifugation step. After the final wash, 30 [d 2x Laemli buffer was added 
to each pellet and heated at 950C for 5 minutes. 15-20 [d of the 
immunoprecipitated samples were loaded on a poly-acrylamide gel and 
proteins separated by SDS-PAGE. Detection was by western blotting, 
using appropriate antibodies. To check co-precipitation of proteins the 
membranes were first blotted with an antibody to one protein and then 
stripped and re-probed with an antibody specific to the second protein. The 
two films were compared for the presence of common bands. 
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2.2. e. Electromobility Shift Assays (EMSA) 
Principle 
Transcription factors are DNA-binding proteins and at least part of their 
specificity for target genes is based on the precise DNA sequence they 
recognise. Such sequences can be identified through immunoprecipitation 
and PCR based methods, like the binding site selection assay (Kispert and 
Herrmann, 1993). The EMSA, also known as gel shift or gel retardation 
assay, is based on the principle that a DNA fragment containing the specific 
site recognised by the transcription factor will bind to this protein under 
specific reaction conditions. This DNA-protein complex will migrate more 
slowly through a gel compared to the DNA fragment alone, and it will be 
possible to visualise it as a slower mobility band. Traditionally, the DNA 
fragment is radioactively labelled- although in recent years labelling can 
occur with other non-radioactive methods, e. g. using the properties of the 
biotin-streptavidin interactions. This labelled double-stranded 
oligonucleotide is then incubated with the protein being studied, in the form 
of in vitro translated, purified and solubilized from transfected bacteria or 
eukaryotic cells or whole nuclear extracts (of native or transfected cells). 
The DNA-protein complexes formed are electrophoresed in a non- 
denaturing poly-acrylamide gel and the position of the DNA visualised by 
autoradiography (in the case of radioactively labelled oligonucleotides). 
The free labelled DNA fragment will usually run to the bottom of the gel, 
where it will be seen as a thick band (the probe concentration is normally 
used in excess), while any protein bound to DNA will hinder the movement 
of the complex and will be seen as a more slowly moving band, located 
higher up in the gel. The sequence specificity of this binding can also be 
studied in these assays. When added at great excess, a specific un- 
labelled probe will compete with the labelled fragments for binding to the 
protein and will result in disappearance of the retarded band (labelled DNA- 
protein complex). Similar concentrations of non-specific oligonucleotides, 
however, will have no effect, since they will not interfere with the specific 
DNA-protein interaction. 
Oligonucleoticle annealing, phosphorylation and labelling 
Oligonucleotides used as primers for amplifications were synthesised by 
Invitrogen or Thermoelectron, GmBH, Germany. Oligonucleotides used as 
probes in EMSA reactions were synthesised and HPLC purified by 
Thermoelectron. To prepare probes for EMSA reactions, the 
complementary oligonucleotides were mixed at equal molar quantities in 1x 
T4 polynucleotide kinase buffer, at a final concentration of 2 pmol/[tl in 50- 
100 [d total volume. The solutions were placed in boiling water inside a 
pyrex beaker for 5 minutes, and then left to cool down overnight, in the 
water, with the beaker placed inside a polystyrene box. The slow cooling 
process to RT facilitates the annealing of the oligonucleotides. The probes 
were labelled with 32 P-y ATIP, in a reaction containing 2.5 [d (5 pmol) of 
annealed oligonucleotide, 1 [tl 10x T4 PNK buffer, 10 units of T4 PNK, 3 ýtl 
ATP and made up to 10 [tl with water. Reactions were incubated at 37'C 
for 45 to 60 minutes, 90 [d of water was then added to the mix, which was 
purified from the free ATP on a G-25 sepharose column, by centrifugation 
at 1100 rpm for 5 minutes. 1 to 4 [d of labelled probe was used in EMSA 
reactions. 
Protein-DNA binding and Gel Electrophoresis 
Interaction of wild-type and mutant TBX22 proteins with specific DNA 
recognition sequences was tested by EMSA. Typically 2 to 5 [LI of in vitro 
translated protein was incubated in 20 ýd of BBO buffer with 1 [tg polydl. dC 
for 10 minutes at room temperature. Polydl. dC is a non-specific competitor 
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DNA that binds to proteins in the mix that are not DNA-binding, thus 
reducing background complexes in the reaction. The protein mix was then 
incubated with 32 P-radiolabelled double-stranded DNA probe for 15 minutes 
at room temperature. 1 to 2 [tl of antibody was added where appropriate 
and the mix incubated for a further 10 minutes on ice. The protein-DNA 
complexes were separated on a 4.5% non-denaturing poly-acrylamide gel, 
run at 30 to 40 milli-Amperes (mAmp) for 5 to 6 hours in 1x Tris-Glycine 
buffer. The complexes migrate more slowly than the unbound probe and 
also at different speed according to their individual size. Thus, the protein- 
DNA complex will show up as a band higher up in the gel than the free 
probe, and the antibody-protein-DNA complex as an even slower one. The 
specificity of the protein for its DNA binding site was confirmed by 
competition assays, using non-radioactive oligonucleotides of specific (DNA 
binding site) and non-specific unrelated sequences. After completion of the 
electrophoresis, the gels were transferred onto Whatman paper and dried 
for 1 hour at 80'C under vacuum. Film was exposed to each dried gel 
inside a cassette with an intensifier screen. The cassettes were placed at - 
80'C o/n and the films developed on the next day. Band shifts and super- 
shifts were assessed from the films. 
2.2. f. Reporter Assays 
Principle 
Transcription regulation assays (trans-activation or trans-repression) are 
used to further study the function of transcription factors in regulating the 
transcription process. They are based on the fact that these proteins 
activate and/or repress transcription of their target genes, usually through 
binding to their specific DNA recognition sequences. Reporter gene assay 
technology is applied in these cases and one of the reporter genes used 
most often is the luciferase. A DNA fragment containing the specific 
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sequence that the transcription factor recognises and binds to is cloned 
upstream of a minimal (or sometimes stronger) promoter into a vector 
carrying the reporter gene. Co-transfection of this construct with an 
expression vector containing the transcription factor's open reading frame 
into an appropriate cell system will bring the protein together with the DNA 
recognition element, which will result in activation or repression of the 
promoter, assessed through the expression of the reporter gene. 
Reporter assays for transient transfection 
The luciferase reporter activity was measured by the LucLite Luminescence 
Reporter Gene Assay (Packard) or the Dual Luciferase Reporter Assay kit 
(Promega). Firefly luciferase is an enzyme that catalyses the conversion of 
Luciferin to adenyl-oxyluciferin, resulting in the rapid emission of light. The 
LucLite Luminescence Reporter Gene Assay utilises this chemical reaction 
by providing the substrate luciferin to measure luciferase activity; it also 
contains several substances that stabilize the luciferase enzyme and slow 
down the adenyl-oxyluciferin/luciferase reaction, resulting in a longer lasting 
signal. Luciferase activity in 293T and COS-1 cells was measured as 
follows: 50 [d of culture medium were removed from each well and 50 [d of 
2x Lucl-ite Reagent (containing luciferin, final concentration 1x) was added. 
Cells were incubated in the dark for 15 minutes at room temperature and 
cell lysates transferred to a 96-well MICROLITE plate (Dynex). Luciferase 
activity was measured using the Victor2 1420 Multilabel counter (Perkin 
Elmer). Renilla luciferase reporter activity was also measured in the same 
samples as an internal control. This enzyme converts coelenterazine to 
coelenteramide, emitting light in the process. The Renilla reagent was 
prepared by diluting Coelenterazine (dissolved in DIVISO at 1 mg/ml) in 
Renilla buffer to a final concentration of 10 ng/ [d. 25 [tl was then added to 
each well and the cells were incubated in the dark for 30 minutes at room 
temperature. Renilla luciferase activity was measured in the same way as 
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firefly luciferase activity. The Dual-Luciferase Reporter Assay Kit 
(Promega) works on a similar principle on measuring luciferase activity, as 
described above, with some technical differences. After transfection, the 
medium was discarded and the cells harvested in Lysis buffer (Promega) 
(25 ýtl per well of a 96-well plate), followed by 20 minutes of shaking at 700 
rpm on a plate shaker, and one freeze-thaw cycle, at -20'C for 2-3 hours. 
After thawing, 20 [d of each sample was transferred into a MICROLITE 
plate (as above) and the plate inserted into the FLUOstar OPTIMA plate 
reader (BMG Labtech). The Luciferase Assay Reagent and Stop & Glo' 
Reagent (to measure firefly and Renilla luciferase values respectively) were 
loaded into the FLUOstar, which was programmed to inject appropriate 
amounts of reagents into the samples. Readings for each luciferase 
activity were taken at 3 consecutive seconds and the highest value chosen 
as the result for analysis. Data is representative of a number of separate 
experiments, as stated in the Results chapter, ad values shown are the 
average of 4 replicates. Error bars are representative of standard deviation 
amongst the replicates. 
2.2. g. Immunohistochemistry 
COS-1 cells were initially grown in complete medium (as described above) 
on round coverslips placed inside wells of a 24-well plate, where they were 
transfected with wild-type and mutant pcDNA3.1. TBX22. V5/His constructs, 
as previously described. After the transfection incubation time was 
complete, the medium was aspired off the wells, the cells were carefully 
washed in PBS, and the fixed in 4% paraformaldehyde (PFA) in 125 mM 
HEPES for 10 minutes, followed by 8% PFA in 125 mM for 50 minutes at 
41C. The fixed cells were rinsed twice with PBS and stored in clean PBS at 
4'C, after the plate was sealed using Parafilms. When starting the 
immunolabelling, cells were transferred to a new 24-well plate and washed 
with 0.5% Triton X-100 in PBS for 30 minutes with shaking, 
followed by 6 
loý 
washes in PBS. PBS+, containing 0.1% casein, 1% BSA and 0.2% fish 
gelatin, was added to the cells for 1 to 2 hours, followed by incubation with 
anti-V5 as the primary antibody, diluted in PBS+ 1: 100, o/n at 40C. Next, 
the cells were washed in IPBS+ for 1.5 hours and were then incubated with 
the fluorescein isothiocyanate (FITC)-conjugated anti-mouse antibody 
(1: 100 in PBS+), as a secondary, for 1 hour, followed by an overnight wash 
in PBS+ at 40C. The next day, cells were rinsed in PBS and mounted on 
SuperFrost microscope slides in a drop of mounting medium with 4', 6 
diamidino-2-phenylindole (DAPI, Vectrashield). The cells were then viewed 
on an Axioskop (Carl Zeiss, Oberkochen, Germany) fluorescence 
microscope, using 10x, 40x and 100x oil objectives. Images were captured 
using the Hamamatsu photonics digital camera (ORCA-ER, Hamamatsu, 
Dulles, USA) and processed using IPLab, version 3.70, scientific image 
processing software (Scanalytics Inc., Fairfax, USA). 
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CHAPTER 3: RESULTS 
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RESULTS 
3.1 TBX22 
palindrome 
binds specifically to a near 
Identification 
site for TBX22 
of a preferred DNA binding 
TBX22 is a member of the T-box family of transcription factors and 
therefore shares their evolutionary conserved DNA-binding domain. Hence 
it was expected that TBX22 would recognise and bind to a specific DNA 
sequence, which would be present in the regulatory region(s) of its target 
genes. To identify the preferred DNA binding sequence for TBX22, it was 
intended to use a similar binding site selection assay as described for the 
Brachyury protein (Kispert and Herrmann, 1993). At this time, we were 
fortunate to set up a collaboration with the Kispert lab (Hanover, Germany) 
where a binding site selection assay for TBX22 had recently been 
performed. Through the terms of this agreement, I joined the Kispert lab for 
a two-month period to learn specific techniques and perform the 
subsequent experiments described from section 3.1.2 onwards (except 
where otherwise stated). 
The TBX22 binding sequence, identified by Dr Manvendra Singh (Kispert 
Lab), is described briefly as follows. In vitro translated TBX22 protein was 
incubated with a pool of random 26-mer oligonucleotides flanked by known 
sequences. Protein-DNA complexes were precipitated with an antibody 
specific to TBX22, the bound DNA eluted from the complexes and used for 
3 further rounds of selection. Finally, eluted oligonucleotides were cloned 
and sequenced. Sequencing analysis revealed around 20 oligonucleotides 
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that could be aligned to one perfect T half-site. From these sequences, a 
consensus DNA fragment was identified as the DNA binding site for TBX22 
that consists of one perfect T half-site and an imperfect one, containing 
variations at two nucleotide positions. In this sequence, the half-sites are 
arranged in the opposite orientation to the T palindrome (Figure 3.1). 
T palindrome TBX22 binding site 
TT TCACACCT AGGTGTGAAA AGGTGTGAAATT GTCACCTC 
AAAGTGTGGATCCACACTTT TCCACAC TTT AACAGTGGAG 
4A 
Figure 3.1: DNA binding site for TBX22. The preferred binding 
sequences for both T protein and TBX22 are presented. T half-sites are 
shown in red and their orientation indicated by arrows. The positions of 
variation in the second half-site within the TBX22 sequence are shown in 
blue. 
3.1.2 Binding properties of TBX22 
Developing an optimised DNA-binding assay for TBX22 was essential for 
confirming the details of its interaction with DNA. Moreover, it would be a 
very useful tool to examine the binding properties of mutant TBX22 proteins 
in comparison to the wild-type. 
The consensus TBX22 DNA-binding site was used in electromobility shift 
assays (EMSA) with in vitro expressed TBX22. myc protein to assess 
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intensity and specificity of binding. TBX22. myc was expressed in a rabbit 
reticulocyte lysate system (RRL) and expression was confirmed by SDS- 
PAGE and Western blotting. Appropriate amounts of the protein, as well as 
mock translation and empty lysate controls, were incubated with 32p_ 
labelled TBX22 DNA consensus sequence (the probe) in the presence of a 
non-specific DNA competitor and extra non-specific protein in BBO buffer 
(see Section 2.1, Materials). TBX22 can bind specifically to the consensus 
sequence, forming a shift when bound to the labelled probe, which showed 
on the gel as a lower mobility complex that migrated considerably more 
slowly than the free probe. This protein-DNA species was then super- 
shifted with the addition of specific anti-myc antibody, showing on the 
EMSA autoradiograph as a new species migrating more slowly than the 
shift. In the super-shift lane the shift band almost disappears, thus 
supporting the fact that the antibody formed a new complex with the probe- 
bound TBX22. The TBX22 shift only showed up in the lanes where TBX22 
protein was present and did not appear in the control lanes of empty RRL 
and mock translation reactions (using empty pSP64G-myc vector). 
Competition reactions with added 100-fold excess non-labelled specific 
probe blocked binding with the labelled probe, while addition of the same 
excess of cold non-specific DNA had no effect on the TBX22 shift (Figure 
3.2). 
Preferred DNA-binding sites have been identified for a number of T-box 
proteins, which bind to their selected sites specifically but can sometimes 
tolerate slight variations in certain nucleotide positions (Kispert and 
Herrmann, 1993; Ghosh et al.,, 2001). In addition to their individual DNA 
sites, many T-box proteins can also bind the T palindrome and/or the T 
half-site (Sinha et al., 2000; Tada and Smith, 2001). TBX22 protein was 
therefore tested against the TBX18 palindrome, and the T palindrome and 
half-site (Figure 3.3). A binding site selection assay for TBX18 identified 
sequences that resemble the TBX22 binding site, but in some cases 
both 
half-sites within the sequence are perfect T half-sites (Farin et al., 2007). 
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TBX22 protein binds to the TBX18 binding site as well as to the TBX22 
consensus sequence, forming a shift and a super-shift after addition of anti- 
myc. 
pSP64 
FP RRL G. myc 
Anti-myc antibody ++ 
Cold T22 probe --- 
Cold non-specific --- 
TBX22. myc 
41M 
8 
Non-specific 
bands 
40MM 4WAM 4QMW 0-0 
+ 
4-TBX22. myc 
+ anti-myc (supershift) 
4-TBX22. myc 
(shift) 
4 
Figure 3.2: EMSA with TBX22. myc protein against 32 P-11abelled TBX22 
binding site. The position of shifts and super-shift are indicated next to the 
autoradiograph by arrows on the right. Arrows on the left indicate non- 
specific bands that correspond to complexes formed between the TBX22 
probe and native proteins present in the RRL solution, possibly even other 
T-box proteins. FP: Free probe; RRL: rabbit reticulocyte lysate; 
pSP64G. myc: mock translation; anti-myc: addition of antibody; Cold T22 
probe: unlabelled TBX22 consensus binding oligonucleotide; Cold non- 
specific: unlabelled non-specific oligonucleotide. 
No shifts can be seen with either the T palindrome or the half-site, however 
a super-shift is formed at the same position as with the TBX22 and TBX18 
probes when antibody is added (Figure 3.3). So TBX22 cannot bind to the 
T palindrome in the same way as to its own binding site, nor to a single 
half-site. The appearance of a super-shift when antibody is added is 
possibly due to the fact that the antibody stabilises the complex of TBX22 
protein bound to the T sites, perhaps by bringing together two protein 
molecules on a DNA sequence, or two protein molecules already bound 
individually to separate DNA fragments. 
BLAST search analysis shows that complete T-like palindromes do not 
appear in the human genome, and it is more likely that two nearby half sites 
may come into apposition through DNA folding (Tada and Smith, 2001; 
Showell et al., 2004). This has previously been the case for other T-box 
proteins, where one or several TBE sequences were identified in the 
promoter regions of their target genes (Casey et al., 1998; Papaioannou, 
2001; Cai et al., 2005). Therefore, the band shift seen for TBX22 with a 
single T half-site, even only in the presence of antibody, represents a 
positive indication that it will be possible to screen for genuine regulatory 
elements in candidate target genes of TBX22. 
112 
TBX18 BS T half-site T palindrome 
FP 
RRL 
TBX22. myc 
Anti-myc 
dw 
-oý - -umm. momb 
TBX22. myc 
anti-myc 
(supershift) 
A-TBX22. myc 
lb 
4ý (shift) 
_O.. 
Non-specific 
bands 
-00. 
Non-specific 
bands 
Figure 3.3: EMSA with TBX22. myc and the TBX18 binding site, T 
palindrome and T half-site. Shifts and super-shifts are indicated by 
arrows on the right, non-specific bands are indicated on the right and left. 
TBX22 binds to the TBX18 binding site producing a shift that is super- 
shifted with anti-myc antibody, while binding to the T half-site and T 
palindrome is seen only after addition of anti-myc, possibly indicating 
formation of a more transient complex that is stabilised in the presence of 
antibody. Each probe includes four lanes, from left to right: free probe (FP), 
reticulocyte lysate (RRL), TBX22 protein without (TBX22. myc) and with the 
addition of antibody (anti-myc). 
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3.2 Missense mutations found 
compromise TBX22-DNA binding. 
in CPX patients 
CPX patients with missense mutations in TBX22 present with the same 
phenotype as those with nonsense, frameshift and splice site mutations 
thus missense changes are considered equivalent to null (Braybrook et al., 
2001; Margano et al., 2004). Nine different missense mutations and one 
polymorphic change (E187K) also seen in healthy individuals, have been 
identified, all of which are located within the T-box domain (Braybrook et 
al., 2001; Braybrook et al., 2002; Margano et al., 2004; Chaabouni et al., 
2005; Suphapeetiporn et al., in press) (Figure 3.4a). These were all 
chosen as a means to investigate their effects on the TBX22 protein at both 
the cellular and molecular levels. According to the crystal structure of the 
T-box domain of the Xenopus T protein (Muller and Herrmann, 1997), some 
of the mutation positions correspond to amino acids that come into direct 
contact with the DNA backbone upon binding, while some others are 
located within a putative protein-protein interaction, and possible 
dimerization domain. 
Mutant constructs were created on the pSP64G. TBX22-myc plasmid by in 
vitro mutagenesis, using the QuikChange mutagenesis kit (Stratagene). 
Complementary primers were designed at the mutation site and used to 
amplify around the vector to produce mutated constructs according to the 
manufacturer's instructions. The resulting constructs along with wild-type 
TBX22 were translated in vitro, using the TNT protein translation system 
manufactured by Promega. 
The mutant proteins were then analysed by SDS-PAGE and Western 
blotting in order to assess expression efficiency and appropriate molecular 
weight. All mutant proteins were found to express with similar efficiency to 
the wild-type, except for the G1 18C mutant that was consistently found at 
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slightly lower concentrations in the TNT reactions. Protein samples were 
normalised according to the Western blot data, as shown in Figure 3.4b, 
and equal amounts of translated proteins were subsequently used in DNA 
binding reactions with the TBX22 consensus DNA sequence. EMSA 
reactions were visualised by autoradiography following electrophoresis on 
non-denaturing poly-acrylamide gels. The DNA-binding ability of the 
mutant proteins was then assessed by comparison to the wild-type TBX22- 
DNA binding (Figure 3.4c). 
Most of the mutant proteins are defective in their DNA binding properties 
(Figure 3.4c). Wild-type TBX22 produces both a shift and a super-shift, as 
expected from previous studies. However, a number of the mutant proteins 
completely fail to form stable complexes with the DNA fragment and show 
neither shifts nor super-shifts, while others show reduced binding to DNA 
compared to wild-type protein. This data highlights the structural 
importance of specific residues within the T-box domain. Amino acid 
changes W102C, R120W, L214P, T260M and N264Y have lost the ability 
to bind DNA completely, as seen in the corresponding gel lanes, with and 
without antibody. These lanes are empty apart from the non-specific bands 
that are also present in the reticulocyte lysate control and the free probe at 
the bottom of the gel. The amino acid positions R120, L214 and T260 are 
highly conserved residues that are predicted to make direct contact with the 
DNA backbone (Muller and Herrmann, 1997; Coll et al., 2002). The mutant 
proteins G118C and M121V, which flank the DNA contact point at R120, 
retain the ability to bind DNA and form stable complexes that can be seen 
on the gel, but at a lower intensity compared to the wild-type. Mutations 
P183L and C184F that are located in the putative dimerization domain 
(amino acids 180-185, Muller and Herrmann, 1997) appear to have less 
effect on DNA binding. The C184F change, although just adjacent to 
position P183, appears to bind DNA better than the other mutants, 
presenting a shift and a much stronger super-shift, with only a slight 
difference to wild-type TBX22. 
I 15 
It is interesting to note that the E187K variant behaves like the wild-type 
TBX22, showing a shift and super-shift of similar intensity. This result fits 
with the expectation that it is a non-causative polymorphism where it was 
found in 14/207 patients and 13/255 controls (Margano et al., 2004), rather 
than a putative mutation as suggested by Chaabouni et al. (2005). The 
E187 position is also found in a less highly conserved position within the T- 
box domain, not at a contact position and outside of the putative 
dimerization domain (Muller and Herrmann, 1997; Figure 1.6, Introduction). 
a 
TBX22 5) =I I 
ATd 
P183L C184F 
Gl 18C L214P 
T-box 
/ 
R120W ' M1'21V E187K 
b 
W102C T260M 
N264Y 
ýGA 
4mmew mom 4mm 
'Rom 4ow ýý qý ýý qmý qmmp lownwa. 
WT W102C G118C R120W M121V P183L C184F E187K L214P T260M N264Y 
Figure 3.4 a and b: TBX22 missense mutations. (a) Positions of the 
mutations on a schematic diagram of TBX22. Exons are presented as pink 
boxes, intronic sequence as a blue line. The T-box domain is indicated as a 
grey box, including exons 2 to 6. Start and stop codons displayed in exons 
1 and 8, respectively. (b) Western blot of wild-type and mutant TBX22. 
Normalised amounts of in vitro translated TBX22. myc proteins probed with 
anti-myc (Roche). 
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3.3 Sequences outside the T-box are essential for 
TBX22 DNA-binding. 
Binding to DNA is a major function of T-box proteins, and this interaction 
occurs mainly via the T-box domain. Although the T-box is the main DNA- 
binding site, sequences outside this region can have a role in the 
specificity and intensity of binding (Kispert and Herrmann, 1993; Sinha et 
al., 2000; Butz et al., 2004). Thus it was decided to examine if the N- and 
C-terminal regions flanking the T-box domain participated in the DNA- 
binding process of TBX22- 
Two truncated TBX22 fragments were cloned, one lacking the C-terminal 
part and consisting of amino acids 1 to 298, the other consisting of amino 
acids 94 up to 528, which deletes the N-terminal part, until just before the 
start of the T-box domain (see Appendix). Both truncated constructs were 
created by sub-cloning restriction fragments from the full-length construct 
into new, empty pSP64G. myc vector. Integrity of the constructs was 
confirmed by DNA sequencing. The truncated proteins were in vitro 
translated by the TNT translation system, and tested by Western blotting 
with the anti-myc and anti-TBX22 antibodies to confirm expression and 
integrity of the proteins (Figure 3-5). 
The truncated TBX22 proteins were used in EMSA reactions in order to 
establish whether the new constructs effectively bind DNA and, although 
both contain intact T-box DNA binding domains, if the deleted sequences 
compromise this interaction. The TBX22 1-298 truncation binds DNA and 
presents a shift with the TBX22 consensus DNA sequence (Figure 3.6a). 
The shift is of higher mobility than that observed with the full-length 
protein, as expected with a complex of lower molecular weight. This 
complex can be super-shifted with addition of anti-TBX22 antibody. 
Addition of anti-myc antibody has no super-shifting effect on this protein- 
DNA species, since the myc tag is no longer in frame with the TBX22 
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ORF. Nevertheless, anti-myc was still used in the reactions with this 
truncated protein as an internal specificity control (Figure 3.6a). 
TBX22 f/I 
TBX22 94-520 10- 
WB. anti-myc 
*- TBX22 fA 
-F*-- TBX22 1-298 
WB: anti-TBX22 
Figure 3.5: Expression of truncated TBX22 proteins. Western blots of 
in vitro translated fragments from the truncated pSP64. TBX22 constructs. 
Different antibodies used for detection, as the myc tag is disturbed in 
TBX22 1-298, and anti-TBX22 does not recognise TBX22 94-520. Protein 
sizes are not comparable between the blots, as SDS-PAGE gels were run 
separately. f/l: full length. 
The second truncation, TBX22 94-528, with the N-terminal part of the 
protein missing, was also used in DNA-binding reactions. However, the 
absence of shifts or super shifts in the EMSA gel autorad show that the 
TBX22 94-528 protein does not bind to the TBX22 DNA sequence at all 
(Figure 3.6b). These results were reproducible and different amounts of 
protein did not have any effect on the binding properties. This experiment 
strongly suggests that although the T-box domain is the main point of 
DNA-binding, the N-terminal region of the protein also has a role in this 
process. 
T-box proteins have been shown to bind to palindromic or near 
palindromic sequences, as well as single TBE sequences resembling the 
T half-site, as monomers or can form homo- and/or heterodimers before or 
during binding to DNA (Tada and Smith, 2001; Showell et al., 2004). 
Since a truncated form of TBX22 was available that could bind the 
consensus TBX22 site, it was decided to test whether TBX22 binds DNA 
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as a monomer or a dimer. It was anticipated that the pattern of the shifts 
that are produced might reveal if the protein binds DNA as a monomer or 
a dimer when the full-length TBX22 and one of the truncated forms are 
combined. Generally, one shift is expected for each of the protein types 
bound to DNA, in either monomeric or dimeric form. If the protein 
dimerizes, it is expected that a heterodimeric complex will form between 
the full-length and the truncated form of the protein. This will appear as a 
band shift of intermediate mobility, between the shifts of the full-length and 
truncated proteins alone (Ghosh et al., 2001). 
In order to assess monomeric or dimeric binding, different ratios of the full- 
length and truncated forms of TBX22 were used together in EMSA 
reactions. Three different ratios were used and in all cases the separate 
shifts of the full length and the truncated protein can be observed with no 
intermediate complex apparent (Figure 3.6a). This preliminary result 
indicates that TBX22 in solution binds DNA as a monomer. However, the 
non-specific band that is present consistently in all EMSA reactions with 
TBX22. myc and the TBX22 consensus sequence (Section 3.1.2,3.2,3.3) 
appears between the two TBX22 shifts. Therefore, the presence of this 
band might conceal a potential intermediate complex between the two 
protein species, as this would be expected to appear around the same 
position. On the other hand, if two complexes of similar size appeared at 
the same position, one might expect to observe an increase in the amount 
of protein at the position of the band. The intensity of the non-specific 
band though does not change when both full length and truncated protein 
species are present in the reaction, and this points against the formation of 
any intermediate complexes. Moreover, full length TBX22 can bind to aT 
half-site, and although the binding is not as strong, the super-shift it 
creates is of the same mobility as the one seen with the consensus TBX22 
site (Figure 3.3). Thus there is no indication of differential monomeric and 
dimeric binding to single and paired T half-sites respectively. 
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3.4 TBX22 functions as a transcriptional 
repressor. 
3.4.1 TBX22 can repress its own promoter. 
A 2kb DNA fragment upstream of a putative non-coding first exon of 
human TBX22 was isolated in our lab, cloned into pGL3-basic luciferase 
reporter vector and shown to have promoter activity in transient 
transfection experiments (personal communication, Dr Erwin Pauws). 
Serial deletions of this construct showed that 500bp was sufficient to act 
as a minimal promoter (hPO) with essentially the same transcriptional 
activity as the longer construct. It was noticed that promoter activity was 
only detected when the construct was transfected into cell lines with no 
endogenous expression of TBX22 (e. g. 293T or COS-1), while in cell lines 
where TBX22 was present (e. g. T47D or HeLa) the activity was almost 
non-existent. This observation suggested possible auto-repression, which 
was tested by co-transfection of the TBX22- expressing construct into cell 
lines devoid of endogenous expression, together with the promoter 
fragment. This resulted in a dose-dependent reduction in promoter activity 
down to 40-50% of the initial activity (E. Pauws, data not shown). Analysis 
of the hPO sequence has revealed the presence of a number of TBE-like 
elements within the 500 bp putative promoter region. Examination of 
these sequences by EMSA reactions has failed to show any binding to in 
vitro translated TBX22 (E. Pauws, data not shown). However, this line of 
investigation is still ongoing. 
Although these experiments do not show categorically that TBX22 
autoregulates in vivo, for example a different T-box gene might have this 
role, the hPO promoter nevertheless provides a useful reporter for TBX22 
activity. 
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3.4.2 Mutant TBX22 proteins show 
compromised repression ability. 
All the TBX22 missense changes examined in this study occur within the 
T-box domain. Although this is the DNA-binding region of the protein, a 
number of mutants still retained some DNA-binding ability (Section 3.2). 
As a transcription factor, TBX22 binds DNA and regulates expression of 
target genes. Thus, it was logical to assess the effect of the CPX 
mutations on the ability of TBX22 to regulate transcription. 
The open reading frame sequence of TBX22 was cloned into 
pcDNA3.1. V5/His mammalian expression vector and the integrity of the 
clone confirmed by DNA sequencing. This plasmid represents the wild- 
type, full length TBX22 construct subsequently used for all transfection 
experiments in mammalian cell lines. Constructs of 
pcDNA3.1. TBX22. V5/His containing the ten missense changes found in 
CPX patients, as described previously, were created using the 
QuikChange mutagenesis kit from Stratagene. These clones were then 
compared with wild-type TBX22 in the TBX22 hPO promoter assay 
(described above) to assess the effect of each missense mutation on 
repression activity. The TBX22 promoter construct (pGL3. hPO) was co- 
transfected with wild-type and mutant TBX22-expressing vectors in 293T 
cells. The behaviour of wild-type and mutant TBX22 proteins were 
compared by measuring firefly luciferase activity and a co-transfected 
Renilla luciferase control which was added to normalise for transfection 
activity. Each assay of wild-type and mutant TBX22 proteins was 
repeated five times, each including four replicate reactions for the 
individual protein variants. These findings were averaged as percentage 
activity of the original promoter construct alone and presented in Figure 
3.7. A representative sample of raw data of a luciferase reading for a 
single promoter assay experiment is presented in the Appendix. 
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Wild-type TBX22 and the polymorphic E187K variant consistently 
repressed the hPO promoter to around 40% of its activity. On the other 
hand, all of the mutant proteins appeared defective in their ability to 
repress the promoter. Some missense changes, like N264Y and P183L 
completely abolished repression, while others variably compromised the 
effect on promoter activity compared to the wild-type. Student Mest 
analysis comparing the wild-type repression activity to that of the mutant 
proteins showed the differences between them to be statistically significant 
(Figure 3.7b). 
Interestingly the specific position of the missense change within the T-box 
domain does not directly correlate with either DNA binding ability or the 
effect on repression (Table 3.1). Moreover, some mutants, such as 
T260M and R120W, attenuated promoter activity despite lack of binding to 
the consensus motif (Figures 3.4c and 3.7a; Table 3.1). Thus, TBX22 
activity may not depend entirely on interaction with cis-regulatory DNA 
elements but could involve trans-repression of other transcription factors, 
possibly different T-box proteins (Cai et al., 2005). 
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TBX22 W102C G118C R120W M121V P183L C184F 
variant 
p value 0.011 0.031 0.015 0.002 0.003 0.0016 
TBX22 E187K L214P T260M N264Y 
variant 
p value 0.580 0.035 0.126 0.002 
Figure IT TBX22 promoter repression assay. Effect of wild-type and 
mutant TBX22 (10ng) on the TBX22 promoter hPO (20ng) in 293T cells. 
(a) hPO promoter activity is presented as 100% in the first bar on the left of 
the histogram. Activity after addition of wild-type and mutant TBX22- 
expressing constructs is presented as a percentage of the initial promoter 
activity (-). Error bars were calculated on averaging all the single relative 
activity points across 5 experiments with 4 replicates each, for each 
TBX22 variant. (b) p values of student West comparing TBX22 mutant 
repression values to the effect of the wild-type protein. Values compared 
as a percentage of hPO promoter activity. 
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TBX22 W102C G118C R120W M121V P183L C184F E187K L214P T260M N264Y 
3.5 Sub-cellular localization of TBX22 
In addition to DNA binding, T-box located missense mutations, have also 
been reported to show impaired protein trafficking and sub-cellular 
localization. For example several TBX5 mutations found in Holt Oram 
syndrome patients potentially due to disruption to a putative nuclear 
localization signal (Fan et al., 2003). Therefore, it was decided to test the 
CPX TBX22 missense mutations for potential effects on the ability of each 
protein to enter the nucleus. 
COS-1 cells were used for this study, because their flat structure enables 
clear reading of the immunohistochemical analysis. 
pcDNA3.1. TBX22. V5/His constructs, encoding either wild-type or each of 
the 10 TBX22 mutants, were transfected into COS-1 cells and the sub- 
cellular localization of the expressed proteins was examined by immuno- 
staining with anti-V5 antibody and FITC-labelled secondary antibody. 
Cells were visualised under fluorescence and the sites of TBX22 
expression were superimpose on DAR nuclear staining of the same 
cells. The resulting images show that wild-type TBX22 and all mutant 
proteins similarly localize within the nucleus (Figure 3.8a). No visible 
differences were observed between the mutants. All TBX22 proteins 
display a diffuse staining pattern with nucleolar sparing, indicating 
exclusion from the areas where the most condensed chromatin is present. 
Nuclear localization of TBX22 variants was also studied by separating 
nuclear and cytosolic extracts from transfected cell lysates and analysing 
them by Western blot with the anti-V5 antibody. TBX22 signals were 
present in both nuclear and cytosolic extracts for all proteins (Figure 3.8b). 
While this confirms nuclear localization, cytoplasmic presence may be due 
to over-expressing TBX22 protein inside the cells. 
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WT L214P N264Y R120W M121V P183L E187KC184FG118C W102C T260M 
Figure 3.8: Sub-cellular localization of wild-type and mutant TBX22. 
(a) Three pictures are shown for each TBX22 variant and a mock 
transfection . From left to right: FITC, anti-V5 antibody with FITC- 
secondary; Merged, anti-V5/FITC on DAPI; DAPI, nuclear staining. (b) 
Western blot with anti-V5 of nuclear (N) and cytosol ic (C) extracts of cells 
transfected with TBX22. 
3.6 Preliminary search for candidate 
downstream target genes of TBX22. 
TBX22 is essential for palate development since mutations in this gene 
account for the CPX phenotype and a percentage of isolated cleft palate 
cases (Braybrook et al., 2001; Braybrook et al., 2002; Margano et al., 
2004; Chaabouni et al., 2005; Suphapeetiporn et al., in press). Identifying 
possible target genes for TBX22 is important to elucidate novel and/or 
complete existing pathways involved in palatogenesis. Bona fide target 
genes that function downstream of TBX22 will also constitute new 
candidates for screening in CPX and CID patients with no TBX22 
mutations. The absence of a Tbx22 null mouse makes deciphering 
genetic interactions between TBX22 and other genes more challenging. 
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3.6.1 Analysis of T1/2 site-containing promoter 
sequences of candidate cleft palate genes. 
Since preliminary information on the preferred binding sites and 
transcription regulation activity of TBX22 were available, possible target 
genes were therefore sought in sifico, through possible interaction of 
TBX22 with their promoter regions. The development and optimization of 
a reporter assay based on the regulatory region of a genuine downstream 
target may provide results more biologically relevant, compared to an 
isolated response element upstream of a general promoter. 
Genome scans for the identification of either the T site or other similar 
palindromic sequences have failed to identify perfect matches, while 
numerous half-site sequences are found throughout the genome. Rather 
than try to identify candidate downstream genes by matching these 
sequences to gene promoters, a more targeted approach was adopted. 
This involved a regularly updated literature search using the key terms 
It cleft lip 77 and II cleft palate" to identify various genes that are associated 
with a cleft lip or palate phenotype, either through reported linkage studies 
in CLP/CP families or through transgenic mouse phenotypes presenting 
with an orofacial phenotype (see Table 3.11). The idea was not to perform 
a comprehensive analysis, rather perform a preliminary study with the best 
available candidate genes prior to performing more sophisticated gene 
chip analysis. This latter analysis was planned as an experiment separate 
from this thesis, contingent on generating a mouse model carrying a 
Tbx22 null allele and future grant funding. Therefore, a limited and 
simplistic attempt to identify the putative transcription start sites for each of 
these genes was then made by visually inspecting each gene for predicted 
full length transcripts and alternative upstream exons using the genome 
sequence browser (hftp: //genome. ucsc. edu/). A fragment of 2000 bp 
upstream of the putative start of transcription and the first exon of each of 
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these genes was identified and scanned for the presence of the TBE-like 
sequences shown in Table 3.1. Sequence matching was performed 
manually using the "Find" function in DNA Stdder 1.4f6 using all the listed 
sequences in both orientations. These TBE-like sequences were chosen 
either as part of the TBX22 binding sequence or as TBEs identified for 
other T-box genes (Tada and Smith, 2001). 
Of the candidate genes analysed, 13 putative promoter sequences were 
shown to contain either one or two TBEs, either identical to the perfect T 
half-site, or containing one or two substitutions. The chosen CL/P-related 
genes are shown in Table 3.1 with the presence or absence of TBE 
sequences noted, along with the position this TBE is found within the 
putative promoter region. Nucleotide numbers for the position of the TBEs 
are given assuming base-pair 1 is 2000 bp upstream of the putative start 
of transcription. Of the 13 gene promoters that contained TBE sites, 11 
had a single TBE and 2 contained 2 TBE sequences (Gli2 and TBX10). 
These are presented in more detail in Figure 3.9, with some of the 
regulatory sequence flanking the TBE from either side. 
13,0 
Table 3.1: Presence of TBE-like sequences in putative promoters of 
CP-related genes. 
Gene TBE-like sequence 
tcacacc aggtgtg tgacacc tcacacgt tctcacct aggtgaga 
Tgfb3 no no no no no no 
Tgfb2 no no no no no no 
Tgfbr2 no no no no no no 
Msxl no no no no no no 
Msx2 no no no no no no 
Lhx8(3) no no no no no no 
Lhx6 no no no no no no 
Jagged2 no yes(1820) no no no no 
Bmp2 no yes(1515) no no no no 
Bmp4 no no no no no no 
Bmp7 no no no no no no 
Pax9 yes(1657) no no no no no 
Fgf8 no no no no no no 
Shh no no no no no no 
Ptch no no no no no no 
lrf6 no no no no no no 
Acod4 yes(1021) no no no no no 
Pvrll no no no no no no 
Pvrl2 no no no no no no 
TP63 no no no no no no 
Rara no yes(474) no no no no 
Mthfr no no no no no no 
Tgfa no yes(172) no no no no 
Bd3 no no no no no no 
Fl3a no no no no no no 
Gabrb3 no no no no no no 
Tfap2a no no no no no no 
Ski no no no no no 
no 
Coll 1 al no no no no no 
no 
Collla2 no no no no no 
no 
Col2al no no no no no yes(877 
Dhcr7 yes(495) no no no no 
no 
Dlxl no no no no no 
no 
ii 
Dlx2 
Dlx5 
Egfr 
Foxel 
Foxc2 
Foxf2 
GH2 
Inhba 
Ryk 
Mmp-2 
Mmp-3 
Mmp-1 3 
Timp-2 
Prx 
Prx2 
Goosecoid 
Decorin 
Biglycan 
Fgfrl 
Fgfr2 
FgflO 
Satb2 
Tbxl 0 
Gad67 
Osr2 
Osri 
Pdgfc 
Pdgfra 
Pdgfa 
LGR5 
Cask L 
Cask M 
Cask S 
Nestin 
BMPRla 
Pitx 1 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
yes (363) no no no no yes (1724) 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no yes (525) no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no yes (2) no no yes (1088) no 
no no no no no no 
no yes (144) no no no no 
no yes (382) no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
no no no no no no 
I 32 
JAGGED2 (Jiang et al., 1998; Shimizu et al., 2000) 
tgcggcgccggcgcacgcctcgccgactcacgcqqagglqtqagcqq. qgcccccgcggcccgcgctgaccccgaggccccgt 
BMP2 (Ashique et a/., 2002; Zhang et al., 2002; Ma et al., 2005) 
ctgcaggagatcgggggcctgggacgcgctq-qccqaqgt-qtqatcgcia, ccccaaactagccacaaagggcacttggccccag 
RARA (Mitchell eta/., 2003) 
ccacctgcctcagcctcccaaagtgctg ggattataqgtqtga-qccaccg cacccaactgactttcgtatttttag tagag a 
TGFa (Passos-Bueno et al., 2004; Abboft et al., 2005) 
ccacccacctcagcctcccaaagtgatggtattacag-qtqtgaqccaccatgcctggcctgcaagftacctcttgatttaaa 
GOOSECOID (Rivera-Perez et al., 1999) 
cftggftaattagcctgagagaaatcgcgaaaaatagqtqtqaqftaaaggcggacftccftcaggaaacccgaggtctccc 
OSR2 (Lan et al., 2004) 
tctgcacccaacgtacacatacftaagggcgggaaaqgtgt-qaagcccgctgctggggagttgcctcccctttgatgaaaag 
OSRI (Lan et al., 2004) 
ccftgaagcfttctgttctggaatctctagqaagg agqtqtqatctcagctctcftctcttccaagggftcftactctagca 
TBXI Oi (Bush et al., 2004) 
cacgccacctcctggtattgagcagtgatat-qaqaaqqtqtqaagqa acgggggcaccagggacaggctggcaggcaagatg 
PAX9 (Peters et al., 1998; Hamachi et al., 2003) 
cgcaacctcctgg fttctftg g ccgg cctatcttctcaca ccjg cgctctcg ccacctg gcatg ga ctg a ag tg agg tag a at 
ACOD4 (Beiraghi et al., 2003) 
gcccttttacftctgctgcctgcccgcaattqcciq tcacacctqcttcagaca cftccagctca atcctccctccattttctg 
GL12i (Mo et al., 1997) 
acagctgcccacccgtccacactctggaagacccttcacaccftcctqagctctgcctggccccagtcctggagctccttgtt 
DHCR7 (Nowaczyk et al., 2001; Witsch-Baumgartner et al., 2005) 
tcctggggtftaaaaaagggctgtagggcaciaqcttcacacctqtaq cccagcactgtaggaggccacagtgggtggatcgc 
COL2a I (Arita et al., 2002; Vu et al., 2003; Nishimura et al., 2005) 
accagctaagccctgg gaagaaggcagfttqqcta aqqt-qaqagaqqg cgctcaccggggaaggtg a ggtg aggcggcaag 
GL12ii (Mo et al., 1997) 
agggcacgcatgccgcacgactgagatcacacicagaggtqaqaacaccgtggctctgtggtggctgtgactgctgagaggcga 
TBXIOii (Bush et al., 2004) 
Aacagacagacccacaggcagagcggacgcccacttctcacctqqqccagcctcaccgtttccactcatgtccagatggggat 
Figure 3.9: Promoter sequences containing T-box elements, of genes 
associated with cleft palate. TBES are shown in red; sequences used as 
probes in the EMSA reactions are underlined; and references providing further 
details of each gene including putative function are given in parentheses after 
the gene name. 
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3.6.2 TBX22 selectively binds to putative TBE- 
containing promoter sequences. 
The promoter regions of the CP-related genes that contained TBE sequences 
were tested for binding to TBX22 to assess possible interactions between 
TBX22 -and any of them, as these genes may constitute candidate target 
genes for TBX22 regulation. 
DNA fragments of around 25 nucleotides were synthesised from the 15 TBE- 
like binding sites shown in Figure 3.9. The oligonucleotides were designed to 
contain the TBE and were flanked by some additional sequence providing the 
genomic context on either side. To make double stranded DNA, two 
complementary oligonucleotides were synthesised for each sequence and 
annealed together for use in EMSA based DNA-binding studies with in vitro 
translated wild-type TBX22. myc protein. Four reactions were performed for 
each putative regulatory element, consisting of free 32 P-labelled 
oligonucleotide only, the RRL control and TBX22. myc without and with the 
addition of anti-myc antibody. Reactions were run on non-denaturing poly- 
acrylamide gels, as described previously (Section 3.2). 
Compared with the TBX22 consensus sequence, none of the putative binding 
sites gave comparable shifts and super-shifts (Figure 3.10a). However, 
previous studies show that TBX22 binds more weakly to the T half-site than 
the full T palindromic sequence, and two out of the 15 sequences showed a 
similar picture here, i. e. although no shift was detectable, a clear super-shift 
could be seen with addition of anti-myc antibody (Figure 3.1 Oa). These were 
the putative regulatory elements of TBXIO and OSRI genes. Interestingly, the 
2 kb fragment upstream of the TBXIO transcription start site contains two TBE 
sequences, one very close and one distal to the first exon. Both were tested 
but only the proximal TBX10 site (TBXIOp) appears able to bind TBX22 and 
form a complex. 
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Figure 3.10b: Binding of TBX22 to the TBX10p and OSRI TBE sites. 
Repeat of EMSA reactions with TBX22. myc and the TBX10p and OSRI 
sites, as shown in 3.1 Oa. 
Several other oligonucleotides also showed evidence for TBX22 specificity, 
such that non-specific bands that form in the RRL control lanes are 
competed out upon addition of TBX22 protein (Figure 3.10a). These 
complexes, however, were not stable enough to generate detectable shifts 
and these sequences were not studied further. To establish that the 
positive results for TBXIOp and OSRI were reproducible, a second set of 
independent reactions was performed, confirming TBX22-specific DNA- 
binding in the presence of antibody (Figure 3.1 Ob). 
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3.6.3 Analysis of the TBX10 and OSRI putative 
promoter fragments. 
The binding site screening assay demonstrated that TBX22 can form 
complexes with the putative regulatory elements of the TBXIO and OSRI 
genes; it was thus decided to test these DNA fragments for promoter 
activity. In order to clone the putative promoter sequences for each gene, 2 
kb of DNA sequence upstream of the respective transcription start sites 
were amplified from human genomic DNA (volunteer normal control sample 
extracted from blood). Both fragments were cloned into pGL3 luciferase- 
basic vector in the coding and the complementary reverse orientations. 
Integrity of the resulting constructs was confirmed by DNA sequencing. 
The TBX10 and OSRI forward and reverse promoter constructs were 
transfected into 293T cells to assess promoter activity using a standard 
Rend/a/firefly luciferase assay. Increasing concentrations of each construct 
were tested, along with the same amount of the promoter fragment in the 
reverse orientation as a control. 
Both TBXIO and OSRI putative regulatory fragments (Figure 3.11 a and b 
respectively) show promoter activity when cloned in the coding orientation, 
while the same fragments in the reverse orientation appear devoid of 
activity. This confirms that there is at least some basic promoter activity 
included within the 2 kb fragments upstream of each gene. Moreover, the 
promoter activity is dose dependant, rising with increasing concentrations of 
each construct until a peak is reached when 20 ng of plasmid are used in 
each well (96-well plate format). Comparison of the luciferase values 
between the two assays shows that promoter activity is higher for the OSR1 
than the TBXIO sequence. TBXIO promoter activity only represents a 10% 
fraction of that obtained for the TBX22 hPO construct. This might be an 
effect specific to the cell line where the assay is performed, since 
TBX10 is 
normally expressed in a very spatially restricted manner. 
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Figure 3.11: Promoter activities of the OSRI (a) and TBXIO (b) 
regulatory elements. Bars represent relative promoter activity at different 
plasmid concentrations shown along the x axis. +ve: fragment in the ORF 
orientation; -ve: fragment in the reverse; pGL3 basic: background 
luciferase activity (negative control). 
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3.6.4 TBX22 can regulate the OSRI promoter 
Having established regulatory activity for the putative TBXIO and OSR1 
promoter fragments, it was next possible to investigate if TBX22 protein 
might have an effect on this activity. Conveniently, the cell lines used for 
the initial promoter analysis have no endogenous TBX22 expression and 
effects can be monitored based on the co-transfection of a TBX22 
expressing plasmid. TBX22 therefore was co-transfected into 293T cells 
together with the either pGL3-TBXIO or pGL3-OSRI promoter constructs, 
as previously described for the pGL3-hPO promoter assay (Section 3.4). 
In addition to wild-type TBX22 protein, the E187K polymorphic variant was 
also used as an internal control, and the W102C was selected as a mutant 
completely devoid of DNA-binding activity to assess specific versus non- 
specific effects. Assays were performed in 96-well plates, with 20 ng of 
the promoter construct used in each well (apart from the empty pGL3 
vector control) and increasing concentrations of the TBX22 proteins. The 
firefly luciferase value was measured and normalized with the 
corresponding Renilla value, to give the relative promoter activity for each 
sample. The results presented here are the average of two independent 
experiments, performed in 293T and COS-1 cells, each one including four 
replicates of every well. 
In 293T cells, wild type TBX22 shows a distinct repressing effect on the 
OSRI promoter (Figure 3.12a). There is a suggestion of increasing effect 
with concentration although this was more evident for the E187K variant, 
with both resulting in a decrease to 40-50% of the initial activity. A similar 
trend was also seen for the W1 02C mutant but with slightly reduced effect. 
All 3 constructs had a similar effect at the highest concentration, perhaps 
because the cell system becomes saturated with over-expressed protein 
and the repression is no longer specific. 
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Figure 3.12: Effect of TBX22 on the putative OSR1 promoter. Promoter 
activity shown without (-) and with addition of TBX22 wild-type and two 
variants, at increasing concentrations, in 293T (a) and COS-1 cells (b). 
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In general, the effect of TBX22 on the OSRI promoter is different when 
performed in COS-1 cells (Figure 3.12b). Here, 5 or 10 ng of TBX22 have 
little effect on the promoter activity and marked repression is only seen at 
the higher 25 ng dose. Again the W1 02C mutant has least effect on 
repression, with only a minor reduction evident at the 25 ng dose. 
A similar situation is replicated when all the TBX22 mutants are tested in 
the OSR1 promoter assay in both 293T and COS-1 cells (Figure 3.13). 10 
ng of each construct (per well of a 96-well plate) was used to avoid 
possible saturation problems. In 293T cells the overall trend resembled 
that seen in the hPO promoter assay (Section 3.4). The highest level of 
repression was seen with wild-type TBX22 and the E187K polymorphism, 
while the different mutants showed either abrogation or complete loss of 
repression (Figure 11a). In COS-1 cells, the overall effect is quite 
different with either no repression or even slight activation seen in all the 
mutants, including the El 87K polymorphism (Figure 11 b). 
This observation is interesting because both 293T and COS-1 cell lines 
have been shown to have no endogenous TBX22 expression (E. Pauws), 
so any effects are likely to be due to externally added protein. 
To assess the possibility that different levels of endogenous OSRI 
expression might play a role in this result, cDNA preparations of 293T and 
COS-1 cells were tested with OSRI exon specific primers. Both cell lines 
expressed OSRI similarly (Figure 3.14), so it is unlikely that this factor 
contributes to the differences seen between cell types. In order to test this 
assay in a cell line where OSRI is not endogenously expressed, several 
other cell lines available in our laboratory were also investigated for OSRI 
transcripts. However, the HeLa, T471D, HEIPM and mouse NIH3T3 cells 
were also positive (Figure 3.14), therefore, these studies were not 
explored further at this time. 
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Figure 3.13: Effect of wild-type and mutant TBX22 on OSR1 promoter 
activity. Promoter activity presented alone (-) and after co-expression of 
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Figure 3.14: RT-PCR for the expression of OSR1 in various 
mammalian cell lines. Key to lanes: 1, HeLa; 2,293T (human embryonic 
kidney); 3,3T3; 4, COS-1; 5, T47D; 6, HEPM (human embryonic palatal 
mesenchyme); 7, blank; M, 1 kb DNA ladder. PCR reactions on positive 
and negative RT samples are presented on separate gels (a and b, 
respectively). 
3.6.5 Effect of TBX22 on the TBXIO promoter 
The TBXIO putative regulatory element cloned in front of the luciferase 
gene shows very low activity (1.4-3.6 fold higher than empty pGL3 vector) 
compared to OSRI promoter sequences (-6-200 fold) over the same 
concentration range. This low level makes it difficult to conclude with 
confidence that the differences were due to a real effect when TBX22- 
expressing constructs were co-transfected with the pGL3-TBXIOP 
fragment. The data presented in Figure 3.15 show an example of typical 
results from a single TBXIO putative promoter assay. TBXIO promoter 
activity appears to be repressed with addition of 5 ng of wild-type TBX22 
expressing construct, while higher concentrations seem to abolish activity 
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1 1 
completely. The E187K variant appears not to have an effect at 5 ng but 
represses at the 10 ng concentration. Addition of the W102C mutant 
results in a complete repression at 5 ng, although this effect appears lost 
when plasmid amounts are increased. It may be of value in the future to 
replicate these experiments in different cell lines or to investigate different 
promoter constructs, which may enhance the signals obtained here. 
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Figure 3.15: Effect of TBX22 on the putative TBXIO promoter. TBX10 
promoter activity shown alone (-) and after co-expressing TBX22 wild-type 
and two variants. A dotted line across the histogram shows the level of 
background luciferase activity, as indicated by the pGL3 basic reading. 
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3.6.6 Regulation of the OSRI promoter by 
TBX22 is not dependent on binding to the TBE in 
the promoter sequence. 
T-box proteins bind to TBEs in the promoter regions of their target genes 
and regulate their expression (Tada and Smith, 2001). Deletion of one or 
more TBE sequences from a target promoter construct can lead to loss of 
the transcriptional activity of the T-box protein (Casey et al., 1998; Sun et 
al., 2004; Cai et al., 2005) 
As detailed above (section 3.6.2 and 3.6.3) the 2 kb sequence upstream of 
the OSRI gene that contains a TBE that binds TBX22 protein in gel shift 
assays appears to function as a regulatory region. The complete 2 kb 
fragment shows promoter activity in mammalian cell lines that express 
OSRI but have no endogenous TBX22 expression. Co-transfection of 
TBX22 in that assay represses this promoter activity and is sensitive to 
natural mutations found in CPX patients. In order to test if this repression 
activity occurs through TBX22 binding to the TBE element within the 
OSRI promoter fragment, a truncated version of the original 2 kb 
regulatory fragment omitting the TBE sequence was cloned into the pGL3 
vector. The integrity of the construct was confirmed by DNA sequencing. 
The OSRI promoter assay was then performed again as described above, 
with both the full-length OSRI regulatory fragment and the TBE negative, 
truncated one (Figure 3.16). Wild-type TBX22 and N264Y mutant 
constructs were co-transfected at increasing concentrations in the assay. 
The N264Y mutant was selected as it showed the greatest loss of 
repression in the OSRI promoter assay. A range of 0.1,1 and 10 ng of 
pcDNA3.1. TBX22. V5/His were used per well of a 96-well plate to 
maximise any differences in resulting effects, where 10 ng of TBX22 
14 5 
construct has previously been shown sufficient to observe a repression 
effect on the OSRI promoter in 293T cells. 
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Figure 3.16: TBX22 regulation of the putative OSR1 promoter in the 
presence and absence of a T-box element. OSR1 promoter activity 
presented alone (-) and after co-expression of TBX22 wild-type and 
variants. The same assay shown with full-length and truncated (in the 
absence of the TBE) OSRI promoter fragments (a and b, respectively). 
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It was interesting to note a possible activating effect seen at the lower 
concentrations. This finding will be investigated in future studies. 
Promoter activity is observed with both the full-length and truncated OSR1 
regulatory fragments (Figure 3.16a and b). Addition of low concentrations 
of wild-type TBX22 (0.1 and 1 ng) had no repression effect on the OSR1 
promoter, in either the full-length or the truncated regulatory fragments. 
Repression of the promoter is seen when 10 ng or more of wild-type 
TBX22 construct is added, while the mutant form of the protein shows no 
effect, consistent with what has been shown previously (Section 3.6.4). 
Comparison of the full-length OSR1 regulatory fragment and the truncated 
fragment showed little difference. Surprisingly and therefore, contrary to 
our prior assumption, it appears that the identified TBE upstream of the 
OSR1 start site has no obvious role in the repression activity of TBX22. It 
might be that there are other unrecognised sequences present within the 
truncated promoter sequence that TBX22 can bind to. Alternatively, the 
repression effect might be independent of direct DNA-binding and an 
intermediate protein-protein interaction is necessary between TBX22 and 
OSR1. Further studies will be required to investigate this interaction, 
including the analysis of additional truncated OSR1 promoter constructs to 
identify the minimal promoter and the sequences required for TBX22- 
dependant repression. 
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3.7 Post-translational modification of TBX22 
by SUMO 
3.7.1 TBX22 is SUMOylated 
Post-translational modification provides proteins with additional groups or 
peptides important for their function. For signalling molecules or 
transcription factors, such modifications can have a marked effect on the 
final activity of the protein, for example making an inert molecule active or 
favouring a transcriptional activity towards activation or repression. 
Modification of mammalian transcription factors by the small ubiquitin- 
related modifier SUMO has been most often linked to transcriptional 
repression (Johnson, 2004). 
Analysis of the TBX22 protein sequence with the ELM (The Eukaryotic 
Linear MOtif) resource for functional sites in proteins (hftp: //elm. eu. org/), 
suggested that it contains at least one putative SUMOylation site (see 
section 3.7.2 below). The idea that TBX22 might be modified in this way 
fitted well with the data establishing that TBX22 acts as a repressor in the 
TBX22hPO and OSRI promoter assays. To investigate functionally 
whether TBX22 is subject to SUMOylation, transfections were performed 
in COS-1 cells with full-length pcDNA3.1. TBX22. V5/His alone, or co- 
transfected with constructs expressing either SUMO-1 wild-type (SUMO-1 
HSTV) or a mutant form of the peptide, with the active C-terminal end 
missing (SUMO-1 AGG). The latter construct produces SUMO-1 but is 
equivalent to a null since attachment of the SUMO peptide occurs through 
the sequence at its C-terminal end and is therefore unable to modify its 
target proteins. 
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SDS-PAGE and Western blotting analysis of the transfected cell extracts 
with anti-V5 antibody showed the free TBX22 protein band at the expected 
size, but also a higher molecular weight species consistent with SUMO 
modification (Figure 3.17). The SUMO-1 peptide is 11 kDa in size, but in 
Western blot analysis, it is frequently reported to increase the target 
protein's molecular weight by an apparent 20 kDa. The slower band 
observed in the cell lysates transfected only with TBX22 corresponds to 
this difference in size. Upon over-expression of wild-type SUMO-1 the 
intensity of this species increases, thus providing preliminary evidence 
than it represents a TBX22-SUMO complex. When the inactive SUMO-1 
AGG mutant is co-transfected with TBX22, the slower band remains at its 
initial intensity, as only the endogenous SUMO-1 is active. 
In order to confirm that the interaction between TBX22 and SUMO-1 is 
real and corresponds to the observed slower migrating band, a co- 
immunoprecipitation experiment was performed to pull down the putative 
TBX22-SUMO complex. COS-1 cells were transfected with TBX22 and 
SUMO-1 expressing constructs, as above, and any complexes were 
precipitated from the lysates using an "in house" rabbit polyclonal anti- 
TBX22 antibody. The samples were then cleared of non-specific 
complexes by washing and analysed by Western blotting with anti-SUMO- 
1 and anti-V5 antibodies. Analysis with the anti-SUMO-1 antibody shows 
one band in the lane of the wild-type SUMO-1, while no bands appear with 
the mutant SUMO peptide (Figure 3.18). When the same blot was 
stripped and re-probed with anti-V5 antibody, the unmodified TBX22 
bands appear in both lanes, as well as a slower mobility band in the lane 
of the wild-type SUMO-1. This is at the same position as the band seen 
with the anti-SUMO antibody (Figure 3.18). These results confirm that the 
higher molecular weight band corresponds to covalent modification of 
TBX22 by SUMO-1. 
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Figure 3.17: TBX22 SUMOylation in the presence of endogenous and 
over-expressed SUMO-11. Western blot with anti-V5 of cell lysates 
transfected with TBX22. V5- and SUMO-expressing constructs. Free 
TBX22 and TBX22-SUMO complex are indicated by arrows. 
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Figure 3.18: Co-immunoprecipitation of the TBX22- SUMO-1 complex. 
Cells transfected with constructs expressing TBX22. V5 and SUMO-1 wild- 
type and mutant (appearing on each gel on the left and right hand side 
respectively). Free TBX22 and TBX22-SUMO complexes are indicated by 
arrows. The same membrane is used, first blotted with anti-SUMO-1 and 
then with anti-V5 antibodies. 
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3.7.2 Site of SUMO-1 modification in TBX22 
The TBX22 protein sequence was screened for the minimal consensus 
motif LPKXE/D, in which LP is a large hydrophobic residue and K is the 
lysine to which the SUMO peptide is attached. The protein sequence of 
human TBX22 was analysed in the SUMOplot prediction application 
(http: //www. abgent. com/doc/sumoplot). Three putative SUMOylation sites 
were identified, one inside the T-box domain at K271, and two at the N- 
terminal part of the protein before the start of the T-box, at positions K54 
and K63 (Figure 3.19a). The K271 is a highly conserved position among 
T-box genes, while the K63 is conserved in TBX22 homologues among 
different species. The K54 site is unique to human TBX22 and not 
conserved in the mouse. When the mouse Tbx22 sequence is analysed 
through the same SUMOplot application, the K63 and K271 (K268 in the 
mouse) positions also come up as potential SUMO modification sites. 
To investigate which of the identified K residues are real SUMO acceptor 
sites, and to examine the effect of SUMO-1 conjugation in vivo, full-length 
TBX22 constructs were prepared by in vitro mutagenesis, with each lysine 
residue individually mutated to a non-SUMOylatable arginine. Presence of 
the TBX22-SUMO-1 complex was assessed for each mutant protein 
following transfection and Western blotting. Mutation of K63 completely 
abrogates SUMOylation, as seen by the absence of the higher molecular 
weight band (Figure 3.19b). In the K271R mutant, SUMOylation is 
attenuated, as seen by the presence of a TBX22-SUMO-1 complex of 
reduced intensity. In contrast, mutation of the non-conserved K54 has no 
effect on TBX22 SUMOylation. It was thus concluded that K63 is the main 
site of SUMO-1 attachment to TBX22. K271 may provide an alternative, or 
possibly accessory modification site, although no evidence such as a 
second, higher molecular weight species has been seen to suggest 
attachment of SUMO peptides at two separate sites. 
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Figure 3.19: SUMOylation site of TBX22. (a) Three SUMO consensus 
sites are shown in the human (H) and mouse (M) TBX22 protein 
sequence. Sites are included in boxes and attachment lysine residues are 
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3.7.3 Functional effect of TBX22 lysine mutants. 
SUMO attachment has been shown to assist or even modify various 
functions of target proteins (Johnson, 2004). In order to assess any effect 
the SUMO site mutations may have on normal TBX22 protein function, the 
three lysine mutants were tested in both the pGL3-hPO promoter assay 
and in DNA binding reactions. 
The promoter assay was performed as described previously (Section 3.3), 
using 10 ng of each TBX22 plasmid per well of a 96-well plate. Co- 
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transfection of both the K63R and K271 R mutants shows that they fail to 
repress the hPO promoter, resulting in the same activity as for the pGL3- 
hPO construct alone, while the K54R mutation is able to repress normally 
and appears indistinguishable to wild-type TBX22 (Figure 3.20a). 
Although K54 and K63 are present outside of the T-box domain, according 
to the crystal structure of Brachyury (Muller and Herrmann, 1997), K271 
(K205 in Brachyury) is within the al-13 that directly bridges the DNA 
backbone and next to 1206, which forms hydrophobic contacts with a 
guanine residue of the target sequence. It was therefore decided to 
investigate whether the effects on hPO repression could be linked to DNA 
binding ability. EMSA reactions were performed with in vitro translated 
TBX22 lysine mutants, as previously described (Section 3.2). Both K54R 
and K63R retain their ability to bind DNA and appear indistinct from wild- 
type TBX22, while the K271 R mutation has resulted in complete loss of 
binding (Figure 3.20b). This strongly suggests that the loss of repression 
obtained in the hPO promoter assay with the K63R mutant is independent 
of DNA binding and most likely due to loss of SUMOylation. In contrast, 
for K271 R, loss of repression is likely to be linked with its impaired DNA- 
binding ability. 
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Figure 3.20: Ability of TBX22 Lysine mutants to repress hPO and bind 
DNA. (a) The SUMO site mutants in the hPO promoter assay. Wild-type 
TBX22 and K54R repress hPO, while no repression is seen with the K64R 
and K271 R variants. (b) Autorad of EMSA reactions with in vitro translated 
SUMO site mutants in the absence (-) and presence (+) of antibody. 
K54R and K63R bind DNA like wild-type TBX22, while K271 R has lost 
binding ability. Shifts, super-shifts and non-specific bands are indicated by 
arrows. 
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3.7.4 SUMOylation of other T-box genes. 
The analysis of the TBX22 lysine mutants showed that K63 is the major 
site of SUMO attachment, while K271 could act as a secondary site. 
Among different T-box proteins, K63 is unique to TBX22, while K271 is 
found ubiquitously (see Figure 1.6, Introduction). If K271 is a SUMO 
attachment site for TBX22, it might be predicted that many other T-box 
genes would also be modified in the same way. In fact this site as a 
consensus motif has previously been implicated (albeit without performing 
functional analysis) as a putative SUMO attachment site for Tbx2 
(Chowdhuri et al., 2006). It was thus decided to test a selection of other T- 
box genes for potential SUMOylation. 
Mammalian expression constructs were obtained for Brachyury, TBX1, 
Tbx2, Tbx8/15 and TBX18 (kind gifts from Peter Scambler, Andreas 
Kispert and Colin Godding). Cells were transfected with each construct 
alone and in the presence of over-expressing SUMO-1. Western blots 
optimised for detection of SUMOylation were then performed (Figure 
3.21). 
TBX2 does indeed appear to be modified by SUMO-1, as seen by the 
higher molecular weight bands appearing on the blot (Figure 3.21a), thus 
confirming previous reports (Chowdhuri et al., 2006). However, TBX1, 
Tbx8/15, TBX18 and Brachyury show no evidence of this modification 
(Figure 3.21 b, c and d). Further experiments might be required to confirm 
this result but preliminary evidence suggests that the K271 is not a 
universal SUMO-site for all T-box proteins. 
Collectively, the data suggests that in TBX22, K63 is the unique SUMO 
attachment site while K271 is required for DNA binding and may effect 
SUMO conjugation through some other mechanism. 
1ýý 
a b 
TBX2-FLAG: 
SUM01-GG-HSTV: 
SUM01-AGG: 
-00. TBX2-SUMO-1 
TBX2 
TBX1 -. ++ 
SUM01-GG-HSTV: 
low 
-00. soft 
TBX1(A, B, C) 
-01-- 
T-myc- +++d 
Tbx8-myc: 
SUM01-GG-HSTV: + 
TBX18-myc: 
SUM01-AGG: + 
SUM01-GG-HSTV: 
SUM01-AGG: 
Bachyury (T) -loo. IN~ 4, Vj" %gW 
Tbx81TBX18-0, ý OW-MW 40m w-&- %00-- Awmww 
Figure 3.21: SUMO-1 modification of other T-box proteins. Western 
blots of cells transfected with TBX2 (a), TBX1 (b), Brachyury (c), Tbx8/15 
and TBX18 (d), alone and in the presence of over-expressing SUMO-1. 
Free proteins are indicated on each gel by arrows, as well as a SUMO-1 
complex only seen with TBX2 (a). Membranes blotted with anti-FLAG (a), 
anti-TBX1 (b), and anti-myc (c, d). In (b), A, B, C correspond to different 
isoforms of TBX1 in the cell lysate (Torres-Juan et al., 2007). 
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3.7.5 Functional analysis of TBX22 
SUMOylation. 
The behaviour of the TBX22 lysine mutants in the hPO promoter assay 
indicates that SUMOylation has an important role in its ability to 
transcriptionally repress. This ability can be dependant on DNA-binding, 
as for example with the K271R mutant, where blocking the ability of the 
protein to bind DNA resulted in loss of its repression function. Loss of 
repression can also occur independently of DNA-binding and may be 
dependant on SUMOylation status, such as for K63R, which binds DNA 
efficiently but is deficient in SUMO attachment. Thus it was decided to 
investigate SUMO modification of wild-type TBX22 as an essential 
regulator of transcriptional activity. 
The covalent modification of target proteins by SUMO-1 is a reversible and 
transient process that is mediated by SUMO-specific peptidases (SENPs). 
These enzymes activate the SUMO peptide by initially cleaving its C- 
terminal end, but also de-conjugate SUMO-modified proteins (Li and 
Hochstrasser, 1999). SENPs are often specific to different SUMO species 
and substrates (Mukhopadhyay and Dasso, 2007). 
To investigate the functional role of SUMOylation on the repression activity 
of wild-type TBX22, SUMO attachment was blocked in co-transfection 
experiments in the hPO promoter repression assay. Two members of the 
family of SUMO proteases, SENP1 and SENP2, were used to obstruct 
SUMO attachment. These enzymes were selected for preliminary 
experiments, as they were likely functional candidates. Although they are 
both localised into the nucleus, their sub-nuclear position is different: 
SENP2 is associated with the nucleoplasmic side of the nuclear pore 
complex (Hang and Dasso, 2002), while SENP1 accumulates in the 
nucleus but is also consistently seen in lower amounts in the cytoplasm 
(Gong et al., 2000). In addition to the wild type enzymes, a mutant form of 
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each one was also used. For SENP1, the mutant enzyme is inactive and 
therefore would be expected to have no effect on SUMO-1 conjugation 
(Bailey and O'Hare, 2004). The SENP2 mutant, however, is an overactive 
form that de-SUMOylates target proteins with overall reduced specificity 
(Hang and Dasso, 2002). 
In order to assay the effect of de-SUMOylation on TBX22 activity, 293T 
cells were co-transfected with the hPO and wild-type TBX22 constructs, 
along with one of the four SENP constructs. The assay was also repeated 
by substituting wild type TBX22 for the N264Y mutant, as a control, since 
this mutant completely loses repression ability. As shown previously, the 
wild-type TBX22 was found to repress the hPO promoter (Section 3.3; 
Figure 3.22). A similar result was also observed upon addition of both 
wild-type and mutant SENP1 enzyme constructs. However, over- 
expression of both SENP2 constructs resulted in complete loss of 
repression by wild-type TBX22 (Figure 3.22). The histogram in this figure 
also shows that addition of SENP2 not only relieves promoter repression 
by wild-type TBX22, but it appears to result in activation of the same 
promoter. This observation was examined with further experiments (see 
section3.7.6, Figure 3.25) and found to be a general cell effect upon 
transfection of SENP2 enzyme, rather than an effect specific to regulation 
by TBX22, as the basic hPO activity increases upon addition of SENP2. 
Western blots to examine TBX22 SUMOylation in the presence of the 
SENP enzymes (kindly performed by Marius Jones) also demonstrate that 
the stability of unconjugated TBX22 as well as the SUMOylated form are 
distinctly reduced in cells over-expressing SENP2 but not with over- 
expressed SENP1 (Figure 3.23). 
Overall these results suggest that SENP2, but not SENP1, ran specifically 
de-conjugate the TBX22-SUMO-1 complex, and that SUMOylated TBX22 
is responsible for the repression effect observed on the hPO promoter. If 
this modification is reversed, wild-type TBX22 loses its repression ability. 
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Figure 3.22: TBX22 effect on the hPO promoter in the presence of 
SENPs. TBX22 wild-type (a) and N264Y mutant (b) in the hPO promoter 
assay, alone and co-transfected with SENP1 and SENP2, wild-type and 
mutant. As SENP2 abolishes repression by TBX22 completely, no further 
activity is seen upon addition of the SENP2 over-active mutant, probably 
due to saturation already having been reached by the activity of wild-type 
SENP2.10 ng of each TBX22 and SENP constructs used per well of a 96- 
well plate. 
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Figure 3.23: TBX22 SUMOylation in the presence of SENPs. Western 
blots of cell lysates co-transfected with TBX22 and increasing levels of 
SENP-expressing constructs (kindly performed by M. Jones). 
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3.7.6 CPX mutations compromise 
SUMOylation. 
TBX22 
Interfering with TBX22 SUMOylation either by mutating the attachment 
lysine or by enzymatically de-SUMOylating has demonstrated a crucial 
role for this post-translational modification in its ability to transcriptionally 
repress. Previously CPX mutations were investigated for both DNA- 
binding and repression ability. Although these appear to have a strong 
relationship, they do not completely correlate in a linear way. To extend 
this study further, the SUMOylation status of these missense mutants was 
investigated. 
Western blot experiments were performed using lysates of cells 
transfected with the various mutant TBX22-expressing constructs, either 
alone or with the addition of wild-type SUMO-1. Perhaps unexpectedly, all 
of the mutants either fail to SUMOylate or have markedly reduced levels of 
SUMO conjugation, even in the presence of over-expressed SUMO-1 
(Figure 3.24 a and b, respectively). The E187K variant is still able to get 
modified by SUMO, although in the figures presented here it appears to 
SUMOylate to a lesser extend than the wild-type. Further experiments 
repeated following the end of my project (Dr Erwin Pauws and Marius 
Jones) showed that the E187L polymorphism does indeed behave in a 
similar way to wild-type TBX22 in SUMOylation experiments (e. g. as 
shown in Andreou et al., 2007). The reduced SUMOylation seen for 
L214P, T260M and N264Y may reflect their position and conservation 
within the T-box domain that is similar to that of the lysine mutant K271 R 
shown above. Despite the disparate location of the various missense 
mutations throughout the T-box domain, impaired SUMO-1 conjugation is 
a consistent finding that may suggest a common mechanism for loss of 
TBX22 function independent of DNA binding ability. 
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Figure 3.24: SUMOylation status of the TBX22 CPX mutants. 
Western blot with anti-V5 of cell lysates transfected with TBX22 variants 
(a) and co-transfected with wild-type SUMO-1 (b). Free TBX22 and 
TBX22-SUMO complexes are indicated by arrows. 
3.7.7 Effect of SUMO-1 and SENP2 
expression on TBX22 mutants. 
over- 
Since SENP2 was shown to de-SUMOylate wild-type TBX22 and through 
this process abrogate its repression ability, it was decided to test the effect 
of this enzyme on some of the CPX mutant forms of the protein that still 
retained some repression activity, to see if this would completely abolish 
repression. Similarly, it was of interest to test the effect of over-expressing 
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WT Wl 02C Gl 18C Rl 20W Ml 21 V Pl 83L Cl 84F El 87K L214P T260M N264Y 
SUMO-1 on the behaviour of some of these mutants, to see if increased 
SUMOylation might rescue repression of the hPO promoter. 
Three mutants were tested in this assay: the W1 02C, because it showed 
the highest repression activity out of the 9 mutants in the hPO promoter 
assay, the L214P and N264Y mutants since they had both lost repression 
ability almost completely. As in the case of wild-type TBX22, co- 
expression of SENP2 relieves the mutants of any remaining repression 
ability and returns promoter activity to the normal hPO level (Figure 3.25). 
As can be seen in this histogram, expression of SENP2 with hPO alone 
results in a higher promoter activity overall, and TBX22 variants appear to 
have no effect on this activity (Figure 3.25, black bars). Addition of wild- 
type SUMO-1 in the assay, however, has no effect on the original 
promoter levels. It also does not seem to affect activity of wild-type 
TBX22, W102C or N264Y mutants (Figure 3.25, grey bars). Interestingly, 
when SUMO-1 was expressed together with the L214P mutant, an 
increase in repression ability was detected (Figure 3.25). In the Western 
blot analysis, L214P appears to retain some SUMOylation potential, but at 
a similar level when compared to N264Y. Thus this effect may reflect 
different abilities to be SUMOylated in the presence of excess free SUMO 
peptide. 
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Figure 3.25: Repression activity of wild-type and mutant TBX22 in the 
presence of SENP2 or over-expressing SUMO-1. The effect of three 
TBX22 variants is shown in the hPO promoter assay alone (white bars), 
and in the presence of over-expressing SUMO-1 (grey bars) or SENP2 
(black bars). 
3.8 Summary of results 
In order to facilitate the characterization of TBX22 function at the cellular 
and molecular level, the DNA-binding ability, transcription regulation, 
interaction with candidate target genes, sub-cellular localization and post- 
translational modification of the protein were studied. 
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The normal function of TBX22 was examined in biochemical and cell 
biology assays along with functional defects caused by CPX-causing 
mutations. TBX22-expressing constructs were created for the wild-type 
protein and nine missense changes identified in CPX patients and one 
polymorphic variant also seen in healthy controls. The mutant constructs 
were assessed in relation to wild-type TBX22 in all assays. 
TBX22 binds to a near-palindromic DNA sequence similar to the T 
palindrome, and can also bind to a single TBE. Binding is sensitive to the 
orientation of the two TBEs in the TBX22 consensus site, as the protein 
does not bind as effectively to the T palindrome. The N-terminal part of 
TBX22, outside the T-box domain, appears essential for DNA binding, 
while the C-terminus is not as important. TBX22 is a transcriptional 
repressor against its own putative promoter (hPO) and the promoter of a 
candidate target gene OSRI in a tissue-specific manner. It is localized 
into the nucleus but absent from nucleoli. TBX22 is a substrate for 
SUMO-1 modification. Attachment of SUMO-1 occurs at aK residue in 
the N-terminal part of the protein and this interaction is reversed by 
SUMO-specific protease SENP2, but not SENP1. SUMOylation of TBX22 
is essential for its repression function. 
Missense mutations in the T-box domain of TBX22 are differentially 
compromised in their ability to bind DNA in EMSA reactions with the 
TBX22 consensus binding site. They also appear defective in 
transcription regulation, as they cannot repress the activity of either the 
hPO or OSRI promoters as well as the wild-type. Although all mutant 
proteins localize into the nucleus, they appear unable to become modified 
by SUMO-1 as well as the wild-type protein, even though the position of 
the missense changes is away from the identified TBX22 
SUMO- 
attachment site. A summary of the behaviour of all mutants 
tested is 
presented in Table 3.2. 
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Table 3.2 Functional analysis of natural TBX22 missense 
mutations 
Missense Location in T- DNA Subcellular Promoter SUMOylation- 
mutation box domain binding localization repressio 
ability n 
Wild-type nuclear 
W1 02C a helix 1 nuclear 
G1 18C Close to DNA nuclear 
contact, NLS 
R1 20W Contact at nuclear 
DNA 
backbone, 
NLS 
M121V Close to DNA nuclear 
contact, NLS 
P183L Putative nuclear 
dimerization 
C184F Putative + nuclear 
dimerization 
E187K a helix 2 + nuclear 
L214P Contact at nuclear 
DNA backbone 
T260M Contact at nuclear 71 
DNA backbone 
N264Y a helix 3 nuclear 
+: wild-type function; -: loss of function; +/-: compromised function 
(signal 
is there, but not as good as with the wild-type protein) 
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4. DISCUSSION 
Following the identification of TBX22 mutations in X-linked CP families, 
mutations have also been identified in isolated CP cases (Braybrook et al., 
2001; Braybrook et al., 2002; Margano et al., 2004; Chaabouni et al., 
2005; Suphapeetiporn et al., in press). The latter group established its 
importance to clefting in general, suggesting that many patients present as 
sporadics or are unrecognisable as X-linked cases through lack of family 
history. This is becoming an increasingly common theme, where genetic 
analysis of syndromic phenotypes has been more straightforward and has 
often provided candidate loci for isolated, non-syndromic forms of clefts 
(Stanier and Moore, 2004). The identification of a novel gene provides an 
important starting point to our objective of understanding the molecular 
pathways and mechanisms that regulate normal and abnormal palate 
formation. The current study sets out to investigate the function of TBX22 
at the molecular and cellular level. This included the basic function of the 
protein as a putative DNA-binding transcription factor, its localization 
within the cell, post-translational modification and interaction with likely 
target genes. During the course of these studies it was possible to 
analyse the effect of various missense mutations found in CP patients. 
4.1 BINDING TO DNA 
4.1. a. Recognition of DNA binding sites 
T-box genes encode transcription factors that share an evolutionary 
conserved DNA-binding domain (Bollag et al., 1994). These proteins also 
share a level of preference for the DNA sequences they bind to, which, in 
general, includes a core sequence (TCACACCT, also known as a T-half- 
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site), first identified within the palindromic recognition site of the T protein 
(Kispert and Herrmann, 1993). This sequence is also known as the T-box 
binding element, or TBE. T-box proteins preferably bind to various 
combinations of one, two or more TBEs, either perfectly matching the 
consensus sequence or with slight variations, and arranged at different 
spacing and orientations (Tada and Smith, 2001). Because of the 
similarity between binding sites for the different T-box proteins, it is 
thought that some of the specificity lies in the arrangement of the TBEs 
within the regulatory regions of the target genes (Sinha et al., 2000; 
Conlon et al., 2001). 
In CPX patients, missense changes in TBX22 occur mostly within the T- 
box domain (Braybrook et al., 2001; Braybrook et al., 2002; Margano et 
aL, 2004; Chaabouni et al., 2005; Suphapeetiporn et al., in press). This 
suggests that these changes might cause a defect in the binding of the 
protein to the regulatory DNA elements of its target genes. In order to test 
this hypothesis, a preferential DNA-binding site for TBX22 was first 
identified using a binding site selection assay (as described in Kispert and 
Herrmann, 1993). A near-palindromic sequence similar to the T site, but 
with the two half-sites arranged at the opposite orientation was 
subsequently identified. Divergence from the consensus TBE sequence in 
two positions in one of the half-sites is tolerated or maybe preferred, but 
the protein binds equally well to a similar DNA sequence where the 
nucleotides in these positions are substituted with the ones present in the 
consensus T half-site, as in the TBX18 binding site (Farin et al., 2007). 
TBX22 specifically binds to its identified consensus sequence and also to 
the TBX18 binding site, however it does not bind the T palindrome nearly 
as efficiently. Other T-box genes have been shown to bind the T 
palindrome as well as their own preferred sequences (Sinha et al., 2000). 
This data indicate that for TBX22 the presence but also the orientation of 
the TBE sequences in its DNA-binding site are important for promoter 
specificity. 
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The binding site selection assay used to identify the preferred DNA 
binding site for TBX22 is an immunoprecipitation method that purifies 
protein-DNA complexes followed by a PCR-based recovery of DNA 
sequences. The source of DNA is a pool of short random sequence 
oligonucleotides, as this has previously been shown to have advantages 
against libraries of genomic fragments for the identification of binding sites 
(Pollock and Treisman, 1990). Nevertheless, along with the protein 
source (in vitro translated protein from a plasmid construct), this 
contributes to the basic limitations of the technique. The DNA fragments 
are selected from random 26-mers that may not completely correlate to 
naturally occurring sequences within the genome. In the case of T-box 
genes specifically, if the required sequence consists of paired TBEs, there 
is going to be a limitation imposed by the size of the oligonucleotides on 
the spacing available between the half-sites. It has been previously 
reported that natural TBEs appear in the promoters of T-box target genes 
separated by a few to tens of even hundreds of nucleotides, and they have 
all been important for the regulation of target promoters by the T-box 
protein (Casey et al., 1998; Tada et al., 1998; Di Gregorio and Levine, 
1999; Conlon et al., 2001). 
Thus it was not considered remarkable that BLAST searches failed to 
identify a complete and identical TBX22 consensus sequence within the 
human genome. In fact no other T-like palindromic sequence has been 
identified in the genome either (Conlon et al., 2001). In vivo, it might be 
that multiple half-sites that are present in the regulatory regions of target 
genes at some distance apart and are then brought together by specific 
folding of DNA to facilitate transcription factor binding (Tada and Smith, 
2001). Nevertheless, the availability of a binding sequence meant that it 
could be conveniently used in EIVISA reactions to test the DNA-binding 
ability of the mutant proteins. 
1-0 
Besides its own consensus site, it was shown that TBX22 would also bind 
to aT half-site, although with decreased affinity. No shift is visible in 
EMSA gels, but upon addition of antibody a super-shift appears. 
Complexes between some T-box proteins and their DNA sites can 
become stabilized in the presence of antibody, as for example the T and 
Xbra proteins (Kispert and Herrmann, 1993; Sinha et al., 2000), while 
others like TBX1 and TBX2 give bands of the same intensity in the 
presence or absence of antibody (Sinha et al., 2000). Moreover, not all T- 
box proteins can bind to single TBEs; TBX1 appears to only bind 
palindromes, while TBX2 and TBX5 bind both single and paired half-sites 
(Sinha et aL, 2000; Ghosh et al., 2001). 
Role of protein domains in DNA binding 
It is not uncommon in T-box protein research to use truncated forms of the 
particular protein of interest, usually consisting of either the T-box domain 
only or omitting the C-terminal part of the protein after the end of the T-box 
(Kispert and Herrmann, 1993; Ghosh et al., 2001; Habets et al., 2002). 
Although sometimes this can be more convenient for experimental 
procedures as it provides with a smaller polypeptide, it is questionable if it 
accurately mirrors the behaviour of the protein in vivo. Studies comparing 
full-length protein with truncated forms have shown that results obtained 
can be quite different, even if it is just in simple DNA-binding assays and 
even if the T-box is still present intact in the truncated protein. For 
example, binding to TBE sequences is more efficient for both TBX2 
(Habets et al., 2002) and TBX5 (Ghosh et al., 2001) when C-terminal 
truncated forms are used. In such cases it might be preferable to use the 
full-length protein, since the C-terminal part (which in many cases 
constitutes half the size of the protein, as for TBX22) may play an 
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important role in mechanical hindrance specifically affecting how tilting or 
bending may occur during protein-DNA interactions. 
For TBX22, omitting the C-terminal appears not to have a significant effect 
on the binding ability of the protein, with both a shift and a super-shlift 
visible. However, lack of the N-terminal part of the protein has a 
completely different effect, abolishing DNA binding. Even though the N- 
terminus (outside the T-box domain) is not very well conserved between 
family members, its deletion has also been shown to eliminate or 
significantly reduce DNA binding for both TBX5 and Brachyury (Kispert 
and Herrmann, 1993; Ghosh et al., 2001). Furthermore, in TBX5 two 
missense mutations in this region have been identified in Holt-Oram 
syndrome patients, confirming a functional role for this domain (Yang et 
al., 2000). Although this is currently not the case for TBX22, where most 
missense mutations are located inside the T-box and only one recently 
reported in the C-terminal portion (Suphapeetiporn et al., in press). 
Further screening of CPX and CP patients will be valuable in terms of 
potentially revealing more sites outside of the T-box domain and possibly 
also within the N-terminal part where mutations have a major effect. 
4.1. c. Initial screening for target genes. 
As described above, full palindromic TBEs are absent in the human 
genome, although sequences resembling half-sites are commonplace. 
Since it is unlikely that in vivo, a half-site alone would encode sufficient 
information to direct specific binding of a transcription factor, other factors 
might include spaced out half-sites or even the specific sequence context 
surrounding the half-site (effectively forming a weaker extended 
consensus). Therefore in a preliminary screen for potential target genes, 
putative promoter sequences were analysed to identify possible TBEs. 
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Since the surrounding sequence may play a role in recognition and/or 
specificity of TBX22 for the promoter(s) in question, flanking sequences 
were included in the design of the oligonucleotide fragments. Two out of 
fifteen TBE sequences, corresponding to regulatory regions of the TBX10 
and OSR1 genes, appeared positive for binding to TBX22 and these were 
further studied to establish any functional interactions between the genes. 
It is interesting to note that out of the thirteen genes tested, eight 
contained the exact sequence of the conserved T half-site that appears in 
the identified TBX22 consensus motif (AGGTGTGA, see Results chapter, 
Figure 3.1 and Table 3.1). The TBX1O and OSR1 promoter sequences 
that appeared positive for binding TBX22 were two of these eight, while 
the remaining six sequences failed to show binding. This observation 
suggests the significance of the sequence context where a TBE may 
appear within a natural promoter, although this remains to be explored 
further. 
It is important to note that the EMSA methodology used here may not be 
conclusive for excluding genes with TBE-like sequences as possible 
TBX22 targets. This is firstly due to limitations in the conditions of the 
EMSA reaction as a biochemical assay, where transient interactions 
between a protein molecule and a DNA fragment might not show up on an 
autoradiograph, particularly if the complexes formed are not stable enough 
to remain intact during the gel electrophoresis. Also, the sequences 
tested only represent an arbitrary 2 kb upstream of an estimated first exon. 
It might be that there are other sequences present within these regions or 
sequences beyond these regions that can interact with TBX22 that are yet 
to be identified. 
It is also likely that not all interactions between TBX22 and its target genes 
will involve direct DNA binding, but may involve cofactors. Similar 
interactions have been described for homeobox-containing proteins that 
share similar specificities for binding to DNA, like many T-box proteins 
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(Scott et al., 1989; Laughon, 1991). It has thus been suggested that their 
selectivity for target genes is likely to be mediated by interaction with other 
proteins, rather than solely by DNA sequence recognition. Target gene 
repression by Msxl has been shown to occur independently of DNA- 
binding, in the absence of homeodomain-binding sites (Catron et al., 
1995). It is thus necessary to test these selected CIP-related genes in 
different ways, for example tissue and stage specific expression in a 
TBX22 null mouse, in order to get more information on potential 
interactions in vivo. 
4.2 
defects. 
CPX mutations and their functional 
The phenotype of patients in CPX families can range, in both males and 
carrier females, from a complete cleft of the secondary palate 
accompanied by ankyloglossia to a bifid uvula or only ankyloglossia, while 
some carrier females can be completely asymptomatic (Braybrook et al., 
2001; Margano et al., 2004). This phenotype variation is also seen within 
single CPX families that share a TBX22 mutation (Margano et al., 2004). 
In the smaller CPX families, where there are insufficient patients to expect 
to see variable phenotypes, there is an obvious selection bias since they 
were usually selected for TBX22 analysis based on the cleft secondary 
palate and ankyloglossia. However, the variability is well illustrated in 
larger families, for example in the Icelandic family (Moore et al., 1987; 
Bjornsson et al., 1989) where all of the above phenotypes were witnessed 
and even one carrier female was reported with a cleft lip and palate 
(Braybrook et al., 2001). The phenotype in the Icelandic family results 
from a splice site mutation at the IVS6+1 of TBX22, which may either 
cause skipping of exon 6 or through use of an ectopic splice site, 
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incorporate some intronic sequence into the mature mRNA product. It is 
interesting to note that the possible alternative splice combinations from 
exon 5-7 or 5-8 are out of frame and introduce premature stop codons. 
Exon 6 encodes only the last few residues of the conserved T-box domain 
and no missense mutations have been identified in these sequences. 
Therefore, it is possible that alternative truncated proteins retaining partial 
function might explain the variable penetrance in this family. The role of 
the C-terminal part of the protein has not yet been established although 
preliminary data in this thesis suggests that its role is not in DNA-binding. 
TBX22 lacking the C-terminal fragment can still bind DNA as efficiently as 
full-length protein, while a recent publication has identified two patients 
with isolated CP, one with a C-terminal missense change and the other 
with a frame shift truncating within the same region (Suphapeetiporn et al., 
in press). Further studies are therefore needed to elucidate the specific 
function of this part of the protein. 
Various mutations in TBX22 can cause the CPX phenotype, and these 
include frameshift, splice site, nonsense and missense mutations, which 
collectively cover the extent of the coding DNA (Braybrook et al., 2001; 
Braybrook et al., 2002; Margano et al., 2004; Chaabouni et al., 2005; 
Suphapeetiporn et al., in press). To date, no direct correlation has been 
established between the type or location of the TBX22 mutation and the 
expression and/or severity of the CPX phenotype (Braybrook et al., 2001; 
Braybrook et al., 2002; Margano et al., 2004). This is similar to findings for 
other T-box genes, for example mutations in TBX5 that cause Holt-Oram 
syndrome (Basson et al., 1997; Li et al., 1997; Brassington et al., 2003). 
Although a genotype-phenotype correlation was initially reported, more 
recent data suggest that the same phenotype can be caused by mutations 
in the DNA-binding and activation domains of the protein (Basson et al., 
1999; Brassington et aL, 2003). For other genes, the rare mixture of CP 
and CLIP phenotypes are sometimes seen. For instance, a single MSX1 
mutation has been described that causes both CIP and CLP to segregate 
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in the same family (van den Boogaard et al., 2000). For p63, the CP or 
CLIP phenotype may depend on the specific domain of the protein that 
mutations affect (Celli et al., 1999). Similarly, IRF6 mutations may cause 
Van der Woude syndrome (VWS) or popliteal pterygium syndrome (PPS) 
depending upon their position within the protein (Kondo et al., 2002). PPS 
mutations segregate with amino acids that make direct contact with the 
DNA, while mutations at positions in the protein-binding domain or even 
within the DNA-binding domain but at positions with no direct DNA 
contact, frequently caused VWS. 
Although all known TBX22 mutations appear to cause the same overall 
CPX phenotype, it was not clear whether the same specific molecular 
defect would be common to all the changes, or whether they can have 
different effects on the final protein product. In the case of nonsense, 
frameshift or splice site changes, the production of a severely truncated 
protein or nonsense mediated mRNA decay due to a premature stop 
codon is likely to lead to loss of function. Missense changes, however, 
may cause a subtle change to the protein but which can also have a 
dramatic effect on function, depending on the specific domain affected. 
This may result in a similar phenotype and suggest equivalence to the loss 
of function mutations. For this reason and because they are likely to 
produce full-length proteins, the missense mutations were investigated as 
a means to assess functional effects of TBX22 at the molecular and 
cellular level. 
4.2. a. Effect of mutations in DNA-binding 
DNA binding sites identified for other T-box proteins in similar binding site 
selection assays have been used to test the binding abilities of mutant 
proteins (Sinha et al., 2000; Ghosh et al., 2001; Fan et al., 2003). 
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Mutations in a number of T-box genes, including TBX2 and 5, have been 
shown to cause loss of DNA-binding. 
As expected, the EMSA reactions in this study showed that the DNA- 
binding ability of all TBX22 mutant proteins was affected to some extent. 
Some mutants were completely unable to bind DNA, others were 
compromised in their ability to bind, and several showed only a slight 
reduction compared to the wild-type protein. If the position of the 
mutations is considered in the stereochemical structure of the T-box, as 
determined for Brachyury and Tbx3 (Muller and Herrmann, 1997; Coll et 
al., 2002), several are located at amino acids positions that make direct 
contact with the DNA backbone, for example T260M and R120W 
(corresponding to Xbra positions T194 and R68, respectively), while 
others, like P183L and C184F (Xbra P128 and N129, respectively), are 
present in the putative protein dimerization domain. Although there is 
some correlation between the position within the T-box and effect on DNA- 
binding, this is not reflected in every mutation. This may be due to 
conformational changes that make certain epitopes unavailable for contact 
with other macromolecules. For example, a missense change at a 
position that does not make direct contact with the DNA backbone may 
change the structure of the protein so that amino acids that interact with 
DNA are concealed and no longer available for binding. Also, in the 
absence of the TBX22 T-box domain structure, there could be slight 
differences to those that have been resolved. The T-box domains of the T 
and Tbx3 proteins have for example, been shown to be similar but not 
identical, the one being slightly tilted in relation to the other (Muller and 
Herrmann, 1997; Coll et al., 2002). The data on TBX22 binding suggest 
that, although it binds palindromic sequences and half-sites, it prefers to 
bind paired rather than single TBEs. Preliminary evidence, however, 
points to the fact that it may bind as a monomer rather than a dimer. 
Thus, if a single TBX22 molecule binds to a palindromic DNA sequence, 
the interface of the protein-DNA complex might be novel compared to the 
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ones described to date; for example the T-DNA complex is crystallised as 
a homodimer bound on a DNA palindrome. Further experiments may 
needed to characterize the specific sites of interaction between TBX22 
and its preferred DNA binding sequence. 
Interestingly, one of the TBX22 mutations, G118C, occurs at the same 
position within the T-box as G80R, a mutation in TBX5 found in a Holt- 
Orarn syndrome patient (Ghosh et al., 2001). Although reports on the 
TBX5 mutation do not completely concur, either suggesting that it 
completely abolishes (Ghosh et al., 2001) or dramatically reduces (Fan et 
al., 2003) the ability of the protein to bind DNA, TBX22 G1 18C still allows 
fairly efficient DNA binding, although less than the wild-type. This 
difference could either be due to subtle structural differences between the 
two proteins, or alternatively, because the glycine is substituted for 
different amino acids in the two proteins, cysteine in TBX22 and arginine 
in TBX5. Another CPX mutation (R1 20W) shares the same position with a 
mutation in TBX2 (R122A) (Sinha et al., 2000). This position is conserved 
in all T-box proteins. Like the TBX22 change, TBX2 R122A is expressed 
normally, has the same molecular weight in western blots as the wild-type 
and localizes correctly into the nucleus (Sinha et al., 2000). Nevertheless, 
the change has a major effect on ability to bind to the DNA target 
sequence. 
4.2. b. 
nucleus 
Localization of TBX22 mutants to the 
Transcription factors need to enter the nucleus in order to regulate their 
target genes. Should they be hindered from localizing correctly within 
the 
cell, it is expected that their ability to act appropriately will 
be severely 
compromised. Single amino acid substitutions may have an effect on 
the 
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ability of a protein to localize to the correct location within the cell. 
Besides changing or hiding potential sites of attachment or interaction with 
DNA and other proteins or co-factors, such missense mutations may 
disrupt a nuclear localization signal or make subtle changes to their 
conformation, thus leading to inappropriate confinement into the wrong 
cellular compartment. 
Nuclear localization signals (NLS) have been identified for a number of T- 
box proteins, including Tbx3, Tbx5, Brachyury and Tbx1 (Carlson et al., 
2001; Collavoli et al., 2003; Zaragoza et aL, 2004; Stoller and Epstein 
2005), and more recently for Tbx1 5 and Tbx1 8 (Farin et al., 2007). There 
does not appear to be one conserved NLS sequence for all T-box 
proteins, and such signals have been found inside the T-box domain and 
outside, at both the N- and C-terminal parts of the protein. Two NLS 
sequences have been described for TBX5, one within the T-box domain 
and one at the C-terminus, and they have been shown to act 
synergistically to achieve nuclear import (Collavoli et al., 2003). Although 
the sequence within the T-box domain is at least partially conserved in 
other T-box proteins, it is not always sufficient for nuclear localization, as 
for example for Tbx1, where another NLS at the C-terminal part of the 
protein seems to be the main signal for correct protein trafficking (Stoller 
and Epstein, 2005). TBX22 also partly shares the putative TBX5 NLS 
sequence located in the T-box, but does not seem to share the C-terminal 
NLS (see Introduction, figurel. 6). It would not be surprising if, as in the 
case of Tbx1, this sequence cannot function as a real NLS for TBX22, as it 
does not seem to be a general NLS for all T-box proteins. TBX22 also 
contains a predicted NLS at its N-terminal part outside the T-box 
(KRKLQ), which is also conserved and shown to be functional in TBX15 
and TBX18 (Farin et al., 2007). Given the close evolutionary relationship 
between these three genes, it would be interesting to test these 
sequences as a candidate NLS for TBX22. Identifying a functional NLS 
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for TBX22 would also provide a very useful control for future sub-cellular 
localization experiments with wild-type and mutant proteins. 
Unlike for TBX22, several mutations have been described in T-box 
proteins that do affect their localization into the nucleus. For example, 
mutations in TBX5 identified in Holt-Oram patients have been shown to 
cause defective localization (Fan et al., 2003). The mutant proteins 
studied seemed to have a significantly decreased capacity to enter the 
nucleus, as only a percentage of the molecules enter while the rest 
remained in the cytoplasm. Only one change appeared to compromise 
nuclear entry almost completely. Interestingly, the position of the mutation 
is not within the identified nuclear localization signal for TBX5 (Fan et al., 
2003; Zaragoza et al., 2004). The G80R change, at the amino acid 
equivalent of TBX22 G1 18C, described above, was one of the mutants 
that seemed partly defective. Apart from compromising nuclear entry, 
mutations could also cause defects in the sub-nuclear localization of the 
protein. This may lead to a disruption in normal function, as although the 
transcription factor enters the nucleus it may become restricted to 
inappropriate areas and thus be unable to contact DNA or other protein 
molecules (Mohaghegh and Hickson, 2001; Sutherland et al., 2001). 
Of the CPX TBX22 mutations examined in this study, G1 18C, R120W and 
M121V occur at the location of a conserved TBX5 NLS that is present 
within the T-box domain (Collavoli et al., 2003). Within this sequence, the 
equivalent of R120 in TBX5 is a basic residue, essential for correct nuclear 
transport (Collavoli et al., 2003). When the CPX TBX22 mutations 
analysed in this study were tested for the ability to enter the nucleus, all of 
them seemed able to localize into the nucleus as efficiently as the wild- 
type protein. This is similar to G80R in TBX5, where nuclear entry is also 
not impaired (Fan et aL, 2003), and suggests that, for TBX22, the NLS 
sequence inside the T-box domain is not functional or at least not the main 
sequence responsible for nuclear localization. 
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In combination with the DNA-binding and the repression activity results for 
these mutants, which did not correlate completely, the nuclear localization 
data suggested that there is probably another aspect of their normal 
function that is impeded. However, since the nuclear localization of the 
CPX mutants was tested by western blot analysis and 
immunohistochemistry, subtle differences, especially in their sub-nuclear 
position, might have been more difficult to observe. Perhaps more 
detailed experiments are needed to assess this possibility, for example by 
confocal microscopy. 
Modification of proteins by SUMO has been shown to affect their 
localization within the cell, particularly the sub-nuclear position they will 
occupy. SUMO modification of SATB2 has been shown to restrict the 
localization of the protein to the nuclear speckles or nuclear periphery, 
while unmodified SATB2 is seen diffused in the entire nucleus (Dobreva et 
al., 2003). SUMO peptides themselves are restricted to specific nuclear 
compartments when they are un-conjugated, and may then be transported 
to other areas when they attach to target proteins. The location of these 
molecules is essential for their proper function, since transcription factors 
need to contact DNA to exert an effect on their target genes. However, 
the defect in SUMOylation seen with the TBX22 missense mutations 
studied does not appear to have a marked effect on their localization. 
When different de-conjugating enzymes were used to block attachment of 
SUMO to the wild-type TBX22, one abolished the TBX22-SUMO complex, 
leading to loss of repression, while another had almost no effect. At least 
some of the specificity of certain SUMO peptidases for a SUMO-target 
protein complex may lie in the precise sub-cellular localization of these 
enzymes in relation to the region where the substrate protein would 
normally be found. In the case of TBX22, the enzyme that negatively 
affected its SUMOylation, SENP2, is localized at the nuclear pore. This 
may hint at the importance of a sub-nuclear position of TBX22, which 
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might be present close to the nuclear envelope. Alternatively, it could 
suggest that SUMO conjugation occurs as TBX22 enters the nucleus and 
prior to reaching its target promoter sequences and/or other molecules of 
the transcription initiation complex. It will be interesting in the future to 
investigate the sub-nuclear localisation more closely to be able to detect a 
potential transport defect associated with the CPX missense mutations. 
Meanwhile, further evidence for the specificity of SUMO peptidases is 
provided by the fact that SENP1, the deconjugating enzyme that appears 
to have no effect on SUMO modification of TBX22, has been shown to 
decrease the SUMOylation of both MSX1 (Gupta and Bei, 2006) and Eyal 
(Alkuraya et al., 2006). 
4.3 
Genes 
Transcription Regulation and Target 
Transcription factors generally have either activator or repressor abilities, 
sometimes possessing the potential for both, depending on their 
environment and/or post-translational modifications (Ogbourne and 
Antalis, 1998). The T-box family provides good examples of all three 
(Naiche et al., 2005). Both activation and repression domains have been 
identified in Brachyury (Kispert et al., 1995) and Tbx2 (Paxton et al., 
2002). It has been suggested that accessory proteins may determine the 
regulatory activity of a T-box protein (Papaioannou, 2001). An example of 
this is Mga, where the expression of genes of the Max-network within 
specific cells dictates if Mga functions as an activator or repressor (Hurlin 
et al., 1999). In addition, Tbet, the ortholog of TBX21 in zebrafish, can 
bind to TBE sequences in the promoters of target genes and activate 
(INFy) or repress (IL-2, IL-4 and IL-5) transcription depending on the 
specific promoter (Szabo et al., 2000). TBX22 has the potential to act as a 
repressor against its own promoter (hPO) and the putative promoter of the 
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OSR1 gene. Limited evidence from this study suggests that it may also 
have a slightly activating effect on the OSR1 promoter at lower 
concentrations. 
Auto-regulation has been investigated as a regulatory mechanism for 
many transcription factors (Serfling 1989; Alon, 2007). Loops of 
transcription factors controlling their own promoters can occur as positive 
or negative auto-regulation, where proteins respectively activate or 
repress their promoters (Alon, 2007). Such networks have been described 
for a number of eukaryotic repressors and activators, and many of these 
loops are present and important during development (Lee et al., 2002; 
Levine and Davidson, 2005). In addition, feedback loops between two 
transcription factors are also common during development, with the 
proteins regulating the expression of each other (Davidson et al., 2002; 
Alon, 2007). Within the T-box family an auto-regulatory mechanism has 
been demonstrated for human TBX5 (Sun et al., 2004) and for the T 
orthologues in zebrafish (ntl) (Schulte-Merker et al., 1994) and Xenopus. 
However, there is no evidence for a regulatory loop in for T in the mouse 
(Clements et al., 1996). The presence of two TBE sequences in the TBX5 
putative regulatory region appears significant for promoter activity and also 
enhances the effect of TBX5 on the expression of the reporter gene (Sun 
et al., 2004). When the TBX5 promoter construct was expressed in a cell 
line with over-expression of TBX5, its activity increased significantly. In 
parallel, hPO shows no activity in cell lines with endogenous TBX22 
expression, and is repressed when TBX22 is ectopically expressed. 
Regulatory loops have been described between different T-box genes; a 
number of them contain TBE sequences in their promoters (Habets et al., 
2002; Cai et al., 2005; Farin et al., 2007). Tbx2O represses Tbx2 in 
cardiomyocytes through binding to TBE elements in the Tbx2 regulatory 
region (Cai et aL, 2005), and Tbx2 competes with Tbx5 for the regulation 
of the ANF promoter (Habets et al., 2002). Tbxl 8 has also been shown to 
compete with TbX5 and repress the ANF promoter while interacting with 
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common partners Gata4 and Nkx2.5 (Farin et al., 2007). Furthermore, 
Tbx18 appears to counteract the activation of DIM by Tbx6 (White and 
Chapman 2005; Farin et al., 2007). Preliminary data from cDNA 
microarrays examining genes that are up- and down-regulated in response 
to Tbx2/TBX2 expression have suggested the possibility for a combination 
regulatory circuit by T-box genes during development (Chen et al., 2001; 
Butz et al., 2004). Such a regulation network has been described in 
zebrafish, where three T-box genes, no tail, spadetail and tbx6, interact 
and contribute to mesoderm formation (Goering et al., 2003). It is thus 
emerging as a pattern that different T-box genes are likely to have roles in 
common pathways and compete for the same TBE elements in target 
promoters ad that the final outcome of such biochemical pathways results 
from a balance between the spatiotemporal expression and activity of the 
interacting T-box genes. 
Tbx22 is closely related to Tbx15 and Tbx18, all three genes belong to a 
subgroup of the Tbx1 sub-family in vertebrates and are believed to have 
arisen from a single ancestor gene (Papaioannou, 2001). Tbx18 and 
Tbx22 share expression domains in the anterior part of epithelial somites 
during mouse development, they both encode transcriptional repressors 
and interestingly, but perhaps not surprisingly, the preferred DNA binding 
sequences identified for both proteins are strikingly similar (Farin et al., 
2007). A possible interaction and even redundancy between the two 
genes during somite development has been suggested as an explanation 
of part of the Tbx1 8-/- mouse phenotype (Bussen et al., 2004). 
In cell culture based luciferase assays, wild-type TBX22 represses its own 
promoter by up to 60%. This appears to be a very specific phenomenon 
since this repression is compromised by the single missense mutations 
tested but not the non-synonymous polymorphism E187K. All of the 
mutations resulted in a significant reduction in repression although the 
extent of this was variable between mutations and could not be correlated 
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according to DNA binding ability. This suggests that other factors besides 
binding to DNA may be important in the process of TBX22 regulating its 
target promoter sequences, for example interacting with certain co-factors 
that might heterodimerize with TBX22 or are bound to a nearby region of 
the same promoter. Other proteins might also be involved in promoter 
recognition or assembly and stability of the RNA polymerase complex 
(Svingen and Tonissen, 2006; Thomas and Chiang, 2006). For Tbx5, 
activation of the ANF promoter region is significantly affected by the 
presence of Nkx2.5, and the regulation probably also occurs in 
collaboration with Tbx2 (Habets et al., 2002). 
When testing the regulatory ability of a transcription factor using 
biochemical experiments, the environment in which the in vitro assay is 
performed may play a vital role. As mentioned before, hPO appears only 
to be able to activate the reporter gene in cells devoid of TBX22 
expression. For the OSRI promoter, over-expression of TBX22 represses 
the promoter in 293T cells, but when the same assay was performed in 
COS-1 cells no transcription regulation activity was evident. Both cell lines 
have no endogenous TBX22 expression, so the difference may be due to 
the presence of specific co-factors or other accessory proteins. 
In 293 cells, both the OSRI promoter activity and the observed repression 
effect upon addition of TBX22 appear to be independent of the presence 
of the initially identified TBE within the OSRI regulatory sequence. This 
could be due to a number of reasons, for example the OSRI promoter 
fragment might contain other TBE-binding sequences that were not 
identified in the TBE search. Alternatively, the interaction may occur 
through a TBX22 binding partner such that TBX22 is recruited to the DNA 
target without direct interaction with it and is thus able to exert its effect on 
repression. Although 293T cells allow interaction between the two genes, 
this may not be an accurate portrayal of the in vivo situation. In a similar 
fashion, TBX5 behaves as a potent activator in both cardiomyocytes and 
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COS-1 cells. However, cardiomyocyte activation is dependent on b1nding 
to the TBE, as shown by the significantly reduced activation upon deletion 
of the binding site, while this is not the case in COS-1 cells, where 
activation is not affected (Ghosh et al., 2001). 
OSRI is an interesting candidate target gene for TBX22. The presence of 
TBE sequences in its promoter, and perhaps more importantly, the 
interaction between TBX22 and the OSRI putative promoter, as 
demonstrated by the reporter assays, provide good evidence to suggest a 
genuine interaction. Moreover, the expression profiles of both genes 
during palate development support the possibility that TBX22 represses 
the expression of OSRI during this period (Braybrook et al., 2002; Bush et 
al., 2002; Lan et al., 2004). During palatogenesis Tbx22 is expressed in 
the growing palatal shelves and at the base of the tongue (Braybrook et 
al., 2002). Its expression is strictly regulated temporally and spatially 
(Braybrook et aL, 2002; Bush et al., 2002). Osrl is also expressed in the 
facial region at this time, with strong signals in the developing tongue and 
the mesenchyme of the palatal shelves (Lan et al., 2004). Its expression 
in the palatal mesenchyme is upregulated at E13.0- E13.5 in the mouse. 
If the expression of Osrl is compared to that of Tbx22 when the palatal 
shelves are growing and elevating, one can observe that although they are 
both present in the palatal shelves, Tbx22 expression occupies the lateral 
part, while Osrl is concentrated in the medial part of each shelf (Figure 
4.1). Expression of Osrl forms a clearly defined boundary, dividing the 
surface area of each palatal shelf in half. The medial part of each shelf, 
where Osrl expression is absent, is the region of most intense expression 
of Tbx22. This barrier formed between the regions of expression of the 
two genes could be due to mutually exclusive expression, or there may be 
a concentration gradient for each gene from one side of each palatal shelf 
to the other. Similarly, both genes are expressed at the base of the 
tongue during palate and tongue development, and their individual 
expression domains appear almost separate. Although there is no sharply 
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defined barrier, Tbx22 is expressed in the tissues at the base of the 
tongue and the base of the mouth around the attachment point, and 
appears to cover the mesenchyme directly under the outside epithelial 
tissue. OsrI expression is more widespread around the tissue either side 
of the tongue and seems to be also present in the lower mesenchymal 
layers (Figure 4-1). 
Although the two genes have clearly defined and almost non-overlapping 
expression domains, consistent with the possibility that OSRI may be 
repressed by TBX22, it has not yet been possible to look at the palate 
phenotype in either null mice. Unfortunately, Osrl-l- homozygous mice 
die with severe cardiac defects at El 2.0-El 3.0 (Wang et al., 2005), before 
normal palatogenesis is completed. Thus it is not possible to assess 
palate development or other genes expressed at this time. Expression 
analysis of Tbx22 null mice may offer further evidence for in vivo 
interactions between the two genes. Furthermore, it would be valuable to 
compare the expression of Tbx22 and OsrI towards the end of 
palatogenesis. When the palatal shelves have fused and Tbx22 
expression declines and eventually turns off, it would be interesting to 
observe the expression pattern of Osrl, since until now it has only been 
studied until E13.5 in the facial region (Lan et al., 2004). One might 
predict that the expression domain may broaden with loss of the defined 
border previously maintained at the time of Tbx22 expression. 
OSR2, a second OSR like-gene with 65% amino acid sequence identity 
with OSR1, is the only other odd-skipped related gene identified in the 
human and mouse genomes. Osr2 has been shown to be essential in 
palate development. Mice lacking Osr2 expression exhibit CP with palatal 
shelf retardation, i. e. their palatal shelves initially grow but still remain in 
the vertical position at E14.5 (Lan et al., 2004). Interestingly, a TBE 
sequence was also identified in the putative promoter region of OSR2, but 
this showed no binding to TBX22 in the EMSA assays. It will be 
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interesting to clone this sequence into a reporter construct to 
experimentally test for a possible DNA binding independent effect. 
The interaction between TBX22 and the putative TBXIO promoter, as 
characterised by the reporter assays performed in this study, did not 
provide results quite as significant as for OSR1. However, TBXIO might 
still be considered a potential target gene of TBX22, and its expression 
data would be consistent with the activity of TBX22 as a repressor. TbxlO 
has been identified as the gene disrupted in the Dancer mutant (Bush et 
al., 2004), a mouse strain with a spontaneous mutation that shows a CLP 
phenotype (Deol and Lane, 1966). In normal development, TbxlO shows 
a very restricted expression pattern, predominantly in the hindbrain but 
absent from the facial region (Bush et al., 2004). In the Dancer mutant, 
TbxlO is ectopically expressed in the whole embryo, suggesting a gain of 
function that leads to mice with CLP and open eyelids at birth (Bush et al., 
2004). Thus it is possible that, TWO is subject to active negative 
regulation, at least in the region of the palate, where Tbx22 represses its 
expression. An alternative, which has yet to be tested, is that ectopic 
TWO expression interferes directly with Tbx22 regulation, which may 
interfere with normal lip and palate development in the mouse. 
188 
. 11 -m 
a, 
m IV 44% 
iow 
a 
b 
Figure 4.1: Expression domains of Osrl and Tbx22 during 
palatogenesis. In situ hybridization on coronal sections of E13.5 mice, 
showing domains of Osr1 (a) and Tbx22 expression (b). The boundary of 
Osr1 expression in the palatal shelves is indicated by arrows. Note some 
differences at the expression of the two genes also at the base of the 
tongue (t). Images adapted from Lan et al., 2004. 
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4.4 SUMO MODIFICATION 
Attachment of SUMO peptides to target proteins has been linked to 
changes in their function, including interactions with other molecules, sub- 
cellular localization and regulation of their target genes. In mammalian 
systems SUMO modification has mainly been associated with 
transcriptional repression, or in some cases compromised transcriptional 
activation (Ross et al., 2002; Schmidt and Muller, 2002; Johnson, 2004). 
4.4. a. SUMO attachment and substrate function 
Protein motif searches revealed the presence of three potential SUMO 
attachment sites in the TBX22 protein sequence, two at the N-terminal 
part of the protein (K54 and K63), and one (K271) inside the T-box 
domain. Of these sites, the K63 was shown to be the main residue for 
SUMOylation, since TBX22-SUMO conjugation disappears upon mutation 
of this lysine. Meanwhile, mutation of the K271 position compromises the 
repression activity of the protein and also leads to loss of DNA-binding 
ability. Therefore it was concluded that K63 is the unique SUIVIO 
attachment site, while K271 is required for DNA binding and effects SUIVIO 
conjugation through some as yet unknown mechanism. 
It is interesting to note that during the search for SUMOylation sites in the 
TBX22 sequence, the SUMOplot search engine 
(http: //www. abgent. com/tool/sumoplot) identifies both K63 and K271 as 
putative acceptor sites, with K271 having a higher score for the human 
protein, while equal scores are given for the two K residues in the mouse. 
However, searching through the ELM motif resource (hftp: //elm. eu. org/), 
the K63 is predicted as a SUMO-1 interaction motif, while the K271 is 
picked up as a possible interaction domain to be of interest only if it is 
present in a surface-exposed loop of the protein. 
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The K63 lysine along with the SUMO motif is conserved in the TBX22 
sequences of all species sequenced so far but is not found in other T-box 
proteins. On the other hand, K271 and the associated SUMOylation 
consensus sequence is located within a highly conserved region in the T- 
box domain and is found ubiquitously throughout the T-box protein family. 
Therefore, if K271 does function as a SUMO attachment site, it might be 
predicted that many other T-box genes would be modified in the same 
way. In fact, this is also the SUMOylation motif predicted to be the SUMO 
attachment site for Tbx2 (Roy Chowdhuri et al., 2006). However, data 
presented in this thesis suggests that K271 is not the SUMO attachment 
site for TBX22. Moreover, other T-box proteins tested, TBX1, TBX8/15, 
TBX18 and Brachyury also appear not to be SUMOylated despite 
containing this site. Meanwhile our preliminary data confirm that TBX2 is 
SUMOylated although it remains to be tested experimentally whether 
TBX2 is modified at its equivalent of K271 or at some alternative site. 
Thus although SUMOylation is likely to be an important regulatory 
mechanism for the function of certain T-box family members, the initial 
data supports an association of SUMO modification at unique sites and 
primarily with the transcriptional repressors within the T-box family. 
SUMO attachment sites are often found in the vicinity of activation or 
repression domains of target proteins, as for example in Msx1 (Gupta and 
Bei, 2006). SUMOylation of TBX22 appears to play an important role in its 
function as a repressor. Mutation of its SUMO attachment site as well as 
hindering the attachment of SUMO to the wild-type protein by over- 
expressing de-conjugating enzymes, both lead to complete loss of 
repression in reporter assays. This is particularly interesting, as only a 
small fraction of the total TBX22 present in the cells appears to be 
SUMOylated. This situation, however, has been observed for most of the 
SUMO target proteins described so far, with only very few examples of 
substrates that appear to be modified at a greater percentage; for example 
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50% of RanGAP1 is modified within the cell at any given time (Mahajan et 
al., 1997). The modified TBX22, which would seem to consist of only a 
small percentage of the over-expressed (or endogenous) TBX22, 
represents the functionally active form. It has been suggested that SUMO 
modification is actually a very transient state, where target proteins get 
modified and un-modified perhaps as part of a loop, rather than specific 
protein molecules staying stably modified within a cell. Attachment of 
SUMO peptides to substrates may facilitate a specific function (for 
example interaction with DNA or other proteins), and specific peptidases 
de-conjugate the SUMO molecules from substrates when this function is 
complete, effectively freeing them up inside the cell for the next round of 
modification (Hardeland et al., 2002; Johnson, 2004). In addition, it may 
also possible that the unmodified TBX22 has a different role within the 
cells, besides transcriptional repression, perhaps regulating transcription 
through a different mechanism. 
De-conjugation of SUMO peptides from modified TBX22 by over- 
expression of SENP2, a SUMO-specific peptidase, appears to have an 
effect on the stability of the protein, as well as its repression activity. 
Unmodified TBX22 seems less stable within the cells when the TBX22- 
SUMO complex is absent. A role for SUMO modification in mediating 
protein stability has also been shown for p73 (Minty et al., 2000) and p63 
(Huang et al., 2004; Ghioni et al., 2005). Co-transfection with SUMO-1 
results in reduced levels of p63a (Ghioni et aL, 2005) but not TBX22, while 
mutating the SUMO acceptor sites of both p63a and TBX22 appears not 
to have any effect on protein levels (Huang et al., 2004). There have been 
reports on SUMO modification of other proteins where the opposite effect 
has been shown; when Smad4 is mutated at its SUMO attachment sites, 
the lysine mutant display increased stability compared to wild-type protein, 
due to reduced poly-ubiquitination (Long et al., 2004). Because SUMO 
peptides can use the same lysine residues as ubiquitin, SUMOylation of a 
substrate protein may lead to protection from degradation through the 
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ubiquitin pathway. However, at the same time, if these sites are disrupted, 
ubiquitin attachment may also be hindered, and thus lead to increased 
stability. This effect is different to addition of SENPs, where the K 
residues of the SUMO sites are still intact and available for interaction with 
ubiquitin. 
Assessment of the SUMOylation potential of CPX TBX22 missense 
mutants revealed an unexpected finding. Compared to wild-type protein, 
all of the mutants tested appear to compromise the ability of TBX22 to 
conjugate with SUMO-1. Naturally occurring mutations in other genes, for 
example p63, have also been associated with defects in SUMOylation of 
the mutant proteins (Ghioni et al., 2005). The p63 results are perhaps 
easier to interpret because the mutations tested resulted in either 
truncation of the protein or directly disrupt the SUMOylation site(s). The 
TBX22 results were initially surprising, since all of the mutation positions 
tested are within the T-box domain and thus distant from the TBX22 
SUMO attachment site, at K63. It may be that conformational changes 
caused by these single substitutions disrupt the availability of the SUMO 
attachment site or cause mechanical problems that disturb the interactions 
with the SUMO peptide and/or the SUMO-conjugating enzymes. The fact 
that all CPX variants are defective for SUMOylation may provide the 
explanation for their lack of repression ability that cannot be fully attributed 
to their DNA-binding abilities. Although clearly deficient compared to the 
wild-type protein, loss of SUMOylation in the mutants is not complete, as 
is also the case with loss of repression. However, over-expression of 
SUMO-1 does not rescue the SUMO phenotype, thus suggesting that the 
intrinsic defect of these proteins cannot be overcome by an increase in 
free SUMO availability. These observations appear to be a specific effect 
that may provide a common pathway for the functional defect that might 
underlie the molecular aetiology leading to the CPX phenotype. 
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The fact that TBX22 is SUMOylated and that this modification has a 
significant effect on its function has become more generally significant in 
terms of craniofacial development in the light of other recent findings. A 
number of proteins with a direct association to CUP have also been 
shown to be SUMOylated recently, including MSX1, SAT132 and P63 
(Dobreva et al., 2003; Huang et al., 2004; Ghioni et al., 2005; Gupta and 
Bei, 2006). SUMO modification has also been shown to be necessary for 
their normal function. In the case of SAT132, SUMO-1 attachment has 
been shown to directly regulate its activation potential and its localization 
into the nucleus (Dobreva et al., 2003), while mutations in the SUMO 
acceptor sites of p63 result in a significant increase of the transactivation 
potential of the protein and affect the transcription regulation of its target 
genes, although they do not appear to disturb its nuclear localization 
(Huang et al., 2004). Mutation of SUMO attachment sites for both TBX22 
and SATIB2 compromise their function, while several other SUMOylated 
proteins have been shown to retain their transcriptional activity when their 
SUMOylation sites are disrupted, for example LEF1, p53, Msx1 and 
STAT1 (Rodriguez et al., 1999; Sachdev et al., 2001; Rogers et al., 2003; 
Lee et al., 2006). In the case of Msx1, interaction of the protein with 
PIAS1, an enzyme that acts as an E3 ligase in the SUMO modification 
pathway, appears to modulate the function of Msx1 as a transcriptional 
repressor, its ability to bind DNA elements in a target promoter sequence 
and inhibit terminal myocyte differentiation, while no significant functional 
defects are observed with mutations in SUMO attachment sites (Lee et al., 
2006). This supports the theory that SUMO modification can affect target 
protein function through different mechanisms, and hints to the fact that 
TBX22 and SATB2 may share the same SUMO regulatory mechanism. 
SUMO modification has also been described for proteins that are linked to 
craniofacial development by their expression pattern or transgenic mouse 
phenotypes with clefts, including SMAD4, EYA1 and SOX9 (Lin et al., 
2003; Long et al., 2004; Taylor and Labonne, 2005; Alkuraya et al., 2006). 
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However, the most direct evidence for a requirement for normal 
SUMOylation in craniofacial development was recently described in a 
patient with CLIP who has a balanced reciprocal translocation with the 
breakpoint disrupting the SUMO-1 gene (Alkuraya et al., 2006). In E13.5 
mouse embryos, strong expression of Sumo-1 was shown in the upper lip, 
primary palate and medial edge epithelia of the secondary palate. Based 
on this finding, the same researchers went on to analyze a mutant mouse 
incorporating a gene trap construct interrupting the Sumo-1 gene. Nearly 
10% of heterozygous mice were found to have a CLIP phenotype while 
homozygotes died early. The same lab had previously reported a mouse 
knock out of the Eyal gene, a model for branch iootorenal dysplasia 
syndrome (BOR; 113650) (Xu et al., 1999). These animals do not have 
CIP although it was an interesting candidate since Eyal is highly 
expressed in palatal shelf epithelium and mesenchyme. Once it was 
discovered that Eyal was also a target for SUMOylation, double 
heterozygous animals were made with the Sumo-1 gene trap mice 
(Alkuraya et al., 2006). This increased the offspring with clefts to 36%, 
suggesting that Eyal and Sumo-1 interact, and that both are required for 
normal palate development, with the SUMO modification acting as a 
regulatory mechanism during this process. 
4.4. b. SUMO, clefting and the environment 
SUMO modification has been shown to be susceptible to environmental 
effects, especially different types of cellular stress (Bossis and Melchior, 
2006b). Comparison of these environmental effects with the risk factors 
described for orofacial clefts reveal striking similarities (Murray, 2002). 
Such factors include oxidative stress, osmotic stress, heat shock, 
exposure to ethanol and viral infection that have been associated with the 
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SUMOylation process (Saitoh and Hinchey, 2000; Kurepa et al., 2003; 
Zhou et al., 2004; Boggio and Chiocca, 2006; Sramko et al., 2006). 
Although initially the SUMO-2 and -3 were mainly associated with cellular 
responses to stress, SUMO-1 has recently also been demonstrated to play 
a role in these processes (Hong et al., 2001; Manza et al., 2004). 
Exposure of cells to oxidative stress led to modification of the targeting 
patterns of the SUMO peptides, which were de-conjugated from original 
complexes and re-distributed to new substrates, including anti-oxidant 
proteins and proteins involved in signaling during DNA damage. Reports 
on the response of the SUMO pathway to oxidative stress have been 
contradictory, with some suggesting an increase in SUIVIO modification of 
target proteins while others demonstrate a disappearance of SUIVIO- 
conjugated species under similar conditions (Manza et al., 2004; Bossis 
and Melchior, 2006a). Experimental design may play a role in these 
results, but since SUMOylation has been associated with a variety of 
diverse cellular functions, it may also be that different mechanisms of 
conjugation and de-conjugation are in place for different signaling and 
transcription regulation pathways. The observation that substrate proteins 
are not all affected at the same time or with the same speed may support 
this theory (Bossis and Melchior, 2006a). Mimicking oxidative stress 
conditions in cell based assays with low, and thus perhaps more 
physiologically relevant, concentrations of reactive oxidative species 
inhibits the activity of SUMO-conjugating enzymes. This leads to a 
general decrease in SUMOylation of substrate proteins, including essential 
transcription factors (Bossis and Melchior, 2006a). This effect was shown 
to be specific to the SUMO modification process, since the Ubiquitin 
pathway was not affected. Such stress can occur in vivo after exposure to 
UV, ionizing radiation, chemotherapeutic agents and hyperthermia (Finkel, 
2003). Cellular responses to elevated temperature has also been linked to 
SUMOylation through the modification by SUMO of heat shock 
transcription factor 1 (HSTF1) (Hilgarth et al., 2003). Interestingly, this 
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study associated phosphorylation of the same target protein with its 
potential for SUMOylation, as HSTF1 needs to undergo a conformational 
change, mediated by phosphorylation of a serine residue, to allow for 
SUMO attachment. 
Another likely influence of the SUMO process is viral infection (Muller and 
Dejean, 1999; Boggio et al., 2004). Gam-1, a viral protein from an avian 
adenovirus, can target El and E2 SUMO ligases for degradation and thus 
inhibits cellular levels of SUMO modification (Boggio et al., 2004). Down- 
regulation and loss of SUMOylated substrates leads to an up-regulation of 
cellular transcription and is thought to enhance viral replication. 
Disturbance of the SUMO modification pathway has recently become 
associated with a number of disease phenotypes in humans. Induction of 
SUMOylation has been shown for cerebral ischernia and it has been 
suggested that this process may have a role in defining the outcome of 
neurons exposed to such conditions (Yang et al., 2007). Other 
neurodegenerative diseases have been implicated in the SUMO pathway, 
including multiple system atrophy and Huntington's disease, where SUIVIO 
peptides have been shown to localize within the protein aggregates 
characteristic for these conditions. The Parkin protein also appears to 
have a role in regulating the turnover of an E3 SUMO ligase (Um and 
Chung, 2006). Furthermore, compromised SUMOylation has been linked 
to some cancers, through regulation by SUMO of nuclear receptor- 
mediated gene expression, for example the androgen and estrogen 
receptors with roles in prostate and breast cancer, respectively (Poukka et 
a/., 2000; Wu and Mo, 2007). The regulation of a number of other genes 
with roles in cancer development has been linked to SUMOylation (Kim 
and Baek, 2006), and a role for SUMO modification in cancer metastasis 
has been suggested recently, through association of the SUMO pathway 
with the regulation of transcription of KAII, a metastasis suppressor gene 
(Baek et aL, 2002; Kim et al., 2006). 
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The estimated genetic contribution for cleft lip and palate is 20-50% 
(Melnick, 1992). The remaining cases are attributed to a wide variety of 
environmental factors during early pregnancy, such as smoking, high 
intake of alcohol and drugs, maternal nutrition and exposure to various 
teratogens (Murray, 2002). More complex factors have also been 
implicated, including parental age (Bille et aL, 2005), low socioeconomic 
status (Krapels et al., 2006), psychological stress in the mother 
(Rosenzweig 1966; Montenegro et al., 1995), altitude (Castilla et al., 1999) 
and conditions of hypoxia (Webster et al., 2006), in some cases with good 
supporting evidence provided by animal models (Johnston and Bronsky, 
1991). In the context of the results in this thesis, along with reports on 
other genes associated with CUP, it seems likely that some of these 
factors may manifest through disturbance of the SUMO pathway. 
Destabilizing the normal balance of expression and activity for genes such 
as TBX22, MSX1, SATB2 and p63 during early pregnancy is likely to 
provide a high-risk environment for CLIP occurrence. Elucidating the 
relationship between environmental factors, the SUMO pathway and the 
networks of craniofacial genes that are influenced by this post- 
transcriptional modification may be crucial for our understanding of 
idiopathic forms of orofacial clefts. 
4.5 FUTURE STUDIES 
Due to time limitations associated with my studentship, a number of 
interesting lines of investigation could not be completely finished. It is 
planned that these will continue in the lab and in some cases may provide 
the introduction to new projects. 
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A missense mutation (P389Q) has recently been identified in the C- 
terminal domain of TBX22 (Suphapeetiporn et al., in press). Since all 
missense mutations reported so far have been in the T-box domain, it will 
be interesting to examine the effect of this change on the function of the 
TBX22 protein. The C-terminus of TBX22 has not been well 
characterised. In this study, it appears not to be essential for IDNA- 
binding, so it may be that sequences outside the T-box domain are 
required for a different range of functions. 
4.5-a. Further characterization of target genes. 
This study provided an initial screening for candidate downstream genes 
of TBX22 and identified two possible targets, OSR1 and TBXIO. DNA- 
binding and reporter gene assays have shown an interaction between 
TBX22 and the putative regulatory regions of these genes. These 
interactions will be further characterised by chromatin immunoprecipitation 
(ChIP) in cell lines with endogenous expression of TBX22 and craniofacial 
embryonic tissues to confirm binding of TBX22 to the OSRI and TBXIO 
promoters. Since the data suggest that the TBE identified in the OSRI 
regulatory sequence is not essential for interaction with this promoter, the 
ChIP assay will also screen for the other CP-related genes included in our 
list of candidate target genes, as there may be other sequences in these 
promoters without readily identifiable T-box binding elements that TBX22 
may recognise. OSR2 is also a very interesting candidate gene, 
especially in light of the data suggesting interaction between TBX22 and 
OSRI. The putative promoter of OSR2 will be cloned and tested for 
interaction with TBX22. 
The putative TBX22 promoter has been shown to activate expression of 
reporter genes only in cell lines devoid of endogenous TBX22. It will be 
interesting to see if other promoters are repressed upon ectopic TBX22 
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expression. A comparative analysis of gene expression will be performed 
using microarray technology to identify genes that are up and down- 
regulated in the presence and absence of TBX22. 
A TBX22 knockout mouse constructed in parallel with this project will be 
used to detect the basic cellular defects that prevent closure of the palate. 
Putative targets will be evaluated both in the TBX22 null mouse and in 
CPX patients without TBX22 mutations. 
4.5. b. Further characterization of the TBX22- 
SUMO interaction. 
TBX22 is SUMOylated and this modification has been shown to be 
essential for the function of the protein. There are a number of aspects of 
this interaction that need further examination. A protein-protein interaction 
screen will be used to identify the specific E3 ligase that attaches SUMO 
peptides to TBX22. Interaction of proteins with enzymes in the SUMO- 
conjugating pathway has recently been shown to have additional roles in 
regulating the function of these proteins, even independently of the actual 
SUMO modification, as is the case for Msx1 and PIAS1 (Lee et al., 2007). 
Such a screen will help complete the TBX22 SUMOylation pathway, 
identifying new protein partners for TBX22 that may in turn lead to 
elucidating novel pathways in which TBX22 is a component. 
The sub-nuclear localization of wild-type and mutant TBX22 in relation to 
SUMO will be looked at in more detail. CPX mutations appear not to 
impede the localization of TBX22 into the nucleus. The sub-nuclear 
localization of SUMO-1 has been shown to alter when substrate protein 
are over-expressed in cell lines (Huang et al., 2004). It will be interesting 
to examine the localization of SUMO molecules within cells in the absence 
and presence of wild-type TBX22 and observe if this localization 
is 
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affected upon over-expression of mutant TBX22. It may be expected that 
wild-type TBX22 will interact with SUMO-1 and thus disrupt the usual 
association of the peptide with PML nuclear bodies, while the mutant 
proteins will have a lesser (or no) effect. 
An association between the SUMO pathway and craniofacial defects is 
emerging from recent data on a number of genes. The CIP phenotype of 
Sumol targeted mice has further supported this observation (Alkuraya et 
al., 2006). Thus, SUMO-I and associated SUMO pathway genes will be 
sequenced and screened for mutations in patients with cleft lip and palate, 
isolated CIP and CPX patients with no identified TBX22 mutations. 
4.5. c. Interaction with co-factors 
Analysis of the TBX22 protein sequence with the ELM (The Eukaryotic 
Linear Motif) resource for functional sites in proteins (http: //elm. eu. org/) 
identified an engrailed homology domain 1 (EH1) motif at residues 9-17 
(AFSVEALVG) of the human protein. These motifs are found in active 
repressors that contain a homeodomain and in other transcription factor 
families, and allow recruitment of Groucho/TLE co-repressors (Copley, 
2005). A recent study on Tbx1 5 and Tbx1 8 has shown interaction of these 
proteins with Groucho co-repressors (Farin et al., 2007). As Tbx22 
together with Tbx1 5 and Tbx1 8 are closely related and part of a Tbx1 sub- 
family, it will be interesting to examine interactions of Tbx22 with these 
molecules. 
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TBX22: alignment of human protein and cDNA sequence 
mALSsRARAFsv 
CCA GGG M GCT CTG AGC TCT CGG GCG CGT GCC TTC TCC GTG 
E A L V G R P S K R K L Q D 
GAA GCC TTG GTG GGG AGA CCC AGC AAA AGA AAA CTC CAA GAC 
P I Q A E Q P E L R E K K G 
CCA ATA CAG GCG GAG CAG CCT GAG CTG CGG GAG AAA AAG GGC 
GEEEEERRSsAAGI 
GGA GAG GAA GAG GAG GAG AGA AGG AGC AGC GCT GCA GGG AAG 
SEpLEKQpITEPST 
AGC GAG CCG CTT GAA AAA CAA CCT AAG ACA GAG CCC TCA ACA 
SAsSGcGSDsGYGN 
TCT GCT TCC TCT GGC TGC GGC AGC GAC AGC GGC TAC GGC AAC 
ssESLEEKDIQ lmlý L 
AGC TCT GAA AGT CTG GAA GAG AAA GAT ATT CAA G CTT 
QGsELwKRFHDIG, T 
CAA GGA TCT GAA CTG TGG AAA AGA TTC CAT GAC ATC GGG ACT 
1-1 EMITKAGRRmFp I-) 
GAG ATG ATC ATT ACT AAA GCG GGC AGG CGG ATG TTC CCC TCT 
VRvKVKGLDpGFQY 
GTT CGG GTC AAG GTG AAA GGG TTG GAT CCA GGG AAG CAG TAC 
V HVAIDvvPVDsKp 
CAT GTG GCC ATC GAT GTG GTG CCG GTG GAT TCC AAA CGC TAT 
I-1, - RYvYHssQWmVA 
AGG TAC GTC TAT CAC AGC TCA CAG TGG ATG GTA GCT GGG AAT 
T D H L C I P R F y v 
ACA GAC CAT TTG TGC ATC ATT CCT AGA TTC TAT GTT CAC CCG 
241 
DS -7- pcsGEWm 
GAC TCA CCC TGC TCG GGA GAG ACC TGG ATG CGG CAG ATC ATC 
S F D R M K L T N ý7 
AGC TTT GAT CGC ATG AAA CTC ACC AAC AAT GAG ATG GAT GAC 
KG H I I L Q s m H ?, y K p 
AAA GGC CAC ATC ATT CTG CAA TCC ATG CAT AAG TAC AAA CCC 
R V H v I E Q G S s V D L s 
CGA GTG CAC GTG ATA GAG CAA GGC AGC AGT GTT GAC CTG TCC 
QIQSLpTEGvKTF IS 
CAG ATT CAG TCC TTG CCC ACT GAA GGT GTT AAA ACA TTC TCC 
FKETEFTTVTAYQN 
TTT AAA GAA ACT GAG TTC ACC ACA GTA ACG GCT TAC CAA AAC 
QQITKLITERNPFA 
CAA CAG ATT ACG AAA CTA AAA ATA GAA AGA AAT CCT TTT GCT 
KGFRDTGRNRGVLD 
AAA GGA TTT AGA GAT ACT GGA AGA AAC AGG GGT GTA TTG GAT 
GLLETypWRpSFTL 
GGG CTT TTA GAG ACC AGG CCT TCT TTC ACT CTC 
DFKTFGADTQSGss 
GAT TTT AAA ACC TTT GGC GCA GAC ACA CAA AGT GGA AGC AGT 
GSspvTsSGGAPsp 
GGC TCA TCT CCA GTG ACC TCT AGT GGA GGG GCC CCC TCT CCT 
LNsLLspLCFsPmF 
TTG AAC TCC TTA CTT TCT CCA CTT TGC TTT TCA CCT ATG TTT 
H L p T S s L G M p c P E A 
CAT TTA CCT ACA AGC TCC CTT GGA ATG CCC TGT CCA GAG GCA 
YLpNVNLPLcYKIc 
TAC CTG CCC AAT GTC AAC CTG CCT CTA TGC TAC AAG ATT TGT 
242 
P T N F W Q Q Q P L V L p A 
CCA ACT AAT TTT TGG CAA CAG CAA CCT CTT GTT TTA CCG GCT 
P E R L A s s N S s Q S L A 
CCT GAA AGA CTA GCA AGC AGC AAC AGT TCT CAG TCT TTA GCC 
PLmMEvpMLsSLGv 
CCA CTC ATG ATG GAA GTG CCT ATG TTA TCT TCC CTG GGG GTC 
TNsKSGsSEDssDQ 
ACC AAT TCA AAA AGC GGT TCA TCT GAA GAC TCC AGT GAT CAG 
YLQAPNsTNQMLyG 
TAT CTA CAA GCA CCT AAT TCT ACC AAT CAA ATG TTA TAT GGA 
LQsPGNIFLpNSIT 
TTA CAG TCA CCT GGA AAT ATT TTT CTG CCA AAC TCC ATC ACC 
PEALScsFHpsYDF 
CCA GAA GCA CTT AGT TGC TCC TTT CAT CCT TCC TAT GAC TTT 
YRyNFsmPSRLIsG 
TAT AGA TAC AAT TTC TCT ATG CCA TCT AGA CTG ATA AGT GGT 
SNHLKvNDDsQVsF 
TCC AAC CAT CTT AAA GTG AAT GAC GAC AGT CAA GTT TCT TTT 
GEGKCNHVHwypAI 
GGA GAA GGC AAA TGT AAT CAT GTT CAT TGG TAT CCA GCA ATT 
NHyL 
AAC CAT TAC CTT GAC AAT AGC ATT ACA TGT AAA CAA 
* Amino acid residues of the T-box domain appear in red. 
* The positions of the CPX missense mutations are highlighted 
in 
yellow. 
*K residues of predicted SUMOylation sites are highlighted 
in light 
blue and the sites underlined. 
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The Ncol restriction site used for cloning the truncated TBX22 
constructs is highlighted in purple. 
TBX22 fragments (truncation sites are highlighted in green): 
TBX22 1-298: from start (ATG) until 298Y (prior to Ncol site) 
TBX22 92-520: from 94M (used as START) to end (TAA) 
Primer sequences 
Sequences are shown 5' to 3'. 
forward, R: reverse. 
Amplification of TBX22 ORF 
T220RFKOZF 
T220RFNOTAAR 
At the end of each primer name, F: 
AGGGATGGCTCTGAGCTCTC 
AAGGTAATGGTTAATTGCTGG 
Forward primer contains the innate Kozak sequence of the genomic TBX22; 
reverse primer amplifies to the end of the coding sequence, omitting the stop 
codon, to allow translation to continue into the vector sequence and incorporate 
the V5 and His tags at the C-terminus of pcDNA3.1 V5/His. 
TBX22 CPX missense mutant constructs 
T22W102CF GGATCTGAACTGTGCAAAAGATTCCATGACATCGGG 
T22Wl 02CR CCTAGACTTGAACACGTTTTCTAAGGTACTGTAGCCC 
T22Gll8CF ATCATTACTAAAGCGTGCAGGCGGATGTTCCCC 
T22Gl 18CR TAGTAATGATTTCGCACGTCCGCCTACAAGGGG 
T22Rl2OWF ACTAAAGCGGGCAGGTGGATGTTCCCCTCT 
T22Rl2OWR TGATTTCGCCCGTCCACCTACAAGGGGAGA 
244 
T22Ml2lVF AAAGCGGGCAGGCGGGTGTTCCCCTCTGTT 
T22Ml2lVR TTTCGCCCGTCCGCCCACAAGGGGAGACAA 
T22P183LF CACCCGGACTCACTCTGCTCGGGAGAG 
T22Pl83LR GTGGGCCTGAGTGAGACGAGCCCTCTC 
T22C184FF CCGGACTCACCCTTCTCGGGAGAGACC 
T22Cl84FR GGCCTGAGTGGGAAGAGCCCTCTCTGG 
T22E187KF CCCTGCTCGGGAAAGACCTGGATGCGG 
T22E187KR GGGACGAGCCCTTTCTGGACCTACGCC 
T22L214PF AAGGCCACATCATTCCGCAATCCATGCATAAGTAC 
T22L214PR TTCCGGTGTAGTAAGGCGTTAGGTACGTATTCATG 
T22T26OMF AGTTCACCACAGTAATGGCTTACCAAAACCAACAG 
T22T260MR TCAAGTGGTGTCATTACCGAATGGTTTTGGTTGTC 
T22N264YF CACAGTAACGGCTTACCAATACCAACAGATTACGAAACTA 
T22N264YR GTGTCATTGCCGAATGGTTATGGTTGTCTAATGCTTTGAT 
Amplification of TBXIO and OSR1 putative promoter sequences 
TBXlOPromF AATCTCGAGATCCATTTCCCTGCGGCCA 
TBXlOPromRl AATCTCGAGCTGGTCTCCGAAGGTGAGAT 
OSR1 PromF GATCTCGAGCAGCAAAGTTCAGCATTGC 
OSR1 PromR GCGCTCGAGGCCGCCTACTTATTTTAATC 
OSR1 PromTruncF CAGCTCTCTTCTCTTCCAAGGGTTC 
For the OSRI promoter, OSRlPromTruncF was used with the same reverse 
primer to amplify the fragment omitting the TBE sequence. 
245 
Amplification of the first insert for TBX22 94-520 for the 2nd step of 
cloning 
T22Trunc2F GAGAGACCATGGATGGAGCTTCAA 
T22Trunc2R GCGCGACATATGAAGGTAATGG 
Sample luciferase reporter assay (raw data) 
Well Cont. 
AOI X1 420 22262 28203 28544 415608 455484 
A02 X2 2728 29543 31012 127774 543422 540545 
A03 X3 3748 39447 39353 145113 606762 601535 
A04 X4 2717 31757 31518 154120 659639 652310 
A05 X5 3104 36162 36112 130511 584003 579658 
A06 X6 2589 29768 29396 108547 470117 464177 
A07 X7 2178 24657 23520 111281 450939 441050 
A08 X8 458 603 603 68847 346679 342729 
A09 X65 2498 30499 31227 100661 396843 394193 
BOI X9 2091 19938 20330 82548 371046 368561 
B02 xio 2855 26127 25944 81298 341329 340439 
B03 X11 2727 33501 34735 123669 557861 551649 
B04 X12 3602 34237 34222 147788 672866 668587 
B05 X13 2503 22782 23433 80055 365971 360492 
B06 X14 2200 20123 20190 89223 346950 338650 
B07 X15 2882 29864 29529 115309 489939 484937 
B08 X16 896 1353 1407 110309 658451 650302 
coi X17 1698 18158 18505 80583 368118 365875 
C02 X18 2884 33912 34789 102043 432088 429884 
C03 X19 3541 33056 34306 117095 480300 475571 
C04 X20 3707 31054 32210 151930 672161 667315 
C05 X21 3592 32283 32632 126979 539066 532372 
C06 X22 2381 21459 21876 89097 407123 402344 
C07 X23 2241 22703 22158 81769 356118 352528 
C08 X24 1063 1260 1253 52143 262195 259455 
DOI X25 1923 20327 19856 74751 365648 363497 
D02 X26 2988 36289 35932 124818 536943 535611 
D03 X27 3854 40722 40950 149543 650381 645792 
D04 X28 2452 18085 18661 81691 396630 393167 
D05 X29 2156 18251 18546 72862 314828 311401 
D06 X30 3693 41827 41496 140854 620568 614293 
D07 X31 2890 23295 23474 105160 483107 478415 
D08 X32 819 1021 1029 64272 329222 325227 
E01 X33 3709 41558 42985 102756 359464 356341 
E02 X34 3068 41562 43947 107696 397948 392557 
E03 X35 4185 57099 58240 123493 453342 449863 
E04 X36 3372 36792 37378 112214 444442 440688 
E05 X37 3877 46729 48366 128275 471138 463856 
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E06 
E07 
E08 
FOI 
F02 
F03 
F04 
FOS 
F06 
F07 
FOB 
GOI 
G02 
G03 
G04 
G05 
G06 
G07 
G08 
H01 
H02 
H03 
H04 
H05 
H06 
H07 
H08 
0 
0 
0 
X38 
X39 
X40 
X41 
X42 
X43 
X44 
X45 
X46 
X47 
X48 
X49 
X50 
X51 
X52 
X53 
X54 
X55 
X56 
X57 
X58 
X59 
X60 
X61 
X62 
X63 
5490 
3288 
795 
3555 
3119 
5078 
3753 
3765 
3777 
3416 
712 
3539 
3247 
5138 
1147 
3834 
4387 
3933 
600 
2682 
3977 
5048 
2213 
4054 
3322 
3621 
652 
37734 
952 
38932 
45626 
70449 
41141 
47820 
50078 
45861 
874 
44400 
38118 
79225 
2037 
46478 
50774 
43076 
728 
40470 
46425 
61186 
29596 
50222 
43516 
45209 
805 
39035 
931 
38874 
46359 
71532 
41518 
48664 
51507 
46116 
867 
45243 
39320 
79330 
2012 
45832 
51526 
41404 
748 
41269 
45233 
57367 
30584 
49011 
42312 
45205 
809 
102488 
49160 
84446 
94898 
153135 
133199 
119055 
111189 
109634 
26751 
108897 
91752 
172922 
3314 
113928 
128411 
107485 
43815 
97523 
89425 
115560 
104000 
117866 
101549 
111295 
59594 
388734 
272523 
332416 
350657 
514480 
534690 
466830 
381376 
417085 
145038 
388774 
319407 
604656 
8762 
398542 
454758 
379091 
237458 
370728 
293735 
415486 
424662 
425774 
373302 
392115 
331081 
383630 
268440 
336063 
349279 
507617 
528584 
460250 
375126 
413277 
143178 
384897 
315179 
596056 
8800 
392435 
447260 
374199 
234996 
367600 
291946 
411763 
418320 
420782 
368773 
386094 
Firefly luciferase values shown in pink, Renilla values in baby blue. 
Sample numbers and well positions in a 96-well plate format are 
given in the first two columns from the left. 
Three readings were taken for each sample. The highest value 
was selected from each row to calculate the luciferase/Reni//a ratio. 
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